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Exosomes are secreted membrane vesicles (30-100 nm) found in tissue culture media and 
various body fluids that have potential as therapeutics and disease biomarkers. Current literature 
has reported regenerative benefits for blood-derived exosomes but the majority of these studies 
purified exosomes using ultracentrifugation (UC), a method that has been found to have high 
levels of protein contamination. Here the regenerative capacity of exosomes isolated by size 
exclusion chromatography (SEC), a method shown to reduce protein contamination, from human 
serum was assessed.  
SEC isolates were found to contain suitably sized vesicles and exosomal markers (CD9, CD81 
and TSG101). These isolates allowed for cellular uptake of a range of fluorescent labels and 
enhanced cellular fibroblast proliferation and endothelial sprout formation in a 3D spheroid-based 
angiogenesis assay. Further to this, functionality was shown to be retained after incubation of the 
isolates for 21 days at 37°C. Though a promising indication of regenerative potential, it was found 
that the isolates contained significant levels of ApoB containing lipoproteins (up to 15 µg 
ApoB/ml). It was shown that these lipoproteins were predominately the very low and intermediate- 
density lipoproteins. 
It was found that low-density lipoprotein can impact exosome uptake studies that use fluorescent 
nucleic acid, protein and lipid dyes. As a substantial extraneous lipoprotein content could also 
interfere with other downstream applications and analyses such as proteomic analysis, a multi-
step purification method was developed. A simple 3-step density gradient (DG) UC was 
introduced prior to SEC that incorporated a high-density iodixanol cushion overlaid by a 18% 
iodixanol step containing UC concentrated human serum that was then overlaid with 6% iodixanol. 
This DG relied on flotation to remove lipoproteins. After the multi-step purification (UC DG SEC) 
ApoB and ApoA1 were not detectable by enzyme-linked immunosorbent assay and western 
blotting respectively. The UC DG SEC isolates were positive for CD9 and TSG101 and 
morphologically, as viewed by transmission electron microscopy, had the canonical exosome 
shape and size. Nanoparticle tracking analysis showed that though exosome marker levels were 
similar, there were 100 times more particles in SEC purified isolates relative to those from UC DG 
SEC, emphasising the extent of lipoprotein removal.  
xxv 
 
Proteomic analysis identified 224 proteins in UC DG SEC isolates relative to the 135 from SEC, 
with substantial increases in exosome-associated proteins and reductions in lipoproteins. The UC 
DG SEC exosomes still elicited a significant increase in cell proliferation of human dermal 
fibroblasts but no increase in endothelial sprout formation. After subcutaneous implantation in a 
rat model, the highly purified exosomes potentially increased an angiogenic response. 
In conclusion, we show that serum SEC-derived exosomes with much reduced protein content do 
have regenerative properties but contain contaminating lipoproteins. Our new isolation technique 
isolated purer serum exosomes that retained cell proliferation stimulation and potentially 
enhanced an in vivo angiogenic response. This approach should render the isolated exosomes 




























Eukaryotic cells communicate with each other using three types of signalling processes: (1) 
through direct interaction or through the release of soluble factors in processes such as: (2) 
paracrine signalling (communication over short distances by the release of these factors) and (3) 
endocrine signalling (communication over long distances) (Yáñez-Mó et al., 2015). These soluble 
factors include hormones, growth factors, cytokines and exosomes. Exosomes provide a 
protective vehicle to transport different biomolecules that include proteins, nucleic acids and lipids. 
Over the last decade these have begun to be intensively investigated for their capacity to 
participate in intercellular communication. In 1946, Chargaff and West initially isolated 
procoagulant membrane-derived vesicles from blood using centrifugation at 31 000 g (Chargaff 
and West, 1946). Several decades later Wolf referred to this plasma pellet as “platelet dust” due 
to particles present in the pellet with a diameter of 20-50 nm (Wolf, 1967). In 1983-1984, in studies 
investigating the differentiation of sheep reticulocytes, vesicles were detected being released by 
multivesicular bodies (MVBs) which could then fuse with the cell membrane (Pan and Johnstone, 
1983, Harding et al., 1984). By 1987, these vesicles of endosomal origin were termed ‘exosomes’ 
and their initially hypothesised function was to remove non-essential proteins from cells 
(Johnstone et al., 1987). Almost 10 years later, exosomes from EpsteinBarr virus transformed B 
lymphocytes were found to elicit a T cell response which suggested a functional role of exosomes 
in antigen presentation in vivo (Raposo et al., 1996). Exosomes started to receive much greater 
attention from 2007, when messenger RNA (mRNA) and microRNA (miRNA) were detected within 
them, indicating they assist generally in intercellular communication (Valadi et al., 2007). A recent 
survey of the literature for English language articles from 2000-2016 using the search terms 
“exosome” and/or “microvesicle” found that research is increasing exponentially with less than 
1% of the 5480 identified papers published in 2000 and more than 20% in 2016 (Roy et al., 2018).  
Exosomes are secreted membrane vesicles which are found in body fluids such as blood, urine, 
saliva and cerebrospinal fluid. Other secreted vesicles include microvesicles, ectosomes, 
membrane particles, viruses and apoptotic bodies. Exosomes originate from MVBs, whereas the 
other secreted vesicles derive from the plasma membrane and have larger diameters of 100-1000 
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nm (Kowal et al., 2014). Exosomes from different cell lines have similar properties in terms of their 
lipid bilayer (7-9 nm wide), diameter (30-100 nm) and they have densities between 1.13 g/ml-1.19 
g/ml (Huang et al., 2015). However, though the above are presently considered characteristic of 
exosomes, a recent cryo-transmission electron microscopy (TEM)-based study of exosomes 
derived from a single human mast cell line (HMC-1) of a defined density of 1.12 g/ml found a wide 
range of morphologies in addition to spherical 40-100 nm vesicles that included vesicles within 
vesicles, oval vesicles and even tubular vesicles (Zabeo et al., 2017). Similar results have been 
reported for exosomes from a range of body fluids emphasises both the complexity of them as a 
class of vesicles and the uncertainties presently associated with them (Yuana et al., 2013, 
Zonneveld et al., 2014). 
 
1.2 Properties of exosomes 
1.2.1 Formation of exosomes 
Many mammalian cells engulf a portion of their plasma membrane to form an early endosomal 
structure that will mature into a MVB (van Niel et al., 2006). Exosomes are the intraluminal 
vesicles (ILVs) present inside the MVBs that are released by the cell. In brief, there is an inward 
budding of the cell’s membrane forming the endosome. During this process the cell’s 
transmembrane and peripheral membrane proteins become a part of the endosome’s membrane. 
Repeated steps of the inward budding of the endosome results in a MVB containing ILVs and as 
the endosome matures these ILVs increase in number. Once these vesicles are released into the 
extracellular space they are termed exosomes (Figure 1.1). An important question is whether only 
specific MVBs fuse with plasma membrane to release the exosomes or all of them are involved. 
One study found specific trafficking of MVBs as they showed that cholesterol rich MVBs were 
preferentially able to fuse with the plasma membrane, detected by immunoelectron microscopy, 
which resulted in the release of major histocompatibility complex (MHC) class II containing 
exosomes (Raposo et al., 1996). Further to this, exosome secretion can be controlled and 
decreased by reducing MVB concentration via ISGylation, which refers to the function of 
interferon-stimulated gene 15 (ISG15) conjugating to cytoplasmic and nuclear proteins analogous 
to ubiquitin modification (Villarroya-Beltri et al., 2016). The components responsible for ISGylation 
in HEK293 cells were overexpressed and the effect on exosome secretion monitored by 
quantifying exosome markers CD63, tumour suppressor gene 101 (TSG101) and CD81. This 
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mainly mediated and stimulated the co-localisation of MVBs with lysosomes and activated 
aggregation and degradation of MVB proteins resulting in the decrease of exosome secretion 

















Figure 1.1: Formation of exosomes. Exosomes are formed from late endosomes and bud off from the plasma 
membrane. GC (Golgi complex); MVB (multivesicular body); RER (rough endoplasmic reticulum). Figure from 
(Waldenström and Ronquist, 2014) with permission.  
 
The mechanisms involved in exosome biogenesis are not fully understood but the endosomal 
sorting complexes required for transport (ESCRT) machinery which form four complexes (ESCRT 
0, I, II, III) and associated proteins (vacuolar protein sorting-associated protein 4 (Vps4) and 
programmed cell death 6-interacting protein (Alix)) appear to be important in the process 
(Colombo et al., 2014). The ESCRT-0 complex recognises and sequesters ubiquitinated proteins 
to certain domains in the endosomal membrane. These mono-ubiquitinated proteins are identified 
by hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) which forms part of another 
protein complex with signal transducing adaptor molecule (STAM), epidermal growth factor 
receptor substrate 15 (Eps15) and clathrin (Babst, 2005, van Niel et al., 2006). The ESCRT-I 
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complex contains TSG101 which is recruited by Hrs to further recognise ubiquitinated proteins. 
After membrane budding, which appears to be controlled by ESCRT-I and -II complexes, the 
sequestered cargo is incorporated into the buds. The ESCRT-III complex is recruited through 
ESCRT-II or Alix, a protein associated with ESCRT. The buds form ILVs and the ESCRT-III 
complex drives the ILV separation and uses ATPase Vps4 for recycling itself or for more budding 
(Wollert et al., 2009, Hurley, 2010). There is indirect evidence for the above mechanisms as 
exosomes isolated from various cell or biofluid sources contain these various ESCRT components 
and ubiquitinated proteins, such as Alix and TSG101 mentioned, which are regarded as exosome 
markers (Liang et al., 2013).  
There are minimal studies that directly interrogate ESCRTs in exosome biogenesis. One study 
conducted an RNA interference (RNAi) screen targeting 23 ESCRT components and associated 
proteins in MHC-II expressing HeLa cells (Colombo et al., 2013). After short hairpin RNA (shRNA) 
silencing, they trapped the exosomes with anti-CD63 coated beads and quantified them using 
flow cytometry detecting exosomal markers CD81 and human leukocyte antigen-DR isotype 
(HLA-DR) (associated with MHC-II). Only 7 ESCRT proteins fell within the criteria that they 
effected exosome secretion of those containing CD63 and either CD81 or MHC-II. Inhibiting the 
ESCRT-0 and -I components (Hrs, STAM1 and TSG101) decreased exosome secretion, whereas 
inhibiting the ESCRT-III component Vps4B increased exosome secretion. The down regulation of 
Alix resulted in upregulation of MHC-II content and increased the relative amounts of larger 
exosomes indicative of Alix’s involvement in regulation of the nature of exosomes (Colombo et 
al., 2013). It has also been reported that Alix, syntenin and syndecan control breast cancer cell 
(MCF-7)-derived exosome secretion as the knock-down of Alix or syntenin inhibited exosome 
secretion, western blot confirmed reduction in Alix and syntenin coupled with down regulation of  
syndecan and exosome markers CD63 and heat shock protein 70 (HSP70) (Baietti et al., 2012). 
These apparent discrepancies between researchers further indicates the complexity of exosome 
secretion and Alix association and that it may depend on the cell type. 
Although research has suggested ECSRT involvement in the biogenesis of exosomes, it is difficult 
to ascertain the absolute involvement of ESCRT proteins as they have multiple important cellular 
functions too. For example ESCRT-III and Vps4 are required for the final cell division step in 
cytokinesis to separate the membranes as depleting ESCRT-III and Vps4 proteins diminishes 
abscission (Morita et al., 2010).  
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Complicating matters further, MVBs still form even after the removal of ESCRT subunits (Stuffers 
et al., 2009) and non-ubiquitinated proteins have become cargo within ILVs (Theos et al., 2006), 
suggesting there are ESCRT independent mechanisms for exosome biogenesis. For example, 
ceramide assists exosome biogenesis by initiating the membrane invagination which is helped by 
its cone-shaped structure (Trajkovic et al., 2008). Tetraspanins associating with cytosolic and 
transmembrane proteins are suggested to be another possible ESCRT-independent pathway. 
CD63 is another possible candidate as it has been shown to be involved in the biogenesis of ILVs 
in melanosomes (van Niel et al., 2011) and in HeLa cells (Edgar et al., 2014) via knockdown. A 
possible mechanism might be that CD63 could play a role in deforming the membrane to separate 
the lipid microdomains or by recruiting other ESCRT-independent components (Edgar et al., 
2014). The exosome secretion and the movement between membranes relies on Rab GTPases, 
Rab27a, Rab27b, Rab11 and Rab35 to help release exosomes once the MVB fuses to the plasma 
membrane (Ostrowski et al., 2010, Blanc and Vidal, 2017).  
Although research has illuminated some parts of the process of exosome formation, the precise 
mechanism of exosome formation and selection of cargo is still unclear. Moreover, the diverse 
literature highlights how complex exosome biogenesis is, though with the substantial increase in 
exosome research, it can be hoped that a more detailed understanding into exosome formation 
will eventually be obtained.  
1.2.2 Membrane composition 
Exosomes are comprised of a lipid bilayer and studies largely report on the lipids contained within 
this bilayer; however, it is possible that trace amounts of lipids could be captured within vesicles 
during ILV formation (Skotland et al., 2019). Ceramides, phosphatidylcholines, 
phosphatidylserines and sphingomyelins are exosomal lipid components (Haraszti et al., 2016). 
A recent review of exosome lipid composition found that out of eight studies of cell-derived 
exosomes, there was a two to three fold increase of cholesterol, sphingolipid, glycosphingolipids, 
and phosphatidylserine content in exosomes compared to the cells (Skotland et al., 2019). This 
higher lipid order of exosomes resembles that of lipid rafts, which are lipid dense domains in the 
plasma membrane that are detergent resistant and contain proteins, suggesting exosomes can 
be derived from lipid rafts (de Gassart et al., 2003). Research into mesenchymal stem cell (MSC) 
(Tan et al., 2013) and cancer cells (Staubach et al., 2009) has provided more direct evidence that 
exosomes can be derived from lipid rafts. The ligands, transferrin and cholera-toxin B chain, that 
are present in receptor-mediated endocytosis and lipid rafts respectively, were labelled and 
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tracked in MSCs (Tan et al., 2013). As both labelled ligands were detected within exosomes, this 
strongly suggests that they are derived from endocytosis that occurs at the lipid raft microdomains 
in the plasma membrane. For the breast cancer cell line, exosomes were isolated from MCF-7 
cells using ultracentrifugation (UC) and the lipid rafts from the exosomes were isolated using 
affinity purification with a bait protein (MUC1-M2 fusion protein) (Staubach et al., 2009). Mass 
spectrometry confirmed the presence of the lipid raft proteins (flotillin-1, prohibitin, G protein and 
annexin A2).  
Lipid rafts are suggested to play a role in various cellular functions including signalling, 
protein/lipid transport and pathogen entry (Munro, 2003). A study supporting this role used 
synthetic exosome-like nanoparticles to investigate the role of lipids and avoiding the influence of 
exosome proteins (Beloribi et al., 2012). Synthetic nanoparticles were constructed with lipid 
formulations of the SOJ-6 human tumour cells as these exosomes, isolated using UC and sucrose 
density gradient, were previously seen to induce cell death of the SOJ-6 tumour cells (Ristorcelli 
et al., 2008). Ristorcelli et al. speculated that the tumour-derived exosomes may exert their 
function through autocrine signalling, promoting the phosphatidylinositol 3-kinase/protein kinase 
B (PI3K/Akt) survival pathway or inducing apoptosis through activation of phosphatase and tensin 
homologue (PTEN) and glycogen synthase kinase 3 beta (GSK-3β). Beloribi et al. found the 
synthetic exosomes, rich in lipid forming raft microdomains also decreased proliferation of the 
SOJ-6 cells and the activation of cell death was caused by inhibition of the Notch pathway through 
interaction with the synthetic exosomes lipid microdomains (Beloribi et al., 2012). 
The exosome bilayer membrane is important in protecting the cargo from degradation during 
circulation through the body (Revenfeld et al., 2014) and the membrane composition of allogenic 
exosomes may also provide a mechanism to deliver therapeutic drugs as they are not likely to 
cause an immune response (Wu et al., 2017). It has been suggested that the exosomal 
membrane is important for signalling to target cells to uptake and fuse with the exosomes 
(Vishnubhatla et al., 2014). This is a critical area as a key function of exosomes, as mentioned 
above, is believed to be to allow cells to communicate and interact with one another (Minciacchi 
et al., 2015). Integral to the communication function is the encapsulation and protection of signals 
within the lipid membrane and the fusion or engulfment of the membrane (Sahoo and Losordo, 
2014). Exosome uptake is thought to occur mainly by endocytosis including micropinocytosis, 
phagocytosis and receptor/raft mediated endocytosis; direct membrane fusion can also occur 
(McKelvey et al., 2015). An acidic pH (pH 6.0) might favour the fusion mechanism, as a study 
showed an increase in cancer-derived exosome release and fusion internalisation at an acidic pH 
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compared to neutral pH (pH 7.4) when analysed using spectrofluorometry and confocal 
microscopy with a lipid fluorescent probe (Parolini et al., 2009). Furthermore, bone marrow 
dendritic cell-derived exosomes have been observed entering other dendritic cells either by 
endocytosis or fusion with endocytosis detected using exosomes labelled with pHrodo which 
fluoresced red at phagosome pH and fusion was detected using a de-quenching assay where 
lipophilic dye R18 was used to label exosomes and once they fused with lipid membranes, 
fluorescence increased proportionally to fusion (Montecalvo et al., 2012). U87 MG cancer cell-
derived exosomes have been shown to be internalised into human umbilical vein endothelial cells 
(HUVECs) and U87 MG cells using lipid raft-mediated endocytosis, indicated by the inhibition of 
exosome uptake using either methyl-β-cyclodextrin or simvastatin which reduced cellular 
membrane cholesterol and intracellular cholesterol respectively (Svensson et al., 2013). 
Furthermore, internalisation was shown to be regulated by caveolin-1 as determined with 
caveolin-1 knock out cells. 
A major difficulty with determining exosome formation and composition is their apparent 
complexity. For example, a recent study detected three different types of MSC extracellular 
vesicles (EVs) ascertained by their differing affinities of their membrane lipids for cholera toxin B 
chain, annexin V and shiga toxin B subunit (Lai et al., 2016). Confocal microscopy showed the 3 
sub-types were derived from various subcellular components with the cholera toxin B chain-, 
annexin V-, and shiga toxin B subunit-binding EVs detected within the plasma membrane, 
cytoplasm and nucleus respectively. It has been suggested in one paper that the cholera toxin B 
chain-binding EVs were considered ‘true’ exosomes (Lai and Lim, 2019) as they contained the 
exosome enriched proteins, CD81, CD9, Alix and TSG101 and are derived from endosomes, 
whereas the other two EV subtypes did not i.e. annexin V EVs were likely from cytoplasmic 
membrane organelles. Further complexity was shown by the lack of RNA in cholera toxin B chain-
binding EVs, which could indicate RNA cargo loading may not involve lipid rafts associated with 
exosome formation (Lai et al., 2016). However, the shiga toxin B subunit-binding EVs contained 
53% of total EV RNA compared to >0.5% for the other two subtypes, inferring nuclear vesiculation 
may load RNA into EVs. The lack of RNA in the considered ‘true’ exosomes (cholera toxin B 
chain-binding exosomes) highlights the discrepancies in exosome research as numerous papers 
claim the presence of nucleic acids within exosomes (Ohshima et al., 2010, Fernando et al., 2017, 
Li et al., 2018a) and the various EV subtypes could influence different cellular functions.  
The membrane contents of exosomes may also be governed by the extracellular milieu they find 
themselves in, with urinary exosomes found to contain a higher cholesterol content compared to 
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PC-3 cancer cell-derived exosomes, which would be expected to confer a greater stability within 
the biofluid (Llorente et al., 2013, Skotland et al., 2017). It should be noted that a significant issue 
with studying exosomal lipids is the lack of an optimal exosome isolation method, as any lipid 
droplets, lipoproteins or mitochondria co-isolated with the exosomes could lead to incorrect 
conclusions drawn about the lipid content of exosomes. Reports of exosomes containing high 
cholesteryl ester and/or triacylglycerol concentrations could indicate contaminating lipid droplets 
are present (van Meer et al., 2008). Biofluids such as plasma have a high content of lipoproteins 
which may further exacerbate the problem (Simonsen, 2017); however, isolating exosomes from 
cell culture is also not free from this issue as lipid droplets and mitochondria could leak into the 
conditioned media used for exosome isolations (Skotland et al., 2019).  
Exosomes contain various transmembrane proteins, such as tetraspanins (CD9, CD63, CD81), 
integrins, lipid raft-associated protein (flotillin), or cell adhesion molecules (Lötvall et al., 2014). 
Tetraspanins are involved in numerous biological process such as motility, invasion, membrane 
fusion or regulating cellular signalling (Andreu and Yáñez-Mó, 2014). Some studies have 
investigated the function of exosome membrane proteins such as tetraspanins. One such study 
found that modified exosomes with decreased CD9 and increased CD151 content promoted the 
invasion of prostate RWPE1 cells (Brzozowski et al., 2018). Furthermore, CD63 has been found 
to regulate the packaging of latent membrane protein 1 (LMP1), which is an Epstein-Barr virus-
encoded oncoprotein, into exosomes. LMP1 associates with CD63 for exosome secretion and 
LMP1 packaging into exosomes requires CD63 as immuno-isolation or clustered regularly 
interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) knockout of 
CD63 lead to a decrease in LMP1 secreted exosomes and LMP1 packaging into exosomes 
(Hurwitz et al., 2017). Continued investigation of exosome tetraspanins may lead to discerning 
cellular mechanisms and exosome trafficking to target diseases such as cancer. 
1.2.3 Exosomal cargo 
Exosomes contain proteins from the cytosol, cellular membrane, endocytic pathway and a scarce 
amount of proteins coming from the nucleus, rough endoplasmic reticulum (RER) and Golgi 
complex (GC). Cytosolic proteins enriched in exosomes include membrane transport and fusion 
proteins (GTPases and annexins), heat shock proteins (HSP70 and HSP90) and proteins involved 
in creating MVBs (Alix and TSG101) (Kowal et al., 2014, Abramowicz et al., 2018). Exosomes 
also contain mRNA, miRNA, cytokines and DNA (Huang et al., 2015). A substantial amount of 
cell-free DNA is located within plasma exosomes (Fernando et al., 2017) and the RNAs are 
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protected from RNases due to their encapsulation in a cholesterol-rich phospholipid bilayer (Chen 
et al., 2010b). ExoCarta (http://www.exocarta.org) or Vesiclepedia (http://www.microvesicles.org) 
list all the proteins and RNAs that have been discovered and reported in exosomes (Tsao et al., 
2014).  
Part of the cargo present within exosomes seems to depend on the cell source. For example, 
antigen presenting cells such as macrophages, B cells and dendritic cells will specifically express 
MHC-II molecules which present the antigen to CD4+ T cells for activation to recruit effector cells, 
whereas all cells will express MHC-I (except for red blood cells), with variable expression among 
cell type and influenced by inflammatory conditions, which present peptide antigens to CD8+ T 
cells (Wieczorek et al., 2017). It has been shown that exosomes secreted from antigen presenting 
cells include these MHC-II molecules suggesting their role in local immune defence. Human 
monocyte-derived dendritic cells, classified as an antigen presenting cell, secrete exosomes 
containing both MHC-I and -II molecules (Admyre et al., 2003, Lynch et al., 2009). Moreover 
exosomes, isolated using UC and dynabead immunoprecipitation, from human bronchoalveolar 
lavage fluid contain MHC-II (Admyre et al., 2003); suggesting they were secreted by antigen 
presenting cells. Furthermore, breast cancer-derived exosomes can transfer metastasis-
associated protein 1 (MTA1), expressed in metastatic cells, to promote breast cancer progression 
by altering the hypoxia and oestrogen receptor signalling environment (Hannafon et al., 2019).   
Proteins that are involved during exosome biogenesis may become exosomal cargo, discussed 
earlier in section 1.2.1, but some of these proteins may also mediate other protein or RNA loading 
into exosomes. These include ESCRT components and tetraspanins. ESCRT components, 
TSG101 (Sundquist et al., 2004), Vps4 (Wei et al., 2015), and Alix (Iavello et al., 2016) found 
within exosomes may control some cargo loading into exosomes. TSG101 binds ubiquitylated 
proteins during MVB formation (Sundquist et al., 2004) and exosomes have been found to contain 
ubiquitinated proteins. Fifty ubiquitinated proteins were identified from myeloid suppressor cell-
derived exosomes using mass spectrometry and bioinformatics analysis; hence, ubiquitination is 
another possible cargo loading mechanism (Burke et al., 2014). Using RNAi against Alix resulted 
in a significant reduction in exosome cargo syndecan, CD63 and HSP70, which suggests its role 
in packaging certain cargo (Baietti et al., 2012). The lipid membrane of exosomes may also direct 
protein cargo loading as a study found that reticulocyte-derived exosomal proteins (exosomes 
isolated using UC and sucrose gradient), Lyn, flotillin-1 and stomatin were associated with the 
lipid domain (Triton X-100 insoluble fractions) of the exosomal membrane inferring their lipid raft 
association for being sorted into exosomes (de Gassart et al., 2003). Cytosolic proteins were 
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found to be randomly engulfed into exosomes by the inward budding of the MVBs membrane 
(Colombo et al., 2014) but cytosolic proteins such as annexin and Rab may stimulate the fusion 
of MVB with the cell membrane and the release of exosomes (Beach et al., 2014).  
Several lines of research have indicated that particular miRNAs are sorted into exosomes. It has 
been identified that kirsten rat sarcoma viral oncogene homolog-mitogen-activated protein kinase 
kinase (KRAS-MEK) signalling controls protein argonaute-2 (Ago2) secretion into exosomes and 
it was suggested that the regulation of Ago2 controls the secretion of specific miRNAs into 
exosomes (McKenzie et al., 2016). A deep sequencing approach and analysis of public data 
including microarray and quantitative reverse transcription polymerase chain reaction (RT-qPCR) 
arrays found that miR-451 was the most enriched in HEK293T cell-derived exosomes and 6 out 
of 8 datasets of various cell types, such as dendritic cells, Jurkat J77, Raji and breast cancer cells 
suggesting that cell lines selectively choose specific RNAs for exosome packaging (Guduric-
Fuchs et al., 2012). Gastric cancer cell line AZ-P7a-derived exosomes were enriched in the let-7 
miRNA family, whereas other exosomes derived from other cancer lines (lung, colorectal, 
stomach) were not (Ohshima et al., 2010). Other mechanisms apart from Ago2 for sorting miRNAs 
into exosomes have been reported. Neutral sphyngomyelinase 2 appears to be involved in 
directing miRNA into exosomes as up-regulated exosomal miRNA was detected after the 
overexpression of neutral sphyngomyelinase 2 in a breast cancer cell line (Kosaka et al., 2013). 
An elegant study showed that a substantial portion of miRNA in exosomes from T-lymphocytes 
were positive for the short sequence GGAG in their 3’ half (Villarroya-Beltri et al., 2013). Further 
to this, it was found that this sorting due to sequence was dependent on heterogeneous nuclear 
ribonucleoprotein A2B1 and that sumoaylation (addition of small ubiquitin-like modifiers) of the 
protein was required. 
Researchers have been striving to identify cargo components that would be suitable markers for 
all exosomes whether cellular or body fluid-derived by identifying a conserved exosome protein. 
However, this has proved challenging as indicated by discrepancies in literature, for instance, it 
has been found that CD9 and CD81 were conserved in 4 human prostate cell lines and 5 human 
breast cell lines (Yoshioka et al., 2013). However, they found TSG101, Rab-5b and CD63 were 
detected at different concentrations depending on the cell source. In contrast, according to 
ExoCarta, CD9 (1), CD63 (7), TSG101 (11) and CD81 (24) are amongst the top 25 proteins 
identified in exosomes, and Rab-5b (86) was not. There are also issues of standardisation in the 
exosome field as the choice of exosome isolation technique influences mass spectrometry results 
used to determine exosome cargo (Kowal et al., 2016). One such study compared the proteins 
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from LIM1863 cancer cell-derived exosomes isolated using UC, density gradient separation, and 
immunoaffinity capture (Tauro et al., 2012). They found nearly two times higher concentration of 
Alix, TSG101, CD9 and CD81 using the immunoaffinity capture method. Furthermore, the 
isolation method can influence the mRNA profile detected from exosomes. Using gene expression 
microarray profiling, there were very different results for OptiPrep™ density gradient separation, 
UC and precipitation methods (ExoQuick-TC™) with correlation values as low as 0.40 (Spearman 
rho-values) (Van Deun et al., 2014). These results highlight the variation and complexity in 
exosomes both as a consequence of cell source and isolation procedure, which can influence 
downstream RNA profiling of the exosomes. 
MSCs are and have been intensively investigated as therapeutic agents for a wide range of 
pathologies with more than 600 clinical trials employing MSCs due to their potential therapeutic 
effects at www.clinicaltrials.gov (Phinney and Pittenger, 2017). It is generally understood at 
present that any potential therapeutic outcome is largely a consequence of paracrine activity and 
so their exosomes have received particular attention. The therapeutic use of MSC-derived 
exosomes will be discussed later in section 1.5 and 1.6.1. The composition of MSC-derived 
exosomes protein and genetic make-up have been reported in ExoCarta and so far, already 938 
genes have been reported (protein, mRNA and miRNA data) (Table 1.1). Some of the MSC-
derived exosomes proteins include ribosomal protein S16, histone cluster 1, nidogen 1 and 
ribosomal protein L23. 
The research into exosomes as biomarkers has been extensive over the last 5-10 years and will 
be very briefly outlined below. There are comprehensive reviews (Properzi et al., 2013, Barile and 
Vassalli, 2017, Nedaeinia et al., 2017, Huang and Deng, 2019). Although less proteins have been 
identified in plasma and serum-derived exosomes compared to MSC-derived (Table 1.1), their 
cargoes are also of great interest due their potential to be biomarkers as a result of their high 
concentration in body fluids and their stability (Jabalee et al., 2018). There are reported potential 
EV miRNA biomarkers in body fluids such as plasma (miR-21 and miR-1246 for human breast 
cancer (Hannafon et al., 2016), miR-103a-3p and miR-30e-3p for malignant pleural mesothelioma 
(Cavalleri et al., 2017), miR-122-5p and miR-300-3p (detected in rats) for transient ischemic 
attack (Li et al., 2018a)); serum (miR-141 for prostate cancer (Li et al., 2016c), miR-200b and 
miR-200c for epithelial ovarian cancer (Meng et al., 2016), miR155 for human hematologic 
malignancies (Caivano et al., 2017)) and urine (miR-21-5p for urothelial carcinoma (Matsuzaki et 
al., 2017)). Furthermore, plasma EVs may have the potential to diagnose glioblastoma due to 
their substantially higher concentration in patients, detected using nanoparticle tracking analysis 
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(NTA), which significantly decreased after tumour removal (Osti et al., 2019), strongly suggesting 
the viable tumour cells released substantial numbers of exosomes into the plasma. A recent study 
further highlighting the potential of plasma exosomes as biomarkers showed that plasma 
exosomes from patients with pancreaticobiliary cancers contained a significant portion of tumour 
DNA with multiple mutations detected such as Notch homolog 1, translocation-associated 
(NOTCH1) and breast cancer gene 2 (BRCA2) (San Lucas et al., 2016). These studies highlight 
the importance of analysing the cargo within blood-derived exosomes to understand the function 
of exosomes as well as finding novel biomarkers for diseases. Exosome cargo can also be 
indicative of their functional activity with proteins such as HSP70 being implicated in 
cardioprotection (Vicencio et al., 2015) (see section 1.7.4.1). 
 
Table 1.1: Number of exosome genes (protein, mRNA and miRNA data) detected in various sources 
and reported in ExoCarta as of January 2019 
Source of exosomes Number of genes reported in ExoCarta 




1.3 Exosome isolation methods 
1.3.1 Ultracentrifugation  
UC was originally seen as the ‘gold’ standard to isolate exosomes. In 2016, UC had been used 
by 81% of researchers (Gardiner et al., 2016). Multiple centrifugation steps are used to separate 
particles according to their buoyant density (Contreras-Naranjo et al., 2017, Konoshenko et al., 
2018). Large particles with a buoyant density higher than exosomes such as cells, apoptotic 
bodies, larger vesicles, cell debris, are removed initially with a standard centrifugation (<20 000 
g). UC is then used to isolate exosomes at (100 000-200 000 g) for 1-3 hours. The rotor type, 
centrifugation time, viscosity of the sample and 𝑘 factor will affect the outcome of the isolation 
(Momen-Heravi et al., 2012, Cvjetkovic et al., 2014). The time of UC is important as UC of HMC-
1 cell conditioned media in a Type 70 Ti fixed angle, showed that 70 minutes didn’t isolate all the 
exosomes and 4 hours resulted in contaminating soluble proteins in the exosome pellet 
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(Cvjetkovic et al., 2014). As biofluids are more viscous than cell culture media they can be diluted 
to improve isolation efficiency. The disadvantages of UC include the high centrifugation speeds, 
long isolation time and the protein contamination (Table 1.2) (Baranyai et al., 2015). In proteomic 
research, co-isolation of protein aggregates and proteins is a major issue. Exosomes can be 
further purified by either repeated UC, sucrose density gradient, or microfiltration with pores <0.45 
µm. However, additional purification steps result in a decrease in exosome yield (Théry et al., 
2006, Konoshenko et al., 2018).  
1.3.2 Precipitation 
In 2016, precipitation had been used by 14% of researchers (Gardiner et al., 2016) and increased 
in 2017 to 26.4% (Konoshenko et al., 2018). Polyethylene glycol (PEG) is a volume-excluding 
polymer used to exclude the particles from the solution by decreasing its solubility. This method 
is modified from viral studies (Leberman, 1966). The polymer solution is mixed and incubated with 
the samples; which are subsequently pelleted down at 1500 g and resuspended in phosphate 
buffered saline (PBS) (Abramowicz et al., 2016). There are numerous commercially available 
exosome isolation kits which are based on using PEG precipitation: ExoQuickTM (System 
Biosciences), Exo-spinTM (Cell Guidance Systems), Total Exosome Isolation reagent (Invitrogen), 
ExoPrep (HansaBioMed), Exosome Purification Kit (Norgen Biotek) and miRCURY Exosome 
Isolation Kit (Exiqon). Commercial isolation kits are less time consuming, do not need an UC, 
have a physiological pH range and are simple to use (Contreras-Naranjo et al., 2017). For a more 
economical option, PEG 6000 can be used which gives similar results to commercial reagents 
when miRNAs were studied in serum exosomes (Andreu et al., 2016).  
A major drawback is that PEG is not specific to isolating exosomes; contaminating proteins, 
protein aggregates and other particles are also isolated (Lobb et al., 2015). Particle purity is 
calculated by the ratio of particle number to protein concentration (Webber and Clayton, 2013). 
Studies have shown precipitation has a high concentration of particles; however, the particle purity 
is low due to the contaminants present (Baranyai et al., 2015). Contaminants are more abundant 
when isolated from plasma due to the excess albumin present. Precipitation is lower in particle 
purity compared to UC even though UC yields a low concentration of particles (Lobb et al., 2015). 
It has been shown that UC isolates were more enriched for serum and cell culture-derived 
exosome markers than those precipitated using commercial kits (ExoQuick and TEI) even though 
particle concentration was lower, as determined by NTA and protein concentration (Tang et al., 
2017). Yet another study found that UC had more albumin contamination and less exosomes than 
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ExoQuick (Caradec et al., 2014). These differences are due to the different UC methods 
implemented. The second study only used one UC spin with a 30% sucrose cushion, whereas 
the first study used two UC spins which removed more contaminating proteins; however, the yield 
of exosomes decreased. Further purification steps appear to be required when using PEG 
precipitation. 
1.3.3 Filtration 
Filtration is often used before other exosome isolation methods (UC or size exclusion 
chromatography (SEC) see section 1.3.6) to remove cells and large EVs. The filters are either 
polyvinylidene difluoride (PVDF) or polycarbonate with a pore size ∽50-450 nm (Muller et al., 
2014, Contreras-Naranjo et al., 2017). Contaminating plasma protein concentration decreases 
when filtration (0.2 µm) or SEC is used with UC (Muller et al., 2014). Ultrafiltration, using 100 kDa 
or 10 kDa filters, has been explored to isolate exosomes free from protein contamination without 
having to use UC. The disadvantage of using ultrafiltration is that exosomes can become trapped 
in the filter, or shear, as well as the filter becoming clogged (Liga et al., 2015). Hence, filters have 
a short lifespan and can lead to a decrease in exosome concentrations or increased unplanned 
contamination (Table 1.2). 
Centrifugal filters can be used to concentrate exosomes or the biofluid before exosome isolation. 
There are various pore sizes and membrane types. A study compared five centrifugal filters when 
concentrating exosomes isolated using SEC from plasma or urine (Amicon Ultra-2 10k (Merck 
Millipore), Amicon Ultra-2 100k (Merck Millipore), Vivaspin 2 PES 10k (Sartorius Stedim Biotech 
GmbH), Vivaspin 2 CTA 10k (Sartorius Stedim Biotech GmbH) and Vivaspin 2 Hydrosart 10k 
(Sartorius Stedim Biotech GmbH)) (Vergauwen et al., 2017). The 10 kDa regenerated cellulose 
membrane filters (Amicon 10k RC) isolated the highest yield (±3.6x1012 particles/ml) of exosomes. 
The 100 kDa Amicon filter decreased the exosome concentration compared to the 10 kDa; 
however, the other membranes had substantial loss of 80% and the particle loss was even higher 
than that for the 100 kDa Amicon filter. 
1.3.4 Density gradients  
Density gradient centrifugation is a popular isolation method technique and the gradient can be 
created in two ways: continuous density gradient (density increases gradually from the top either 
formed by centrifugation or beforehand) or discontinuous density gradient (density increases in 
discrete steps) (Konoshenko et al., 2018). After a long high-speed centrifugation, the particles 
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separate according to their densities. The floatation density of exosomes is 1.1-1.2 g/ml (Théry et 
al., 2006, Li et al., 2017b) and either sucrose or iodixanol density gradients (OptiPrep) can be 
used. Reports have found that an OptiPrep gradient separates exosomes from viruses better than 
sucrose (Cantin et al., 2008). OptiPrep density gradient UC isolates a purer concentration of 
exosomes than by either UC alone or the ExoQuick and Total Exosome Isolation precipitation 
methods (Van Deun et al., 2014). They showed the density gradient isolated exosomes had an 
increase in exosome markers (Alix, HSP70, TSG101 and CD63), a decrease in contaminating 
proteins (extracellular Ago2 complexes) and a specific mRNA profile related to cellular functions. 
Their gradient was discontinuous ((40% (4 ml), 20% (4 ml), 10% (4 ml), 3.5% (3.5 ml)) and 1 ml 
of conditioned cell culture media was overlaid. A gradient is usually spun for >18 hours and >100 
000 g at 4°C which is time consuming and the high velocity of UC may rupture the EVs (Van Deun 
et al., 2014). Another study found that adding a density gradient after UC and miRCURY kit of 
human serum removed the contaminating human serum proteins; however, even with increasing 
the total protein the exosome markers (CD81 and TSG101) were not detected using western 
blotting (Buschmann et al., 2018) again indicating loss due to multiple step isolations. Actually, a 
potential drawback for density gradients alone is a low yield of exosomes, where a 5-40% 
OptiPrep density gradient isolated only 0.3 µg of exosomes from 106 Rab27B-expressing MCF-7 
cells compared to 0.7 µg using UC and 5 µg using precipitating agents (Van Deun et al., 2014). 
It is to be noted, that the density gradient would have isolated purer exosomes resulting in a lower 
protein concentration. Overall the disadvantages of density gradients are the low yield of 
exosomes, long isolation time, laborious method and potential loss of exosomal biological function 
(Table 1.2).  
1.3.5 Immunoaffinity purification  
Affinity purification selectively isolates exosomes using exosome related antibodies attached to 
differing devices (enzyme-linked immunosorbent assay (ELISA) plates, immuno beads and 
microfluidic plates) (Abramowicz et al., 2016). A microfluidic device such as the immuno-chip 
captures the exosomes based on their surface markers (Chen et al., 2010a). There are a set of 
micro-channels engraved into a structure designed to separate and specifically isolate the 
exosomes. The first immuno-chip using CD63 isolated and purified exosomal RNA within 1 hour 
using 100-400 µl of serum. The RNA extracted was enough for potential use in diagnosing tumour 
cancer. A low cost approach that has been developed is ExoChip, a microfluid device made from 
polydimethylsiloxane with CD63 antibodies (Kanwar et al., 2014). The exosomes were quantified 
using a plate reader after being stained with fluorescent carbocyanine dye and had an exosome 
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protein yield of 15-18 μg and 10-15 ng of total nucleic acids. This device has potential for 
diagnosing cancers as there was a significant increase in fluorescence from five pancreatic 
cancer patients compared to five healthy patients. Microfluidics has the potential in clinical 
settings to diagnose diseases based on quickly characterising their exosomes. However, though 
these devices are useful for analysing exosomes containing specific proteins they are not 
necessarily suitable for broader based exosome research which concern applies to any immune-
based approach. 
Immunoprecipitation (IP) is a widely used small scale immunoaffinity technique for isolating 
biological agents through precipitation of a solid phase attached to the targeting antibody. An 
early study directed at exosome purification was the isolation of B-lymphocyte-derived exosomes 
by targeting human MHC-II (Clayton et al., 2001) with anti-MHC-II antibodies attached to 
paramagnetic beads. Subsequently, the isolated exosomes were analysed by flow cytometry and 
were found to contain immunological molecules MHC class-I and II, B7.1 (CD80) and B7.2 (CD86) 
and ICAM-1 (CD54), as well as B cell marker CD20 and CD59 membrane attack complex-
inhibitory protein. The expression of CD59 may indicate a possible role of antigen present cell-
derived exosomes in complement regulation. As shown above, bead-based isolations can be 
analysed by flow cytometry to quickly quantify binding achieved using fluorophore conjugated 
antibodies or the isolates can be denatured and studied by immunoblot (Théry et al., 2006). 
Exosome attached beads can also be embedded in resin and sectioned for analysis by TEM.  
IP has been used to enrich exosomes, derived from the brain, to provide a potential biomarker for 
neurological disorders to allow for possible detection and treatment (Mustapic et al., 2017). The 
study first used ExoQuick to precipitate the exosomes followed by IP targeting neuronal surface 
markers (neural cell adhesion molecules, NCAM and L1CAM) or control CD81 on plasma 
exosomes. Analysis using immuno-TEM showed IP was specific as the isolated L1CAM 
exosomes had less CD81 present, whereas the CD81 isolated exosomes had an increase in 
CD81. The neuronal-derived EVs enriched from plasma contained increased concentrations of 
signalling components compared to plasma EVs which may provide insight into possible 
biomarkers or therapeutic treatments. In 2017, 1.9% original research papers used IP for isolation 
of exosomes (Konoshenko et al., 2018). The disadvantages of IP are the cost, problems eluting 
the exosomes from the beads whereby the elution can damage the function of exosomes, low 
yield, only specific exosomes isolated and also the potential of non-specific binding (Konoshenko 
et al., 2018) (Table 1.2).  
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1.3.6 Size exclusion chromatography 
By 2014 it became apparent that UC, or density gradient UC, isolated contaminating proteins and 
protein complexes (Yuana et al., 2014). SEC separates molecules according to size using a 
porous stationary phase (variable pore sizes available). Small molecules such as soluble proteins 
will spend time passing through the pores, whereas wider molecules such as exosomes will elute 
first without entering the pores. Sepharose CL-4B or -2B have been used to isolate exosomes 
from blood plasma (Baranyai et al., 2015), saliva (Ogawa et al., 2008) and urine (Lozano-Ramos 
et al., 2015). An early study in 2014 suggested that SEC was an effective single-step exosome 
isolation method, briefly they loaded 1.5 ml of platelet-free supernatant from platelet concentrates 
on a 10 ml Sepharose CL-2B and collected 0.5 ml fractions (Böing et al., 2014). Their results 
showed SEC fractions 9-12 had the highest concentration of vesicles bigger than 70 nm (Figure 
1.2A) as well as platelet-derived exosomes detected using CD61. They also found these fractions 
had <5% of high-density lipoprotein (HDL) (Figure 1.2B) and <1% of protein. The majority of HDL 
was found in fractions 18-20 and proteins in fractions 19-21. An Exo-spin kit is a commercial kit 
combing precipitation and SEC, in which the SEC bed volume is 500 µl with bead pore sizes of 
30 nm and up to 100 µl sample can be loaded. The Exo-spin blood kit was inferior to SEC when 
analysing the proteins in plasma exosomes using mass spectrometry (de Menezes-Neto et al., 
2015). This was due to numerous plasma proteins present in an Exo-spin exosome preparation. 
Their report also supported the use of SEC as a stand-alone method and using mass 
spectrometry identified possible markers for plasma exosomes (CD5 antigen-like (CD5L) and 
galectin-3-binding protein (LGALS3BP)). 
Ultrafiltration-SEC isolated more HEK293T cell culture exosomes than using UC, as determined 
with NTA and western blotting of exosome markers Alix and CD9 (Nordin et al., 2015). The 
structural integrity and biological activity of exosomes after SEC makes it a good candidate for 
therapeutic use, plasma exosomes were isolated from 0.5-1.0 ml plasma loaded on a 10 ml 
Sepharose 2B column and the plasma exosomes from acute myeloid leukaemia cancer patients 
inhibited NKG2D expression which is important for protecting cells by playing a role in anti-tumour 
immune responses (Hong et al., 2016). Furthermore, head and neck squamous cell carcinoma 
plasma exosomes decreased proliferation of T cells which is important for immunity. Hence, SEC 
allows for functional analysis of plasma exosomes particularly for clinical application.  
Sepharose CL-4B and Sephacryl S-400 columns have been shown to isolate plasma exosomes 
whereby the exosome markers (CD9 and CD81) were present in the peak before plasma proteins 
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such as albumin eluted (Baranyai et al., 2015). SEC columns are reproducible, relatively 
inexpensive, remove ~95% of plasma proteins and are quick to use compared to UC. A drawback 
is that the exosomes are diluted which may require ultrafiltration to concentrate them (Baranyai 
et al., 2015) (Table 1.2). However, as mentioned above it has been shown that centrifugal filters 
such as Vivaspin 2 PES 10k, Vivaspin 2 CTA 10k and Vivaspin 2 Hydrosart 10k lead to a 80% 
loss of exosomes isolated from plasma or urine (Vergauwen et al., 2017). Furthermore, 
concentrating the plasma SEC exosomes using either Exo-spin precipitant or UC decreases the 
particle purity by exosome loss (Welton et al., 2015). Another commercial column qEV (Izon) was 
shown to isolate purer plasma exosomes as compared to those isolated with a density gradient, 
ExoQuick and Exo-spin with ExoQuick having the least pure exosomes due to low particle purity 
calculated by particles per µg of protein indicating contaminating proteins present (Lobb et al., 
2015). Co-isolation of lipoproteins in the size range around 40 or 75 nm and above when using 
SEC has been recently reported to be an issue (Sódar et al., 2016, Vergauwen et al., 2017, Karimi 
et al., 2018). This aspect will be discussed in Chapter 3. Interestingly, Sepharose 2B even though 
having a larger pore size was found to have greater albumin contamination of SEC isolated 
plasma exosomes, whereas Sepharose CL-4B or Sephacryl S-400 columns isolated purer plasma 
exosomes without significant albumin contamination (Baranyai et al., 2015). Upscaling SEC may 
be challenging as no increase in plasma exosomes was detected when a 120 ml Sephacryl S-









Figure 1.2: Presence of vesicles and HDL lipoproteins per SEC fraction of platelet-free supernatant from 
platelet concentrates separated on a Sepharose CL-2B column. (A) Vesicles (larger than 70 nm) measured by 








Ultracentrifugation No expensive reagents needed, 
can accommodate large volumes 
of fluid to isolate exosomes 
Expensive equipment needed, long 
isolation time, protein contamination, 
high-speed centrifugation could lead to 
exosome damage 
Precipitation Less time consuming, no 
expensive equipment needed, 
simple to use 
Not specific to exosome isolation, co-
isolation of contaminating proteins, low 
purity, requires pre- and post-
purification steps 
Filtration Decreases protein contamination, 
simple to use, centrifugal filters 
can concentrate exosomes 
Exosomes can become trapped in the 
filter, filter clogging, exosomes can 
shear, increasing filtration steps 
decreases exosome concentration, 
unplanned contamination 
Density gradients Purer exosomes as contaminating 
proteins removed 
Low yield of exosomes, long running 
time, laborious method 
Immunoaffinity Simple, fast, isolates specific 
exosomes, purer exosomes 
Expensive reagents, difficulty eluting 
the exosomes from the solid phase 
resulting in low yield or damage, 
potential of non-specific binding, only 
subset of exosomes isolated 
Size exclusion 
chromatography 
Retains exosomal structural 
integrity and biological activity, 
reproducible, relatively 
inexpensive, minimal protein 
contamination, quick, simple to 
use 
Exosomes are diluted, co-isolated 
lipoproteins, difficult to optimise scale 
up, only one sample processed in one 
column run 
Modified from (Li et al., 2017b). 
 
1.4 Characterising exosomes 
As discussed above, all the exosome isolation methods have drawbacks and currently there is no 
“gold standard method” to isolate pure exosomes. The International Society for Extracellular 
Vesicles (ISEV) provides researchers with a set of minimal experimental requirements to identify 
the presence of exosomes to ascertain their specific composition and function (minimal 
information for studies of extracellular vesicles 2014 (MISEV2014); updated in 2018 
(MISEV2018)) (Lötvall et al., 2014, Théry et al., 2018). When reporting a study, the exosome 
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isolation method used should be described in detail, the characteristics of the exosomes should 
be clearly displayed and examined. Although exosomes do not have definitive markers they have 
been found to be enriched in certain biomolecules and together with other techniques their 
isolation is confirmed based on their biophysical and molecular properties. In 2014, ISEV 
suggested that a minimum of 2 different characterisation methods be used to identify exosomes 
(Lötvall et al., 2014). Western blotting, ELISA, flow cytometric analysis, electron microscopy, RT-
qPCR, NTA and atomic force microscopy (AFM) are some of the popular techniques used to 
identify and characterise exosomes. In 2016, the 3 most commonly used exosome 
characterisation methods were western blotting (74%), particle tracking (72%) and electron 
microscopy (60%) (Gardiner et al., 2016). About a third of publications report 3 characterisation 
methods with only 12% of researchers using 5 or more methods. The guidelines for nomenclature, 
collection and pre-processing of fluids for EV extraction, EV preparation and concentration, EV 
characterisation, functional studies and reporting were revised and updated which are found in 
MISEV2018 (Théry et al., 2018). EV-TRACK (http://evtrack.org/) encourages researchers to 
upload their published and unpublished experiments to assist in standardising EV research. 
1.4.1 Electron microscopy 
In general, electron microscopy (either transmission or scanning) will reveal the presence, size 
and morphology of vesicles obtained using various exosome isolation methods. However, 
electron microscopy is not quantitative due to the variability of vesicles attaching to the grid for 
visualisation and the numerous and variable steps involved in sample preparation (Turchinovich 
et al., 2015). Multiple electron micrographs can be taken to measure the average diameter of the 
exosomes, which should reveal a diameter between 30-100 nm. When using TEM with negative 
staining the exosomes will have a cup-shaped morphology (Figure 1.3A), opposed to when using 
cryo-electron microscopy where they are round vesicles (Figure 1.3B) (Conde-Vancells et al., 
2008, Banizs et al., 2014). It must be considered that the cup-shaped morphology could be due 
to an exosome collapsing during TEM preparation (Banizs et al., 2014). Considering the literature 
on electron microscope analysis of exosomes, it is apparent that results vary in terms of diameter 
and morphology of exosomes. For example, TEM analyses have revealed that serum-derived 
exosomes isolated using ExoQuick are spherical and 30-100 nm (Jia et al., 2017), 293T cell-
derived exosomes isolated using Exosome Isolation Kit (Invitrogen) are spherical and 40-120 nm, 
whereby the exosome pellet was fixed in 2.5% glutaraldehyde prior to TEM analysis (Li et al., 
2016a) and porcine reproductive and respiratory syndrome infected cell-derived exosomes 
isolated using PEG precipitation and CD63 IP, are cup-shaped and 30-150 nm (Wang et al., 
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2018c). Thus, it is challenging to interpret and compare different research studies. It may be 
accounted by different exosome isolation methods, differing methods to prepare the micrograph 
grids, and possibly selective imaging and publishing of micrograph grids. One study found 
differences when they used four different TEM protocols which are commonly used in the 
exosome field that varied with fixation, absorption and negative staining methods (Rikkert et al., 
2019). They found only one method that had similar images (comparable and reproducible) when 
either the image location was either selected by the operator or was at a predetermined location, 
this method used 400 mesh carbon coated copper grids, absorption of 2 minutes, blotting for 
washing and 2% uranyl acetate for <2 min. Hence, standardisation is required for TEM protocols 
for grid preparation and image selection. For both TEM and AFM, ISEV suggests capturing a wide 
field image containing numerous EVs and a close-up image of single EVs to allow the analyses 
of the entirety of the isolate (Lötvall et al., 2014, Théry et al., 2018). A further complication, is if 
the exosome isolates are not pure, it is difficult to identify the difference between proteins, 
exosomes, lipoproteins and other EV subtypes using TEM (Simonsen, 2017). A possible 
alternative method is visualising the EVs using immunogold TEM to reveal the presence of 














Figure 1.3: TEM analysis of primary endothelial cell-derived exosomes. (A) Classic TEM showing cup-shaped 
vesicles, inset of a collapsed exosome; (B) Cryo-electron microscopy showing circular membrane bound vesicles. 





1.4.2 Enzyme-linked immunosorbent assay and western blot 
Due to exosomes budding off from endosomes they contain integrins and tetraspanins (e.g. CD9, 
CD63 and CD81), membrane transport and fusion proteins (e.g. annexins, flotillin and Rab 
GTPases), proteins needed for MVB biogenesis (Alix and TSG101) and heat shock proteins 
(HSP70 and HSP90) needed for cellular processes (Yu et al., 2014). Moreover, they have lipid-
related proteins and raft lipids (e.g. cholesterol, ceramide, phospholipases and sphingolipids). 
ELISA and western blot are commonly used to identify the presence of enriched proteins in an 
exosome sample. Most research groups use western blotting with anti-CD63, anti-CD9, anti-
CD81 and anti-HSP70 antibodies to confirm exosome isolation where the size of the bands should 
be about 53, 28, 26 and 53-70 kDa respectively (Lai et al., 2010). There are commercial exosome 
ELISA kits available to quantify exosomes such as ExoQuant™ Exosome ELISA Kit (BioVision), 
ExoELISA-ULTRA CD63 (System Biosciences) and ExoAssay™ Human Plasma Overall 
Exosome ELISA Kit for CD9 (Creative Diagnostics®). One group developed their own sandwich 
ELISA (Exotest) to quantify exosomes in plasma using CD63 and Rab-5b (Logozzi et al., 2009). 
Their study showed CD63 positive melanoma-cell derived exosomes were detected in a dose-
dependent manner as the exosome concentration increased from 3.1 µg to 50 µg. The Exotest 
only required a minimum of 3 µg of exosome protein which was more sensitive than the western 
blot which required 12.5 µg of exosomes. However, there are major differences in exosome 
protein content using different purification protocols and a high exosome protein yield may 
indicate contaminants, discussed earlier (Section 1.3). 
ISEV recommend a minimum of 3 proteins to be detected and they should come from different 
categories such as transmembrane proteins (CD9, CD63 and CD81) and cytosolic proteins 
(TSG101, annexins and Rabs) (Lötvall et al., 2014). ISEV also suggests that the proteins from 
cell culture-derived exosomes should be compared to the cell’s proteins to detect the enrichment 
of markers after exosome isolation. A negative protein marker control is used to confirm the 
absence of cellular proteins not found in exosomes, such as calnexin, in exosome samples. 
However, this is not possible for body fluid-derived exosomes due to the variety of cells secreting 
exosomes. ISEV suggests the antibody details (company name, catalogue number, dilution), 
exposure time and SDS-PAGE conditions should be reported (Lötvall et al., 2014). Western 
blotting or ELISA have issues in representing the actual quantity of exosomes isolated, as any 
co-isolated exosome proteins will also be detected. Furthermore, they will not differentiate 
between microvesicles and exosomes (Tauro et al., 2012). This again highlights the need for a 
specific exosome marker to be discovered.  
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1.4.3 Flow cytometry 
Flow cytometry is a method used to reproducibly analyse the varying physical and chemical 
characteristics of cells using analysis of the scatter of laser light and concomitant emitted 
fluorescent light. Ideally flow cytometry relies on the analysis of a single cell at a time but particles 
less than 300 nm cannot be detected by conventional flow cytometry (van der Pol et al., 2010). 
The latter necessarily limits the analysis of exosomes and therefore indirect measurement of 
exosomes captured on microbeads is performed. Exosomes can be captured relatively non-
specifically on aldehyde containing beads (Suárez et al., 2017) or through beads coated with 
exosome markers such as anti-CD9. The beads containing exosomes are then stained with 
fluorescently labelled detector antibodies (Wiklander et al., 2018). Using a capture antibody 
approach is inherently more precise but also has the potential for greater bias. Flow cytometry 
especially with a multiplex approach allows for significant information but the use of beads does 
introduce variability and can only be semi-quantitative in nature. A major and very recent advance 
is through the use of imaging flow cytometry which promises to allow for detection of single 
exosomes across the entire range of sizes (Mastoridis et al., 2018). Though a significant advance, 
the method requires dedicated specialised equipment and still needs standardisation with regards 
to issues such as differential forward scattering by exosomes, low intensity fluorescence of single 
exosomes and for “swarming” to contaminate data (Welsh et al., 2017). 
1.4.4 Quantitative PCR  
RT-qPCR due to its great sensitivity is the technique of choice for quantifying the miRNA present 
in exosomes. It is used to monitor the changes in exosomal miRNA levels in patients, animal 
models and cell culture media. The exosomal cargo does change depending on the parent cell 
and the environmental condition the cells are in.  For example, radiation induced changes in 9 out 
of 214 plasma exosome proteins and significantly increased the concentration of miR-204-5p, 
miR-92a-3p and miR-31-5p (Yentrapalli et al., 2017). Numerous miRNAs such as miR-16, miR-
24, miR-26a, miR-451 and let7e have been detected in exosomes using RT-qPCR (Schageman 
et al., 2013). A much-discussed concern with respect to RT-qPCR-based quantification of miRNA 
in exosomes is the lack of consensus on normalising the PCR output. Presently, the most 
accepted approaches are complex and involve application of a global mean or identification of 
stably expressed miRNAs through the use of specialised algorithms (Thorsen et al., 2017).  
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1.4.5 Nanoparticle tracking analysis 
NTA is a method used to determine the size and concentration of exosomes isolated from cell 
culture media or biological fluids. The measurement is based on the properties of the laser light 
scattering on particles experiencing random Brownian motion. The exosomes are tracked by 
recording a video of their movements and their hydrodynamic radius is calculated by their mean 
squared displacement and the data is shown as a distribution graph (Soo et al., 2012). Specificity 
and sensitivity of NTA can be improved by either fluorescently labelling the general exosome 
population with CellMask Orange™ (Carnell-Morris et al., 2017) or using fluorescently labelled 
antibodies (Oosthuyzen et al., 2013). NTA has detected the size of bone marrow stromal cell and 
multiple myeloma cell-derived exosomes to range from 50-250 nm (Wang et al., 2014). These 
diameters were larger than the diameter of the cup-shaped exosomes measured by TEM (50-80 
nm). A reason for this could be that NTA has a lower sensitivity for particles between 20-60 nm. 
Another study using NTA had similar results, also detecting larger diameters (mean 175 nm) for 
adipose tissue MSC-derived exosomes (Katsuda et al., 2013). In 2016, NTA was the most 
commonly used particle analyser (80% of researchers) followed by 18% using tunable resistive 
pulse sensing and 12% using dynamic light scattering (Gardiner et al., 2016). NTA results should 
also be analysed with caution as a previous study detected the majority of plasma exosomes 
isolated using a large scale Sephacryl S-400 SEC column appeared in a different fraction using 
NTA (fraction 4, ±85-105 ml) as compared to their western blot detection of exosome markers 
CD63 and TSG101 (pooled fraction 1-3, ±40-85 ml), which it was speculated was due to NTA 
being unable to accurately detect particle diameters less than 70 nm (Baranyai et al., 2015). 
Another major drawback of non-fluorescent NTA is its inability to distinguish between synthetic 
nanoparticles, protein aggregates, lipoproteins and EV subtypes including exosomes (Gercel-
Taylor et al., 2012). Furthermore, one study showed 1-12% coefficient of variation of sequential 
NTA readings of the same sample within one day and 2-25% coefficient of variation of day-to-day 
readings of EVs and artificial vesicles with the same operator and machine (Vestad et al., 2017). 
They also detected significant variation in NTA results between two instruments from different 
laboratories using the same software settings. These findings highlight the need for standardising 
NTA analysis.  
1.4.6 Atomic force microscopy 
AFM is a quantitative and sensitive nanoscale method used to characterise exosomes. It has only 
recently begun to be utilised as in 2016 only 9% of researchers used AFM (Gardiner et al., 2016). 
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This method can characterise the exosomes’ shape, size and density. A 3D image is created 
without using electron dense staining, fixation or extreme temperatures that normal electron 
microscopes use (Sharma and Gimzewski, 2012). Biological fluid-derived particles from plasma 
(Yuana et al., 2010) and exosomes from human saliva (Palanisamy et al., 2010) have been 
analysed using AFM. The saliva-derived exosomes revealed a flattened donut-like shape in a 3D 
image, and had a diameter of 65 nm and a height of 2.5 nm (Palanisamy et al., 2010), correlating 
to previously mentioned TEM findings for exosomes. The plasma analysis revealed spherical 
microparticles with a range of 10 to 475 nm and mean diameter of 67.5 nm ±26.5 (Yuana et al., 
2010). After 0.22 µm filtration the mean diameter was 37.2 nm ±11.6. The study did not investigate 
the proportion of exosomes present in the microparticle population. A drawback of AFM is the 
slow scan speed and cost. Additionally, image analysis of AFM results is also tedious requiring a 
standard linear regression subtraction, Labview IMAQ to locate the vesicles and a background 
subtraction calculation to create a flatter surface (Ashcroft et al., 2012). 
 
1.5 Function of exosomes 
The physiological function of exosomes is an undoubtedly complex subject that is constantly 
evolving as research progresses. The initial hypothesis was that exosomes were involved in 
waste management allowing for removal of unwanted proteins (Johnstone, 1992). Currently 
exosomes are known to be involved in paracrine signalling and integral to the communication 
function is their lipid membrane which protects the signalling cargo (Sahoo and Losordo, 2014). 
In the last decade, the role of exosomes in cell to cell communication have been studied with 
respect to influences on physiological and pathological processes, such as immune response, 
angiogenesis, therapeutic regeneration and pathology.  
1.5.1 Immune function 
The role of exosomes in immune responses have been explored and been recently and 
thoroughly reviewed in (Wu et al., 2019b). It is difficult to tell that exosomes are the driving entities 
of cellular physiology and pathology with the present technology. Exposure to magnetic iron oxide 
nanoparticles has been shown to cause a dose-dependent increase in exosome release into the 
alveolar region of BALB/c mice which quickly circulated into the immune system resulting in a 
maturation of dendritic cells and activation of splenic T cells, implicating exosomes in immune 
activation (Zhu et al., 2012). It was suggested that the MHC-I, MHC-II and CD80 detected on the 
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exosomes may have assisted in the immune defence mechanism. Further to the in vivo-based 
study on exosome involvement in immunity discussed above, in vitro studies support this 
immunity involvement. Human breast milk-derived exosomes may play a role in immune 
modulation, as a functional in vitro assay (enzyme-linked immunospot assay) showed they 
inhibited cytokine production of IL-2, interferon gamma (IFN-γ), and tumour necrosis factor alpha 
(TNF-α) which was induced by anti-CD3 blocking T cell activation in peripheral blood mononuclear 
cells (Admyre et al., 2007). Removing both CD81 and MHC-II exosomes decreased the inhibition 
of IL-2 production showing that the exosomes were contributing to the inhibition; however, they 
couldn’t rule out the possible effect of co-isolated soluble milk proteins. Furthermore, peripheral 
blood mononuclear cells incubated with 500 µg/ml milk-derived exosomes increased specific T 
regulatory cells, which may have suppressed the effector T cells to release cytokines. T and B 
lymphocytes have a key role in cell-mediated immunity, the antigen presenting cells (such as B 
cells or dendritic cells) present the antigens bound onto MHC-I or MHC-II complexes to the T cells 
for an immune response (Germain and Margulies, 1993). It has been shown that human and 
mouse B-cell derived exosomes carry these peptide-MHC-II complexes for antigen presentation 
to CD8+ and CD4+ T cells (Raposo et al., 1996, Segura et al., 2007). Exosomes derived from 
cancerous and non-cancerous amniotic fluid also have potential immunomodulatory capacities. 
A study showed the exosomes to be internalised into human monocytic THP-1 cells which 
activated secretion of inflammatory cytokines IL-1β, TNF-α, and IL-6 (Bretz et al., 2013). Analysis 
of phosphorylation revealed stimulation of nuclear factor kappa-light-chain-enhancer of activated 
B cells/signal transducer and activator of transcription 3 (NF-kB/STAT3) mediated cytokine 
release via a toll like receptor (TLR)-dependent signalling pathway.  
1.5.2 Angiogenic function 
Angiogenesis is a vital part of healing and reproduction (Otrock et al., 2007). Platelet-derived EVs 
have been detected at sites of angiogenic sprouts, vessel sprouts composed of endothelial cells 
which are activated in response to angiogenic stimuli, in mice which underwent hypoxia-induced 
retinal neovascularisation and may deliver pro-angiogenic components (Rhee et al., 2004). 
Endothelial progenitor blood cell-derived exosomes have been reported to stimulate angiogenesis 
in vivo (Deregibus et al., 2007). Severe combined immunodeficient (SCID) mice injected 
subcutaneously with human microvascular endothelial cells (HMEC) (pretreated with 30 µg/ml 
exosomes for 30 minutes at 37°C) in Matrigel, formed vessels after 7 days whilst untreated HMEC 
did not. Here horizontal mRNA transfer was the proposed mechanism as RT-qPCR detected 
mRNA within the exosomes, which is associated with PI3K/Akt signalling pathway that is linked 
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to the angiogenic response. It should be noted that HMEC treated with exosomes exposed to 
RNAse also did not form vessels. In light of the present knowledge that the contents of exosomes 
are protected from RNAses, it is not immediately clear how this abrogation of the angiogenic effect 
occurred. There is a fairly substantial body of in vitro evidence supporting the involvement of 
exosomes in angiogenesis. Using a real-time cell imaging system, it has been seen that placental 
MSC-derived exosomes help placental HMEC migrate after a scratch wound assay (Salomon et 
al., 2013). The exosomes increased the tube formation as the oxygen concentrations decreased 
(hypoxia). Another experiment also used a cell invasion assay which showed that adipose MSC 
EVs increased the invasiveness of HMEC and promoted in vitro vessel-like structures (Lopatina 
et al., 2014). It was further found that adipose MSCs stimulated with platelet-derived growth 
factor-BB (PDGF-BB), but not vascular endothelial growth factor (VEGF) and basic fibroblast 
growth factor (bFGF) increased exosome release with pro-angiogenic molecules such as stem 
cell factor which improved their angiogenic response. It has also been shown that cardiosphere-
derived cell exosomes induced tube formation in a HUVEC angiogenesis assay, moreover, they 
stimulated angiogenesis to a greater extent than normal human dermal fibroblast (HdFb) 
exosomes (Ibrahim et al., 2014). In the same study it was also shown that neonatal rat 
cardiomyocytes had greater proliferation with cardiosphere-derived cell exosomes as well as 
decreased apoptosis. 
1.5.3 Cardiac function 
Myocardial infarction (MI) is a worldwide problem causing death and heart failure. It affected 7.6 
million Americans in 2015 (Mozaffarian et al., 2015). Heart attack or MI is most commonly caused 
by a blood clot and MI refers to the damaged heart muscle. Exosomes have been shown to 
partake in remote ischemic preconditioning (RIPC), which is phenomenon where brief ischemia 
events in a remote tissue can protect the target organ from ischemia injury. Exosomes may also 
decrease cardiac dysfunction and remodelling. The damage caused by a MI (Enoki et al., 2010) 
or diabetic cardiac disease (Huynh et al., 2010) can be protected by cardiac activation of insulin-
like growth factor-1 receptor (IGF-1R). Serum-derived exosomes from rats that underwent RIPC 
contained a high concentration of IGF-1R protein (Yamaguchi et al., 2015). IGF-1R was also 
expressed in the remote non-infarcted myocardium and skeletal muscles of the hindlimbs. Their 
in vitro study revealed that hypoxic conditions (which occur during an ischemic event) increased 
the concentration of IGF-1R in C2C12-derived exosomes and not in the cell lysates. Overall, their 
results indicate that exosomes may have transferred IGF-1R from the hindlimb into the 
cardiomyocytes. Plasma exosomes are suggested to be cardioprotective, the study isolated 
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human plasma exosomes before and after male volunteers underwent RIPC, which involved four 
cycles of 5 min upper limb ischemia and 5 min reperfusion (Liu et al., 2015). They assessed for 
in vitro cardioprotection whereby rat ventricular cardiomyocytes underwent 2.5 hours of simulated 
ischemia and 1 hour simulated reperfusion and the plasma exosomes were administered either 
30 minutes or 24 hours before hypoxia. Their findings showed that control or RIPC exosomes 
were able to elicit in vitro cardioprotection acutely or after 24 hours. The lack of difference between 
the control and RIPC exosomes may be due to their varied particle dosage, ~1.06×107 control 
exosomes and 1.80×107 RIPC exosomes as equal volumes were used in the experiment. Further 
literature on the regenerative properties of cell and blood-derived exosomes will be discussed in 
section 1.6.1 and 1.7.4 respectively.  
1.5.4 Pathological function 
Not all exosomes have therapeutic benefits as tumour cells appear to release exosomes to assist 
in tumour growth (Whiteside, 2016). It was reported that mouse melanoma cells secreting tumour-
derived exosomes primed a bone marrow environment to transform into a melanoma environment 
using a MET receptor (Peinado et al., 2012). In addition, tumour-derived exosomes were found 
to inhibit maturation of dendritic cells and human monocytes in vitro, and in vivo though tumour-
derived exosomes caused less inhibition of bone marrow dendritic cell differentiation in IL-6 
knockout mice, suggesting a relationship between tumour exosomes and IL-6 in bone marrow 
dendritic cell differentiation (Yu et al., 2007). There are studies that suggest that exosomes can 
alter cellular phenotypes by interacting with surface receptors. Tumour-derived exosomes 
promoted the metastatic phenotype of primary tumours using the MET-receptor on bone marrow 
progenitor cells (Peinado et al., 2012). Exosomes also play a role in diseases such as 
neurodegeneration (prion, Alzheimer’s and Parkinson’s disease) and harbour neurodegenerative-
associated proteins (prion protein, β-amyloid and α-synuclein) (Vella et al., 2016). Microparticles, 
100-1000 nm vesicles released from cells undergoing cellular activation and apoptosis, are also 
suggested to contribute to  a variety of disease states, reviewed in (Bebawy et al., 2013). Though 
pathological in nature, these findings do reinforce the understanding that EVs function as cell-to-
cell communication vehicles. 
In summary, exosomes derived from cultured cells, blood and other biofluids have various 
functional properties. It should be noted that above are indirect evidence of physiological and 
pathological functions. The inability to knockout or overexpress exosomes, or directly modify their 
contents in vivo is a clear limitation in gaining direct evidence for their roles. Understanding the 
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mechanisms of exosomes also remain challenging as most research relies on a mixed population 
of exosomes to determine their function. A very recent paper suggested a way forward to 
overcome some of these issues through the development of an in vivo model using zebrafish 
embryos to track individual exosomes (Verweij et al., 2018). They developed a CD63-pHluorin 
reporter which is a fluorescent tetraspanin-based pH-sensitive reporter that targets late 
endosomes, labelling exosomes for detection. Using this reporter, they live tracked individual 
exosomes and observed a large exosome release from the yolk syncytial layer into the blood 
stream which was regulated by syntenin as shown through knock-down. Furthermore, they found 
the exosomes were internalised by macrophages and endothelial cells for lyosomal degradation 
near the tail using high-speed imaging. This technique could be used to examine more directly 
exosome function in vivo (Verweij et al., 2019).  
 
1.6 Source of therapeutic exosomes 
Exosomes have been isolated from many cell types that include dendritic cells, cancer cells, stem 
cells, endothelial cells, B cells, T cells, tumour cells, mast cells and neurons (Tsao et al., 2014, 
Huang et al., 2015). They are also isolated from almost all body fluids inclusive of blood, saliva 
and urine. Though exosome studies have been dominated by cell culture-based approaches due 
to their potentially more defined nature, there is increasing interest in those from body fluids, 
mainly due to their promise as biomarkers but also more recently for their possible therapeutic 
effects. MSCs have been most extensively studied for application in regenerative medicine, thus 
they were focused on. 
1.6.1 Cell culture exosomes 
MSCs and their secretome has been extensively reviewed as a possible therapy to treat human 
diseases (Salgado et al., 2015, Konala et al., 2016, Cunningham et al., 2018). Bone marrow 
culture was where MSCs were first discovered (Friedenstein et al., 1976). These stem cells can 
be obtained from various species and tissues (adipose, bone marrow, dental pulp and umbilical 
cord). They are heterogeneous in shape (spindle shaped to cuboidal), have plastic adherence 
and express markers such as Sca-1, CD105, CD73, CD29 and CD90 (Konala et al., 2016). MSCs 
are adult stem cells which are capable of self-renewal and differentiation into various cell types 
such as adipocytes, chondrocytes and osteoblasts (Pittenger et al., 1999). They can be used in 
autologous or allogeneic stem cell transplants as they are suggested to be hypoimmunogenic 
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(Beyth et al., 2005) and have been widely explored in regenerative-based therapeutic strategies. 
The initial hypothesis was that their ability to differentiate was behind therapeutic effects observed 
in tissues such as the heart and brain but it has become clear that a paracrine effect is responsible 
(Fitzsimmons et al., 2018). Human MSC-conditioned media has been found to be effective for MI 
(Timmers et al., 2008), liver (Van Poll et al., 2008) and kidney injuries (Zarjou et al., 2010). In 
2008, conditioned media from human embryonic stem cell-derived MSCs decreased infarct size 
by 60% in pig and mouse models of myocardial ischemia/reperfusion injury (Timmers et al., 2008). 
Their fractionation studies identified the cardioprotective component was 50-200 nm in size. In 
2010, the cardioprotective component was identified as exosomes determined by TEM and 
enrichment of exosome markers Alix, CD9 and CD81 (Lai et al., 2010). These MSC-derived 
exosomes were then shown in mice suffering from an ischemia/reperfusion injury to reduce 
myocardial injury. A follow up study showed that mice suffering from ischemia/reperfusion injury 
had decreased levels of misfolded proteins when treated with MSC exosomes indicated a 
possible mechanism for their cardiac protection (Lai et al., 2012). Exosomes derived from MSCs 
had proteasome subunits and the 20S proteasome was detected using mass spectrometry. The 
20S proteasome may contribute toward the cardiac therapeutic benefit of MSC-derived exosomes 
as their function is to breakdown oxidatively damaged proteins; which correlated with the fact that 
misfolded proteins are reduced in mice suffering from a myocardial ischemia/reperfusion injury 
when injected with MSC-derived exosomes.  
There are some studies that investigated the regenerative potential of exosomes derived from 
cells other than MSCs. It has been demonstrated that cardiomyoctyes that had undergone 
simulated ischemia and reperfusion when preincubated with 108/ml preconditioned HUVEC-
derived exosomes, had significantly decreased apoptosis from 88% ±4 to 55% ±3 (Davidson et 
al., 2018b). Ischemic preconditioning of the HUVECs (hypoxic chamber for 30 minutes) increased 
exosome concentration three times to control HUVEC-derived exosomes. Cardioprotection 
needed ERK1/2 MAPK signalling pathway, shown by inhibition using PD98059 and U0126. 
Dendritic cell-derived exosomes have seen to promote migration of MSCs through a transwell 
system in a dose dependent manner (10 µg and 50 µg exosomes) and through a 2D chemotaxis 
chamber (10 µg exosomes) (Silva et al., 2017). However, their analysis revealed dendritic-cell 
derived exosomes did not influence MSC proliferation or differentiation. 
It has been shown that MSCs can secrete more exosomes than other cells (myoblast and human 
embryonic kidney cell line), as determined with CD81 ELISA to detect the relative exosome 
concentration secreted after 3 days by various cell lines (Yeo et al., 2013). The MSC-derived 
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exosomes express adhesion molecules from their MSC parent cell (CD44, CD73 and CD90) as 
well as the common surface markers (CD9 and CD81) (Ramos et al., 2016). There have been 
attempts to compare the therapeutic effects of MSC-exosomes to MSCs, such as in a rat MI model 
(Bian et al., 2014) and mice with brain ischemia (Doeppner et al., 2015), where they show similar 
regenerative effects. A recent study has indicated that exosomes from different MSC are not 
identical. Bone marrow- and umbilical cord-derived MSC exosomes inhibited cell proliferation and 
caused apoptosis of glioblastoma cells in vitro whilst adipose tissue-derived MSC exosomes 
increased cell proliferation and had no effect on cell survival of glioblastoma cells (Del Fattore et 
al., 2015).  
Exosomes also play a role in the niche function of different stem cells. MSC-derived exosomes 
from multiple myeloma patients increased multiple myeloma cell growth in vitro and promoted 
tumour growth in SCID mice more than those from normal patients (Roccaro et al., 2013). 
Fluorescent exosome internalisation studies confirmed the multiple myeloma MSC-derived 
exosomes were secreted and transferred to the multiple myeloma cells. The multiple myeloma 
MSC-derived exosomes contained a decreased concentration of tumour suppressor miR-15a and 
an increased concentration of oncogenic cytokines and proteins compared to those from healthy 
MSC-derived exosomes. It has also been found that healthy limbal stromal (eye) cell-derived 
exosomes increase wound healing, migration and proliferation of limbal epithelial cells in healthy 
and diabetic corneas relative to diabetic limbal stromal cell-derived exosomes (Leszczynska et 
al., 2018). Western blot analysis identified increased Akt phosphorylation in the wounded limbal 
epithelial cells and organ-cultured corneas treated with the healthy exosomes which may have 
promoted the wound healing. Next generation sequencing revealed small RNA differences in the 
diabetic exosomes versus the healthy exosomes which may have brought about the diseased 
niche. 
It should be noted that cell culture conditions are of necessity not optimal as a potential contributor 
of contamination within cell culture-derived exosomes is foetal bovine serum (FBS), due to its 
own EVs and lipoproteins. Researchers tend to use FBS that has been ultracentrifuged for 18 
hours at 100 000 g to remove the exosomes. However, FBS RNA could still interfere with RNA 
analysis of exosomes (Wei et al., 2016b). Using serum-free conditions also poses problems as 
the cells may stop growing and enter apoptosis which could influence exosomes released (Sluijter 
et al., 2018). 
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1.6.1.1 Clinical trials with cell-derived exosomes 
The move towards therapeutic use of exosomes in clinical trials has grown due to increasing 
evidence on the benefits of exosomes. Dendritic cell-derived exosomes can induce T cell 
responses and tumour rejection as the exosomes contain MHC-I and MHC-II (Pitt et al., 2016, Liu 
et al., 2017a). From 2000 to 2002 the first phase I clinical trial used exosomes derived from 
autologous dendritic cells. Each of the 15 patients suffering from stage III/IV melanoma received 
4 exosome vaccinations intradermally and subcutaneously over one month (Escudier et al., 
2005). The exosomes were pulsed with melanoma-associated antigen 3 (MAGE3) peptides, 
which tumours express, to immunise the patients. Only one patient had a slight response when 
using the Response Evaluation Criteria In Solid Tumours (RECIST). This phase I trial showed 
that the exosomes were safe to use as no MAGE3 specific CD4+ and CD8+ T cell immune 
reaction was detected. Furthermore, autologous dendritic cell-derived exosomes have also been 
administered to patients with non-small cell, lung cancer (Morse et al., 2005). The dosage was 
the same where 4 injections were given at weekly intervals. The exosomes were also loaded with 
tumour antigens MAGE-A3, -A4, -A10 and -3DPO4 peptides. In contrast to Escudier et al. the 
results showed that 1/3 of the patients had a MAGE specific T cell response. Some patients also 
did not have the cancer spread while undergoing treatment. 
Another phase I clinical trial subcutaneously injected autologous ascites-derived exosomes four 
times at weekly intervals to 40 patients with colorectal cancer (Dai et al., 2008). Granulocyte 
macrophage colony stimulating factor (GM-CSF) was used as an adjuvant together with the 
exosomes. Their results showed that the exosomes alone are immunogenic; however, only the 
exosomes with the GM-CSF promoted an anti-tumour specific cytotoxic T lymphocyte response 
specific for carcinoembryonic antigen peptide-1 (CAP-1) (20% response exosome alone versus 
76.9% exosome plus GM-CSF). Hence, ascites-derived exosomes with GM-CSF adjuvant could 
be used as a vaccine. This is a potential immunotherapy method to treat colorectal cancer and it 
is safe and viable. 
The market of exosome diagnostics and therapeutics is expected to increase from $16.1 million 
in 2016 to $111.8 million in 2021 (Tcherpakov, 2016). Moreover, USA grants by National Institutes 
of Health (NIH) increased by 201% from 2000 to 2016 for research done on exosomes or 
microvesicles (Roy et al., 2018). Interestingly blood as the source reflects over 93% of the market 
share (Tcherpakov, 2016) but this most likely reflects the immense amount of research directed 
towards finding exosome biomarkers for diagnosing diseases such as cancer. A crucial question 
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now is how to standardise exosome isolations to allow clinical trials to proceed with more defined 
preparations of exosomes. 
1.6.2 Blood 
1.6.2.1 Regenerative plasma and platelet-rich plasma 
Serum and plasma samples are commonly investigated for biomarking potential as blood is easy 
to collect and process. Serum and plasma samples are processed differently after blood collection 
(Liu et al., 2018a). Serum is generated by allowing the blood to clot at room temperature (RT) for 
about 30-60 minutes and may contain coagulation enhancers. A clots forms which removes the 
majority of the fibrinogen and platelets which have either activated or attached to the clot 
(Lundblad, 2005). Plasma blood collection tubes contain materials to prevent coagulation (Liu et 
al., 2018a). There is also increasing evidence that blood may contain components that have 
regenerative potential function (Villeda et al., 2014, Wyss-Coray, 2016, Sun et al., 2019). Perhaps 
one of the more dramatic indications of this is the range of studies that have shown that blood 
plasma from young mice can reverse cardiac hypertrophy and cognitive dysfunction in aging mice, 
though it must be emphasised that these benefits were accrued after extensive periods of 
parabiosis (Pusic and Kraig, 2014). A further broad indication of this potential is the extensive 
research into the use of platelet-rich plasma (PRP) in regenerative approaches. PRP contains a 
high concentration of platelets in a small volume of plasma and once these platelets are activated 
they release a pool of proteins, growth factors, cytokines and exosomes (Anitua et al., 2015). 
Plasma isolations use higher centrifugations speeds compared to PRP e.g. 1000-2000 g for 1 
minutes to remove cells, followed by 2000 g for 15 minutes to remove majority of the platelets. 
PRP methods vary; however, they all use “soft spins” compared to plasma isolation e.g. 180 g for 
10 minutes to centrifuge the blood, followed by 890 g for 10 minutes to centrifuge the plasma and 
obtain the platelet concentrate i.e. PRP, which is the lower 1/3rd fraction (Etulain et al., 2018). The 
platelets are enriched in growth factors which are important for wound healing initiation (Marx, 
2004). 
Human PRP has the potential to treat late stage cerebrorenal syndrome which is associated with 
acute kidney injury and ischemic stroke. A late stage cerebrorenal syndrome rat model was 
injected with 80 µl PRP via left common carotid artery and abdominal aorta followed by acute 
kidney ischemia-reperfusion and acute ischemic stroke (Yip et al., 2019). At day 28, PRP treated 
rats showed protection in the brain and kidney through inhibition of inflammation as well as 
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improved neurological function and decreased expression of brain-related DNA, mitochondrial 
damage and oxidative-stress biomarkers and; improved renal function, increased podocyte 
components and decreased collagen deposition and fibrosis. 
PRP is being studied in clinical trials for various regenerative purposes in therapeutic targets as 
wide-ranging as ulcer wounds, tendon injuries, cosmetic purposes, scar healing and hair loss 
(Alves and Grimalt, 2018). One study using freeze-dried PRP together with a gelatin sheet 
showed an ulcer wound had substantially epithelised (phase 1, randomised controlled single-
center trial) (Lin et al., 2019). The gelatin hydrogel allowed for a sustained release of the PRP. 
Interestingly, PRP (1 ml) has been found to have a more pronounced affect than MSCs (3×106 
cells in 1 ml) on wound healing suppressed by corticosteroid in rats after 10 days (Aydin et al., 
2018). 
PRP has been used to treat various musculoskeletal indications, especially for tendon pathologies 
caused by sport injuries (Kon et al., 2011). A randomised blinded phase 1 clinical study enrolled 
36 patients for intraoperative injection of control or PRP for acute Achilles tendon rupture repair 
(Zou et al., 2016). The PRP patient group had significantly better isokinetic muscle at 3 months 
and increased Short Form-36 and Leppilahti scores (protocol for evaluating outcome) at 6 and 12 
months. At 24 months, PRP patient group had significantly improved ankle range of motion. A 
level I, meta-analysis of level I studies showed that intra-articular injection of PRP for knee 
osteoarthritis compared to hyaluronic acid and saline, significantly improved the function and pain 
relief at 1 year (Dai et al., 2017). The study included 10 randomised control trials (1069 patients). 
It has recently been found that there was no difference in using PRP compared to platelet-poor 
plasma (PPP) in a phase 1 trial on patients with chronic plantar fasciitis (Malahias et al., 2019). 
Both treatments yielded significant improvement after 6 months following PRP or PPP injection, 
relative to baseline control. 
For a cosmetic dermatology application, a clinical trial (phase 1) enrolled 4 healthy patients for 
assessment of the histological changes induced in human skin by 0.5 ml PRP-fibrin matrix 
injection into the human deep dermis and immediate subdermis (Sclafani and McCormick, 2012). 
Histology results revealed collagen deposition, activated fibroblasts by day 7, angiogenesis and 
adipose tissue formation by day 19. Another application of PRP is for the treatment of scars (Alser 
and Goutos, 2018). A split-face trial (phase 1) was carried out in 14 Korean patients with acne 
scars who received ablative CO2 fractional resurfacing for removal of damaged skin (Lee et al., 
2011). One side of the face was injected with PRP and the other side received saline. The PRP 
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treated side had significantly decreased erythema at day 4 and oedema time (6.1 ±1.1 versus 7.1 
±1.5 days) and crusting (5.9 ±1.1 versus 6.8 ±1.0 days) was also significantly reduced on the PRP 
treated side. After four months the overall clinical improvement was significantly greater. 
However, there are discrepancies in clinical trials using PRP for scar treatments. Another phase 
1 clinical trial found significant clinical improvement after fractional surfacing; however, there was 
no difference between the control (no PRP) and PRP topical treated side (Kar and Raj, 2017). 
They do justify the use of PRP as it significantly reduced the redness, swelling and pain 
associated with the fractional surfacing.  
PRP treatment has also been considered for hair loss such as that occurring in androgenetic 
alopecia. One clinical trial (phase 1) enrolled 23 male patients with hair loss and injected PRP 
(0.1 ml/cm2) to one side of the affected area of the head and placebo control to the other half, one 
treatment every 30 days for 3 months (Gentile et al., 2015). The PRP treated side had a significant 
increase of 33.6 in the mean number of hairs and 45.9 hairs/cm2 increase in mean total hair 
density, as well a tiny significant increase in angiogenesis around the hair follicles. Although, a 
recent meta-analysis of pooled results from seven studies with 194 patients revealed no 
significant increase in hair number or hair thickness between patients administered with PRP 
(Giordano et al., 2018). The authors suggest this is due to the lack of controlled clinical trials and 
standardised protocols. 
The proposal of using standardised terminology to ascertain how the PRP is derived, may lead to 
a better understanding of the data. In 2009, four PRP classifications defining the leucocyte and 
fibrin content was suggested: 1. pure-PRP (no leucocytes and a low concentration of fibrin after 
activation), 2. leucocyte-PRP (leucocytes are present and a low concentration of fibrin after 
activation), 3. pure platelet-rich fibrin (PRF) (no leucocytes and a high concentration of fibrin 
forming an activated gel), 4. leucocyte-and PRF (leucocytes are present and a high concentration 
of fibrin forming an activated gel) (Dohan Ehrenfest et al., 2009). In 2016, another proposed 
classification was DEPA (Dose, Efficiency, Purity, Activation) which includes defining the platelet 
concentration used (Magalon et al., 2016).  
The regenerative potential of PRP is considered to be caused by the supra-physiological 
concentrations of growth factors (Qian et al., 2017). Platelets have also been found to release 
exosomes (Heijnen et al., 1999, Aatonen et al., 2014, Tan et al., 2016). This raises the possibility 
of obtaining a more concentrated and defined bioactive component from blood for potential use 
in regenerative therapies. This will be discussed further in sections 1.7.3 and 1.7.4.  
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1.6.2.2 Blood-derived exosomes 
Blood-derived exosomes are easily accessible which makes them more appealing in clinical 
applications. Blood-derived exosomes are slightly more complex to study due to the various cells 
contributing to the exosomes present but it is estimated that roughly two thirds of circulating 
exosomes in human peripheral blood are derived from platelets (Hunter et al., 2008). Other cells 
such as erythrocytes, endothelial cells and leukocytes can also secrete exosomes in differing 
quantities (Gyorgy et al., 2014). One study investigated the cell source of plasma-derived 
exosomes from normal mice or those suffering from sleep fragmentation (Khalyfa et al., 2016). 
The cell source of the exosomes was identified by expression of the various cell markers on the 
exosomes i.e. CD41 for platelets (absence of CD45 and CD144), CD45 for leukocytes 
(additionally CD115 for monocytes) and CD144 for endothelial cells (additionally CD34 for 
progenitor endothelial cells) using flow cytometry. There was a significant increase in the 
concentration of exosomes from sleep fragmented mice from platelet-derived cells (22 100 versus 
13 017), progenitor endothelial-derived cells (7 308 versus 5 300) and monocyte-derived cells (10 
832 versus 7 782). However, there was no significant difference in exosome content from other 
leukocyte-derived cell sources. Exosomes are isolated from both plasma and serum (Vicencio et 
al., 2015, Chen et al., 2018b) and serum is expected to have more platelet-derived exosomes 
than plasma (Tao et al., 2017a). There are roughly 3 000 000 exosomes per µl of serum (Vlassov 
et al., 2012); however, the presence of contaminating lipoproteins could be influencing this 
number (Sódar et al., 2016). This confounding issue in exosome research will be discussed in 
Chapter 3. 
Exosomes from blood plasma have been isolated using various techniques such as differential 
centrifugation combined with UC (Kalra et al., 2013), epithelial cell adhesion molecule 
immunoaffinity pull-down, OptiPrep density gradient separation (Cavallari et al., 2017) and 
recently SEC (Böing et al., 2014); which can cause variability in data obtained from various 
exosome research groups. In a comparative study, where out of 213 proteins only 30 common 
proteins were identified in all three isolation techniques (density gradient, UC and epithelial cell 
adhesion molecule-based immunoaffinity pull-down) (Kalra et al., 2013). Furthermore, as with 
MSC exosomes, there is a variability among proteins found within plasma exosomes. Two studies 
have shown only 59 plasma exosomal proteins being commonly identified during isolation using 
mass spectroscopy e.g. HSP70, transferrin, transferrin receptor, ubiquitin B, and ubiquitin C 
(Bastos-Amador et al., 2012, Kalra et al., 2013). Kalra et al. had 147 unique proteins compared 
to 44 proteins for Bastos-Amador et al. (Kalra et al., 2013). This variability is likely linked to the 
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different exosome isolation methods used, Bastos-Amador et al. used UC to isolate plasma EVs, 
whereas Kalra et al. used a density gradient as they found UC and epithelial cell adhesion 
molecule immunoaffinity pull down isolated contaminating plasma proteins.  
The miRNA within blood-derived exosomes has gained immense attention in the research field, 
with human plasma and serum-derived exosomal miRNA having the potential to be biomarkers 
for diseases such as esophageal squamous cell cancer, cardiovascular disease, breast cancer, 
lung cancer, prostate cancer and ovarian cancer; discussed earlier in section 1.2.3. It has been 
shown that the exosome isolation method could influence the miRNA profile of serum exosomes 
as different clusters of miRNAs were detected with the isolation method significantly affecting 
miR-92a and miR-486-5p levels, although, the most common miRNAs were still similar between 
the ExoQuick and UC exosome isolation methods used (Rekker et al., 2014). Again, this 
highlights the need for optimised exosomes isolation methods particularly for blood-derived 
sources. Research has also illuminated the fact that blood-derived exosomes have regenerative 
properties which will be discussed later in section 1.7.4. 
 
1.7 Exosome-based therapeutics 
As exosomes, at least in part are designed to deliver effectors to cells, it is not surprising that 
extensive research is being devoted to determining their potential as therapeutic agents. Due to 
the paracrine mechanism through which MSC are believed to achieve their therapeutic outcome, 
the majority of analysis is devoted to their exosomes though exosomes from other cell sources 
has received attention. Furthermore, recently there has been increasing research into the 
regenerative capability of blood-derived exosomes. The latter will be discussed in depth at the 
conclusion of this chapter. 
Several authors have reported the regenerative potential of MSC-derived exosomes for MI injuries 
(Lai et al., 2010, Arslan et al., 2013, Bian et al., 2014, Wang et al., 2018d). An early study found 
that 0.4 µg (protein) of MSC-derived exosomes administered intravenously to a mouse model of 
MI/reperfusion injury decreased the infarct size, whereas 3 µg of MSC conditioned media was 
required to achieve the same effect (Lai et al., 2010). Recently, it has been shown that MSC-
derived exosomes can be modified with a peptide CSTSMLKAC to home in on the ischemic 
myocardium (Wang et al., 2018d). A mouse MI model was used and exosomes (4×109 
particles/50 μg of protein) were intravenously administered via the tail vein. There were 
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significantly more modified exosomes in the ischemic heart region compared to control exosomes, 
detected using a near‐infrared fluorescence tracer. The modified MSC-derived exosomes also 
decreased inflammation and cardiomyocyte apoptosis, increased angiogenesis, reduced infarct 
size and ameliorated cardiac function. Tumour angiogenesis has been seen to decrease after 
treatment with mice MSC-derived exosomes (Lee et al., 2013). The exosomes decreased the 
VEGF expression in vitro and in vivo. It was also detected that the exosomal cargo had a high 
content of miR-16 which could have caused the anti-angiogenesis effect. Other cell-derived 
exosomes apart from MSCs have also shown regenerative potential for MI injuries. 
Immunodeficient mice with acute MI treated with cardiosphere-derived cell exosomes were shown 
to have improved heart function, decreased scar size and increased infarcted wall thickness 
compared to treatment with serum-free media or normal HdFb exosomes (40 µl injections at 15 
and 30 days) (Ibrahim et al., 2014). Mouse embryonic stem cell-derived exosomes injected into 
the infarct border zone of a mouse MI model (10 µl injections on each side of the ligation) had 
increased neovascularisation, cardiomyocyte survival and decreased fibrosis; compared to 
treatment with mouse embryonic fibroblast-derived exosome and saline (Khan et al., 2015). 
Furthermore miR-294 from the embryonic stem cell-derived exosomes was linked to the 
enhanced cardiac progenitor cell survival and proliferation. 
Other than MSC-derived exosomes being cardioprotective, they have shown potential to treat 
other diseases too. MSC exosomes have potential to treat certain types of cancers. A study 
showed that exosomes from bone marrow MSCs contain miRNA-23b which promotes dormancy 
in breast cancer cells (Ono et al., 2014). 
Human adipose tissue MSC-derived exosomes contain active neprilysin which degrades the β-
amyloid peptide that builds up in the brain of those suffering from Alzheimer’s disease (Katsuda 
et al., 2013). It was found that 1 µg of protein from the exosomes had the same neprilysin activity 
as 0.3 ng of recombinant human neprilysin. The adipose tissue MSC-derived exosomes were 
able to incorporate into N2a cells and assisted in down regulating the β-amyloid peptides. It was 
found that bone marrow MSC-derived exosomes were less effective than adipose tissue MSC-
derived exosomes. 
Another study investigated the effect of exosomes in liver injuries. Carbon tetrachloride-induced 
mouse liver fibrosis has also been effectively treated with umbilical cord MSC-derived exosomes 
(250 μg in 330 μl PBS) (Li et al., 2013). After 2 weeks, the exosomes reduced hepatocyte 
apoptosis and hepatic lobule destruction in the injured liver and after 3 weeks liver injury was 
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significantly reduced. The exosomes reduced liver injury by inactivating the transforming growth 
factor beta 1 (TGF-β1)/Smad pathway and decreased epithelial-to-mesenchymal transition 
(believed to play a central role in liver fibrosis). In agreement, Tan et al. showed that MSC-derived 
exosomes administered to mice with carbon tetrachloride-induced liver fibrosis had an increase 
in liver cell proliferation and a higher cell viability than the mice treated with the PBS control (Tan 
et al., 2014). Immunoblotting showed that the markers for hepatic proliferation (NF-κB, cyclin D1 
and cyclin E) increased in mice treated with the exosomes relative to PBS control. 
MiR-133b improves functional recovery in spinal cord injury shown in adult zebra fish (Yu et al., 
2011) and regulates the function of  midbrain dopaminergic neurons (Kim et al., 2007) and the 
proposed mechanism has recently been explored (Xin et al., 2012). Upregulation of miR-133b 
was detected when neurons and astrocytes were treated with exosomes derived from MSCs 
treated with an ischemic brain extract from rats subjected to middle cerebral artery occlusion 
(stroke) (Xin et al., 2012). The proposed therapeutic mechanism is that the MSC-secreted 
exosomes transferred the miR-133b to the neurons and astrocytes which increased neurite 
outgrowth. Even though numerous exosomes have seen to have therapeutic effects in diseases 
such as Alzheimer’s, liver injuries and tumour angiogenesis, their therapeutic potential might be 
significantly increased by using them as a delivery vehicle for therapeutic agents. 
1.7.1 Exosomes used as delivery vehicles 
Due to exosomes being nano-sized vesicles that naturally transport RNA, mRNA and miRNA 
around the body, they are potentially an optimised delivery vehicle for exogenous bioactive 
reagents (Valadi et al., 2007). These types of agents can be packaged into exosomes via 
engineering the cells to self-incorporate proteins and mRNA (You et al., 2018). For investigation 
into a cell-free vaccine for hepatocellular carcinoma, mouse dendritic cells were transfected with 
α-fetoprotein and the secreted α-fetoprotein-enriched exosomes isolated (Lu et al., 2017). Foetal 
liver protein, α-fetoprotein, is utilised as a tumour antigen due to its high concentration in 
hepatocellular carcinoma patients. The engineered exosomes were administered intravenously 
into mice with hepatocellular carcinoma (40 or 150 µg/mouse/week for three weeks). The 
engineered exosomes enhanced antigen-specific anti-tumour-immune responses as shown by 
increased IFN-γ-expressing CD8+ T lymphocytes, higher concentration of IFN-γ and IL-2, less 
CD25+Foxp3+ regulatory T cells, lower concentration of IL-10 and TGF-β in the tumour 
microenvironment and induced a significant tumour suppression. Cell transfection can be used to 
load mRNA or miRNA into exosomes. Exosomes (50 μg protein in 5 μl) isolated from marrow 
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stromal cells transfected with a miR-146b expression plasmid significantly decreased glioma 
xenograft growth in rat brain tumour model compared to the miRNA-67 loaded-exosomes or PBS 
control (Katakowski et al., 2013). The exosomes were able to deliver miR-146b which assists in 
decreasing glioma cell invasion, migration and viability. 
Exosomes may be particularly desirable for delivering short interfering RNA (siRNA) as they can 
prevent siRNA degradation, prevent immune responses and help the siRNA cross the cell 
membrane (El-Andaloussi et al., 2012). Exosomes are most commonly directly transfected with 
siRNA using electroporation which uses an electric field to create pores in the exosome lipid 
membrane to assist the cargo to enter the exosomes but other means such as liposomal delivery 
are also used. An early study showed that HeLa and HT1080 human fibrosarcoma cell-derived 
exosomes transfected with siRNAs against targets for cancer cells, RAD1 and RAD52, either by 
liposomal or electrophoretic delivery to the exosome caused specific gene silencing which both 
led to similar levels of cancer cell death in vitro (Shtam et al., 2013). Blood-derived exosomes 
have also been explored as delivery vehicles, due in part to the more ready availability. Human 
plasma exosomes electroporated with mitogen-activated protein kinase-1 (MAPK1) siRNA have 
been shown to deliver effectively to monocytes and lymphocytes (Wahlgren et al., 2012). By 
isolating exosomes after electroporation, they showed that the siRNA was contained in the 
isolated exosomes. Their gene silencing was effective as MAPK1 was down-regulated in 
monocytes and lymphocytes as confirmed by western blotting. Furthermore, confocal microscopy 
and flow cytometry have also been used to confirm that siRNA is successfully transfected into 
exosomes by fluorescently labelling the siRNA. Caution should be taken when using 
electroporation as it has been reported using NTA and confocal microscopy that siRNA can 
aggregate thereby overestimating the amount of siRNA loaded into exosomes (Kooijmans et al., 
2013). The addition of EDTA or using an acidic citrate electroporation buffer can reduce siRNA 
aggregates; however, these methods are not considered effective enough. The use of liposomes 
to transfect exosomes is complicated by the similarities in size and composition of the two 
components.  
Loading of agents through simple incubation with exosomes is another route. Curcumin was 
loaded into tumour cell-derived exosomes through incubation at 22°C for 5-15 minutes and the 
curcumin loaded exosomes were seen to reduce brain inflammation in GL26 brain tumour mice 
models treated intranasally (Zhuang et al., 2011). In a follow up study by another group, curcumin 
was loaded into embryonic stem cell-derived exosomes with the aim of combining the 
regenerative potential of embryonic stem cells (Khan et al., 2015) with the anti-inflammatory 
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activity of curcumin. The curcumin loaded embryonic stem cell-derived exosomes were shown to 
restore neurovascular units after an ischemia-reperfusion injury in mice (Kalani et al., 2016) but it 
should be noted that only the combination was tested. 
Loading DNA into exosomes is more sterically challenging than loading siRNA. Linear DNA 
smaller than 1000 bp will transfect easier into exosomes than using larger DNA or plasmid DNA 
as exosomes have a small inner volume (Lamichhane et al., 2015). Larger microvesicles have a 
higher capacity for DNA loading than exosomes. It has been shown that exosomes can deliver 
transfected DNA into recipient cells; however, no functional gene activity was detected 
(Lamichhane et al., 2015). Their data supports the idea that microvesicles are more efficient for 
DNA delivery as exosomes reach saturation. To overcome the small size of exosomes for DNA 
delivery, one study modified HEK293FT-cell derived exosomes to encapsulate plasmids (Lin et 
al., 2018). They created hybrid exosomes by incubating liposomes, exosomes and pEGFP-C1 
plasmids for 12 hours at 37°C. Moreover, they showed MSCs internalised the hybrid exosomes 
to express the genes of a CRISPR/Cas9 expression vector which liposomes alone could not do. 
A significant problem in delivering cargo loaded exosomes is directing the exosomes toward a 
specific site if they are injected systemically. Modifying exosomes to allow for targeted delivery is 
being explored. For example, autologous dendritic cell-derived exosomes were used to deliver 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) siRNA (electroporated) to mice brains 
(Alvarez-Erviti et al., 2011). Dendritic cells were engineered to express lysosome-associated 
membrane protein 2B (Lamp2b) with neuron-specific rabies virus glycoprotein (RVG) peptide 3 
to achieve specific targeting of the released exosomes. The peptide (derived from the rabies virus) 
was expected to facilitate crossing blood-brain barrier to occur. There was significant gene 
silencing of GAPDH in many brain regions (neurons, microglia and oligodendrocytes) 
intravenously injected with the siRNA loaded exosomes. Their study also tested a therapeutic 
benefit where exosomes loaded with a gene target against Alzheimer’s disease (beta-secretase 
1 (BACE1)) caused a knockdown of BACE1 mRNA (60%) and protein (62%). The research into 
exosomes as specific cargo delivery vehicles holds great promise. The stability of exosomes will 
necessarily both here and generally impact on their translation to the clinic.  
1.7.1.1 Stability of exosomes 
Pharmaceutical companies have an obligation to prevent loss of therapeutic properties during 
delivery of drugs. Hence, a temperature-controlled environment is required for certain therapeutic 
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products. It is good practice for drug products to be tested for stability (Ammann, 2011). A 
guideline is given by the World Health Organization Technical Report Series, No. 953, 2009, 
Annex 2 (Organization, 2009). Due to exosomes having a potential to be used for therapeutic 
purposes, it is important to determine the temperature stability of the exosomes to be suitable 
delivery vehicles or potential biomarkers for diseases. Cancer LIM 1863 cell-derived exosomes 
stored in plasma have been shown to be stable over 3 months when stored at 4, -20 and -80°C 
as detected by TEM and exosome marker TSG101 (Kalra et al., 2013). They also stored plasma 
for 30 days at 37°C and exosomes were stable to an extent as TSG101 was detected. It was also 
reported that protease inhibitors had no effect on the stability of plasma exosomes. Furthermore, 
it was reported that the exosomes recovered from plasma, stored for 30 days at -20°C, were still 
functional as they were uptaken by LIM 1215 colorectal cancer cells. However, another study 
revealed that cell-derived exosomes from HEK 293T cells, endothelial colony forming cells and 
MSCs decreased in size when stored at 4°C and 37°C over 8 days as detected by NTA suggesting 
structural change and deterioration (Sokolova et al., 2011). The exosome size was stable after 
multiple freeze-thaws at -20°C. This indicates the need for further studies in this area with well-
defined isolation methods and characterisation. Bioactivity studies need to be carried out to 
determine the functional stability of stored exosomes. 
1.7.2 Exosomes embedded in hydrogels 
1.7.2.1 Hydrogels for regenerative treatment 
Hydrogels are a type of biomaterial which is defined as a synthetic substance used as an 
implanted medical device. Hydrogels are three-dimensional polymer networks that swell in size 
as they can absorb up to thousands of times their dry weight in water; hence, mimicking properties 
of tissues suitable for an extracellular matrix (ECM) (Hoffman, 2002). A desirable property of 
hydrogels in tissue regeneration is that it should allow for synchronicity between its degradation 
and replacement by tissue (Otrock et al., 2007). Certainly, no toxic by-products should form. 
Hydrogels are suitable for tissue engineering as their pores are either broad enough for cells to 
enter or they can be designed to allow ingress through dissolving or enzymatic degradation. 
Hydrogels can be formed either physically or chemically. Chemical gels involve using a cross-
linker and physical gels rely on hydrophobic interactions. Handling hydrogels poses a challenge 
as they can have very low mechanical strength (Hoffman, 2002). An advantage is that they be 
able to gel in vivo at body temperature when injected as a liquid. 
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Hydrogels are suitable as a localised delivery vehicle and have been used in various therapeutic 
applications such as cardiac illness, ocular pain, cancer and wound healing (Li and Mooney, 2016, 
Narayanaswamy and Torchilin, 2019). Some of the desirable characteristics of hydrogels include 
the high concentration of water which makes them compatible with the aqueous tissue 
environment (Li and Mooney, 2016). Their porosity allows for a sustained release of the loaded 
therapeutic agent either through control of their mesh size or through swelling, mechanical 
deformation (such as ultrasound) or the use of covalent linkages (either stable or cleavable). 
Hydrogel stiffness can be adjusted (0.5 kPa-5 MPa) to be compatible with the tissue where they 
are to be administered (Arakaki et al., 2010, Li and Mooney, 2016). 
1.7.2.2 Fibrin hydrogel 
A fibrin gel is formed when fibrinogen is activated by thrombin in the presence of Ca2+. Fibrin gels 
do not require invasive surgery as they can be injected into the target site (Jeon et al., 2005). 
VEGF promote angiogenesis; however, with direct delivery there is low efficacy due to rapid 
clearance from the intended delivery site. A study modified VEGF to incorporate matrix-binding 
to fibrin to prevent the rapid clearance of native VEGF mixed into fibrin (Ehrbar et al., 2004). The 
modified VEGF was released from the fibrin implant by cell-associated enzymatic activity. Their 
engineered VEGF significantly induced vessel formation more than native VEGF, in embryonic 
chicken chorioallantoic membrane and in adult mice. Moreover, those vessels were structurally 
intact and permeability data showed they did not leak. Another study examined the effects of 
varying the concentration of fibrinogen, thrombin and heparin on the kinetics of bFGF release 
(Jeon et al., 2005). bFGF has been known to induce the regeneration of various tissues. Their 
studies revealed that incorporation of heparin and increasing the concentration of fibrinogen 
decreased the release rate of bFGF. The fibrin gel stabilised the bioactivity of bFGF, compared 
to a free form of bFGF, and there were more microvessels present in mice ischemic limbs injected 
with bFGF-loaded fibrin gels than those with no treatment. Infarcted rat myocardium has been 
previously treated with bone marrow mononuclear cells implanted within a fibrin matrix (Ryu et 
al., 2005). The results showed more tissue regeneration, more extensive neovascularisation and 
significantly higher microvessel density when the cells were implanted with the matrix than without 
it. The drawback of using fibrin is its quick degradation time, gel shrinkage and a low mechanical 
stiffness (Ahmed et al., 2008). A study showed a fibrin hydrogel (3.5 mg/ml) mixed with human 
myofibroblasts degraded in 2 days when incubated in cell culture medium without aprotinin, 
examined with light microscopy using haematoxylin and eosin (H&E) staining (Ye et al., 2000). 
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Overall fibrin is a flexible scaffold for use in delivering therapeutic agents for regenerative 
medicine. 
1.7.2.3 Exosomes delivered in hydrogels 
Very recently, hydrogels have been investigated for their ability to deliver exosomes for 
therapeutic purposes in wound healing (Tao et al., 2017c), MI (Chen et al., 2018a), hindlimb 
ischemia (Zhang et al., 2018) and enzyme prodrug therapy (Fuhrmann et al., 2018) (prodrugs are 
converted into an active drug at a targeted location with the introduction of artificial enzymes). 
The hydrogels are used in part to potentially localise and sustain the delivery of the exosomes as 
for example numerous studies have shown bone marrow stem cells injected into the myocardium 
to be washed out (Sheikh et al., 2012, van den Akker et al., 2017) and it is expected that exosomes 
will behave similarly. Endothelial progenitor cell-derived exosomes, delivered via an injectable 
hyaluronic acid hydrogel, improved the peri-infarct angiogenesis and function of the heart after MI 
in rats (Chen et al., 2018a). Chitosan hydrogels have been used to deliver exosomes for various 
regenerative purposes. One study compared chitosan/silk hydrogel sponges, embedded with 
either the polysaccharide rhizomes of curcuma zedoaria (ZWP-is an Asian remedy used to treat 
inflammation, pain, wounds and skin problems) or PRP-derived exosomes (100 µg protein) (Xu 
et al., 2018). The combined treatment showed the best wound closure in diabetic rats as the ulcer 
reduced in size and the epidermis thickened. Sustained delivery of miR-126-3p-overexpressing 
synovium MSCs exosomes, from a chitosan hydrogel, also promoted angiogenesis in a diabetic 
rat wound healing model (Tao et al., 2017c). Another study tested gingival MSC-derived 
exosomes (50 µg protein) loaded in a 1 x 1 cm chitosan/silk hydrogel sponge to treat 10-mm 
diameter full-thickness wounds in diabetic rats (Shi et al., 2017). The exosome loaded hydrogel 
promoted wound healing via neuronal ingrowth, increased angiogenesis and deposition and 
remodelling of collagen with the exosome loaded hydrogel having the highest microvessel density 
and nerve density. Furthermore, tissue regeneration in a murine hindlimb ischemia model has 
been shown using MSC-derived exosomes delivered in a chitosan hydrogel (Zhang et al., 2018). 
The hydrogel also enhanced the exosomes therapeutic function. 
A sodium alginate hydrogel loaded with PRP-derived exosomes (1% (v/v)) has also been reported 
to promote skin wound closure in diabetic rats (Guo et al., 2017). The PRP exosomes caused 
significantly improved wound healing at days 7 and 14 compared to the untreated control wound 
groups, although wound healing with PRP exosomes was not significantly different to PRP treated 
wounds. There was significantly increased blood vessel area and blood vessel number with the 
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PRP exosomes compared to the control groups and PRP. In vitro, the PRP exosomes significantly 
increased cell proliferation and migration of fibroblasts through yes-associated protein (YAP) 
activation, increasing collagen synthesis suggesting a mechanism for the improved wound 
healing. MSC exosomes have been investigated for enzyme prodrug therapy, where they carried 
and delivered β-glucuronidase (loaded by permeabilising the exosomes using saponin treatment), 
which reacted to release curcumin, an anti-inflammatory product (Fuhrmann et al., 2018). A 
poly(vinyl alcohol) hydrogel assisted in the precise delivery. A photoinduced imine, crosslinking 
hydrogel glue, has been tested to deliver human induced pluripotent MSC exosomes to a cartilage 
defect site (Liu et al., 2017b). The hydrogel patch was able to integrate in vivo and there was 
promotion of cartilage repair due to positive cell regulation. A silk fibroin hydrogel has been used 
to deliver miR-675 loaded human umbilical cord MSC-derived exosomes (50 µl at 11 mg/ml) to 
repair ischemic hindlimb injury in an aging mouse model (Han et al., 2019). MiR-675 was delivered 
at it inhibits the aging process by preventing the TGF-β1/p21 signalling pathway. The silk fibroin 
hydrogel enhanced the retention of the miR-675 loaded MSC-derived exosomes and significantly 
increased blood perfusion compared to mi675 loaded MSC-derived exosomes alone. Overall, 
various hydrogels have provided a scaffold for the sustained delivery of exosomes for diverse 
regenerative purposes. No prior studies have examined delivery of serum exosomes using a fibrin 
hydrogel which could be a suitable candidate.  
1.7.3 Blood-derived exosomes use in disease  
As mentioned previously, blood-derived exosomes are predominantly researched for biomarkers. 
However, plasma and serum exosomes also seem to have a biological purpose as detected by 
various researchers as mentioned briefly in the function of exosomes (Section 1.5). A study 
showed removing exosomes from FBS altered the gene and miRNA expression in muscle cells 
and decreased their proliferation and differentiation (Aswad et al., 2016). Bovine serum exosomes 
may also assist in proliferation and migration of human cardiac progenitor cells as depleting the 
exosomes decreased the cardiosphere size, concentration and ECM production; however, this 
may have been caused by the depletion of other factors (Angelini et al., 2016). FBS exosomes 
can also cause significant migration of lung cancer epithelial cells (A549 cells) in a dose-
dependent manner (0.03-100 µg/ml) (Shelke et al., 2014). Overall, this highlights the potential of 
blood-derived exosomes to be useful in either treating or detecting diseases.   
The amount of serum-derived exosome mitochondrial DNA and proteins is significantly increased 
in children with autism spectrum disorder (Tsilioni and Theoharides, 2018). The exosomes from 
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the autism spectrum disorder serum increased secretion of pro-inflammatory cytokine IL-1β from 
human microglia in vitro compared to the control serum exosomes. Hence, a possible explanation 
of the inflammation in the brain in children with autism spectrum disorder. Further research on a 
brain disease, an Alzheimer’s disease mouse model has shown that peripheral plasma exosomes 
can diffuse from the dentate gyrus hippocampus to the cortex and by day 20 most of the 
exosomes were in the cortex (Zheng et al., 2017). The study showed that exosomes mainly 
targeted microglia and were still internalised by day 20; however, Alzheimer’s disease mice had 
less exosomal uptake in the astrocytes and neurons. The clustering of plasma exosomes around 
amyloid-β plaques and exosomes taken up by activated microglia, suggests a role in Alzheimer’s 
disease pathogenesis. 
The role of blood exosomes in pregnancy has also been investigated. Plasma exosome 
concentration in pregnant women (n=20 for each trimester) was 50 times more than non-pregnant 
women (n=9) (Salomon et al., 2014). The plasma exosome protein significantly increased with 
gestational age and was 0.94 mg/ml ±0.41 (second trimester) and 1.40 mg/ml ±0.11 (third 
trimester). Exosomes from the first and second trimester (100 µg/ml) significantly increased 
HUVEC migration compared to exosomes from non-pregnant woman. The contribution of 
placental exosomes decreased in the third trimester. Furthermore, the increase in placental-
derived exosomes correlated with the increase in total plasma exosome concentration during the 
first and second trimester, albeit there was a reduction during the third trimester. This could have 
been caused by a decrease in secretion of placental-derived exosomes, enhanced secretion from 
non-placental sources or both. Their data may provide clinical value to detect placental problems 
if the exosome profile changes during pregnancy; however, the role of placental-derived 
exosomes requires further investigation. Multiple sclerosis relapses decrease during pregnancy 
and studies have seen that serum exosomes (20 µg/ml), from pregnant and non-pregnant 
controls, suppress T cell activation (which normally target and destroy myelin antigens during the 
active disease) (Williams et al., 2013). Also shown in another study, pregnancy serum-derived 
exosomes (10 µg) elicited significantly more T cell suppression, as well as being at a higher 
concentration and having a larger diameter (Gatson et al., 2011). Furthermore, pregnant serum 
exosomes also assist in migration of oligodendrocyte precursor cells into the central nervous 
system lesions and interestingly both pregnant and non-pregnant-derived serum exosomes 
contribute to the reduction of experimental autoimmune encephalomyelitis induced by pregnancy, 
shown in mice (Williams et al., 2013). Hence, serum exosomes may play an important role in 
neuroprotection and immune regulation during pregnancy. 
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Intriguingly there is a connection between plasmodium infection and tumour angiogenesis. Intra-
tumoural injection of mice plasma exosomes isolated using either UC or ExoQuick-TC 
precipitation (50 μg exosome protein) from malaria infected hosts decrease tumour angiogenesis 
(Yang et al., 2017). In vitro studies confirmed that these exosomes inhibit VEGF receptor 2 
(VEGFR2) expression and tube formation in endothelial cells. 
1.7.4 Regenerative properties of blood-derived exosomes  
The above looked at instances that have revealed potential physiological and pathological 
functions of blood-derived exosomes. There are also an increasing number of studies that have 
investigated their delivery for therapeutic purpose. 
1.7.4.1 Myocardial injuries 
Intravenous administration of rat plasma-derived exosomes (isolated using UC) via the tail vein 
15 minutes before induction of an ischemic reperfusion injury in the recipient rats heart resulted 
in a decrease in infarct size (Vicencio et al., 2015). They also used a Langendorff-perfused rat 
heart, in which the heart is removed from the rat and the perfusate is pumped through the aorta 
into the coronary vessels towards the heart. This removes the complications of the live animal 
and the influence of blood. The exosomes were administered during perfusion (15 minutes) prior 
to the rat hearts undergoing 35 minutes of ischemia and 2 hours of reperfusion and here too the 
exosomes significantly decreased the infarct size. Furthermore, they performed in vitro studies 
where they administered exosomes to cardiomyocytes that underwent hypoxia-reoxygenation 
(simulating ischemia-reperfusion). Cell death was reduced indicating that the exosomes were 
cardioprotective via direct interactions with the cardiomyocytes. It was revealed that HSP70 on 
the surface of exosomes communicated with TLR4 in cardiomyocytes which lead to a signalling 
pathway involving various kinases which activated cardioprotective HSP27. It has also been found 
that serum exosomes activate an ERK1/2 and HSP27 signalling pathway to prevent apoptosis of 
H9C2 cardiomyocytes treated with hydrogen peroxide (Bei et al., 2017, Li et al., 2018c) 
suggestive of another potential therapeutic mechanism for myocardial injuries. One of those 
studies compared the difference in serum exosomes (isolated using ExoQuick precipitation) 
between exercised (swimming) and non-exercised mice (Bei et al., 2017). Both the exercised and 
non-exercised serum exosomes significantly enhanced the protective effect of mice with acute 
ischemia/reperfusion injury when injected with equal quantities (10 μg diluted in 25 μl PBS). 
However, the concentration of exercised serum exosomes was 1.85X more which significantly 
increased the protective effect when injected as an equal volume, thus exercise stress causes 
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secretion of exercise-induced exosomes that enhance the therapeutic function of endogenous 
exosomes against myocardial injury. Another mechanism is that the serum exosomes (isolated 
using ExoQuick precipitation) are regulating miR-17-3p/TIMP3 to increase the proliferation of 
cardiomyocyte H9C2 cells (Liu et al., 2018b).  
Thus, though there are relatively few studies at present, it appears that plasma or serum 
exosomes can induce cardioprotective effects through a range of mechanisms.  
1.7.4.2 Peripheral ischemia 
Angiogenesis is vital for repair and regeneration after ischemia; hence, the importance in isolating 
bioactive agents that induce angiogenesis. It has been shown that coronary serum exosomes 
(isolated using UC) from myocardial ischemia patients improved HUVEC proliferation, migration 
and tube formation better than control exosomes from healthy patients (Li et al., 2018b). Both the 
ischemic and control exosomes increased the migration of HUVECs in transwell and scratch 
wound assays, with the ischemic exosomes showing the most pronounced effect. The ischemic 
exosomes also enhanced blood flow recovery and neovascularisation in a mouse hindlimb 
ischemia model better than the control exosomes after 21 days post-injection and it was believed 
that cardiomyocytes are the potential cells releasing the bioactive exosomes in response to 
ischemic stress. Furthermore, they found that the ischemic exosomes had reduced miR-939-5p 
levels, which improved angiogenesis by regulating the nitric oxide signalling pathway. 
To determine the pro-angiogenic activity within 18 different serum exosome samples (healthy 
blood bank donors in Italy and exosomes isolated using an OptiPrep density gradient), it was 
found that 14 out of 18 were able to elicit 50% or more of the increase that the potent angiogenic 
VEGF was able to produce in HMEC proliferation and tube formation (Cavallari et al., 2017). Using 
gene ontology (GO) functional analysis, they identified enriched genes linked to TGF-β1 signalling 
pathway associated with the treatment with active exosomes and not with inactive exosomes and 
it was speculated that this cascade could be driving the angiogenic response. The findings in vitro 
were found to correlate with those in vivo when the active and inactive serum exosomes were 
subcutaneously injected (2x1010) into SCID mice with induced hindlimb ischemia (1x1010 injected 
immediately, 0.5x1010 on day one and day two). Only the active exosomes increased vessel 
number and hindlimb perfusion, preventing muscle damage after hindlimb ischemia in mice. This 
indicates that exosome from serum may need to be screened for angiogenic potential before use 
in the clinic. Further research is required to identify the mechanism of angiogenesis caused by 
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plasma and serum exosomes and investigated in large animal ischemic models, to enable clinical 
trials to move forward. 
1.7.4.3 Other diseases 
The use of blood-derived exosomes in various other diseases have also been explored recently. 
Human serum exosomes have the potential to treat dysferlinopathy, which is a muscle disease 
noted by the atrophy and weakness of the muscles. Exosomes have been found to contain the 
dysferlin protein which is deficient in dysferlinopathic patient serum exosomes (isolated using UC 
and sucrose density gradient) relative to normal controls (Dong et al., 2018). The serum 
exosomes (100 µg/ml) assisted the repair of human dysferlin-/- myotube membranes after laser 
injury, in vitro for 48 hours. Therefore, exosomes can be used as a possible treatment method 
and also for diagnosis. 
Serum exosomes have also been investigated for the potential treatment of hepatic fibrosis. 
Serum exosomes from healthy mice (isolated using UC or targeted filtration using PureExo® kits), 
but not fibrotic mice, were able to repress liver injury in mice (induced by carbon tetrachloride or 
thioacetic acid) (Chen et al., 2018b). The exosomes had anti-fibrogenic properties, identified by 
a decrease in hepatocyte death, circulating aspartate transaminase/alanine aminotransferase 
levels and pro-inflammatory cytokines. In vitro, the exosomes reduced proliferation and fibrosis-
associated molecule expression, as well as repressing the anti-proliferation effects of carbon 
tetrachloride or ethanol on hepatocytes. Specific miRNAs (-34c, -151-3p, -483-5p, -532-5p and -
687), identified in the serum exosomes, caused the above therapeutic actions in hepatic stellate 
cells (principal cell type in liver fibrosis) or injured hepatocytes (symptom of liver injury). 
An in vitro study has shown that both serum and PRP (10% (v/v)) from umbilical cord blood 
significantly increase proliferation of fibroblasts and MSCs more than the serum-free control 
(Hashemi and Rafati, 2016). Furthermore, exosomes derived from PRP or serum have shown to 
promote wound healing in vivo (Nakamura et al., 2016, Guo et al., 2017). A recent study 
investigated PRP-derived exosomes (isolated using UC and sucrose cushion) for the use in 
stimulating neovascularisation (Guo et al., 2017). They showed that the PRP exosomes 
encapsulated growth factors PDGF-BB, TGF-β, bFGF and VEGF. PRP exosomes stimulated 
important cellular responses such as assisting proliferation and promoting migration of HMEC-1 
and fibroblast cells. PRP exosomes also promoted angiogenesis of HMEC-1 cells as seen by 
formation of elongated vessels. They overlaid an ECM gel with HMEC-1 cells treated with or 
without the PRP exosomes. In vivo, PRP exosomes embedded in a sodium alginate hydrogel 
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promoted cutaneous healing of chronic wounds in a diabetic rat model. Mouse serum-derived 
exosomes (isolated using ExoQuick precipitation) have been shown to increase the healing of 
full-thickness wounds (10 mm) in mice (Nakamura et al., 2016). The diameter of the wound was 
significantly smaller with exosome treatment than without (daily treatment), at day 4, 6 and 8. 
Wound healing was suggested to occur through collagen expression as the mRNA levels of 
COL1A1 and COL1A2 were increased in the tissues of the exosome-treated wound though not 
significantly relative to the control without treatment. Furthermore, the concentration of exosomes 
decreased in human serum from systemic sclerosis patients compared to healthy controls. 
Systemic sclerosis patients are prone to skin ulcers and pitting scars due to a decrease in 
collagen. The study proposed that the reduction in serum exosomes, could be the reason of slow 
wound healing in patients. Contrary to their results, another study found that the serum exosome 
(isolated using ExoQuick precipitation) particle concentration was higher in systemic sclerosis 
patients compared to normal control (Wermuth et al., 2017). The differences could be accounted 
for by the different detection methods used, CD63 ELISA (Nakamura et al., 2016) versus NTA 
(Wermuth et al., 2017). This further highlights the difficulties of interpreting and comparing data 
whilst analysis methods are not fully established. The latter also found that the systemic sclerosis 
serum exosomes were enriched for a few miRNAs anticipated to induce profibrotic genes and 
decreased for antifibrotic genes, alluding to a possible mechanism for elevated fibrotic tissue in 
systemic sclerosis patients (Wermuth et al., 2017). 
Further research has shown blood-derived exosomes to accelerate wound healing. Mouse skin 
wounds (12 mm) treated with human umbilical cord blood plasma-derived exosomes (200 µg/100 
µl PBS) enhanced wound healing compared to PBS control; as detected by enhanced re-
epithelialisation, decreased scar width and increased angiogenesis over 8 days (exosomes 
isolated using UC and ultrafiltration) (Hu et al., 2018). Their in vitro studies revealed a possible 
mechanism as the exosomes were enriched for miR-21-3p, and inhibition of miR-21-3p resulted 
in decreased angiogenesis and migration of endothelial cells and fibroblasts. Another research 
group found that maternal serum-derived exosomes (isolated using ExoQuick precipitation) 
caused significantly enhanced migration of HUVECs compared to umbilical cord serum-derived 
exosomes, in vitro (Jia et al., 2018). This may be explained by the miRNA differential expression; 
11 miRNAs were up-regulated and 15 were down-regulated in maternal serum-derived exosomes 
compared to umbilical cord serum-derived exosomes. Albeit, both maternal and umbilical cord 
blood-derived exosomes significantly increased HUVEC proliferation, migration and tube 
formation compared to the control of no exosomes added. 
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The role of serum-derived exosomes in preventing an allergic reaction has also been investigated. 
Serum-derived exosomes (isolated using UC) were isolated from ovalbumin (antigen) fed mice 
and injected intraperitoneally (exosomes from 1 ml serum in 1 ml PBS) into a mouse allergic 
asthma model and analysed for the potential transfer of tolerogenic exosomes (antigen-specific 
tolerance) into the mice exposed to the antigen (Almqvist et al., 2008). Day 0 mice received 
exosomes, day 7 and 17 mice were sensitized with ovalbumin (intraperitoneal 10 µg), day 25, 26 
and 27 mice were exposed to ovalbumin (intranasal 100 µg) and 24 hours later samples were 
processed. The antigen-fed serum-derived exosomes inhibited allergic sensitization/inflammation 
in the airway of the recipient mice, as shown by decreased concentration of total and ovalbumin-
specific IgE in serum and significant increase of CD4+ CD25+ regulatory T cells. 
Intranasal administration of young rat serum-derived exosomes (isolated using ExoQuick 
precipitation) (100 µg in 50 µl) to aged rats, have been found to significantly enhance myelin in 
the motor cortex after 3 days, quantified by FluoroMyelin staining and western blotting (Pusic and 
Kraig, 2014). The in vitro studies revealed that both young and environmentally enriched rat 
serum-derived exosomes contained miR219, and inhibiting exosomal miR-219 prevented 
myelination in a slide culture. MiR-219 increases the differentiation of oligodendrocyte precursor 
cells into myelin-producing cells by decreasing the expression of inhibitory regulators of 
differentiation. Multiple sclerosis lesions contain no miR-219 (Junker et al., 2009). Hence, serum-
derived exosomes could be a possible therapy for remyelination for diseases such as multiple 
sclerosis (Pusic and Kraig, 2014) . 
Although research has highlighted the benefits of serum exosomes in various diseases as well 
as in pregnancy, they are inconsistent with the use of different exosome isolation methods. 
Furthermore, there are major differences in the concentration of exosomes administered between 
different research groups e.g. cardiomyocytes treated with 108/ml (0.1 µg) rat or human plasma 
exosomes isolated using UC (Davidson et al., 2018a) versus 10 μg/ml mice serum exosomes 
isolated using ExoQuick (Bei et al., 2017). This could impact the results reported as any 
contamination may obscure the data. A new approach is therefore needed to standardise 
exosome isolation methods, to enable comparison of research studies and identifying the true 





1.8 Summary and aims 
Although EV isolation techniques are limited in separating the different types of EVs, they are 
often termed exosomes, EVs or microparticles (Lötvall et al., 2014). In this thesis, we will refer to 
the isolated EVs as exosomes. Certain components in blood are regenerative and studies have 
indicated that exosomes are one of these. Exosomes are multifunctional for use in: biomarking 
diseases, delivery vehicle for drugs and regenerative purposes. Due to blood containing a high 
concentration of exosomes released by platelets and various other cells (Davidson and Yellon, 
2018, Sluijter et al., 2018), numerous studies have investigated and shown that plasma/serum 
exosomes have regenerative potential in injuries such as myocardial injury (Liu et al., 2015, 
Vicencio et al., 2015), hindlimb ischemia (Li et al., 2018b) and hepatic fibrosis (Chen et al., 2018b).  
Aim 1: Though regenerative potential has been found for blood-derived exosomes, these have 
almost exclusively been isolated using methods that have been shown to result in high protein 
contamination levels (UC and precipitation). Thus, it was considered necessary to assess the 
regenerative potential of exosomes purified from human serum by a low protein contamination 
method, namely SEC. 
Objectives 
1. Determine protein purity of SEC isolated exosomes relative to those isolated by UC 
and precipitation. 
2. Assess the uptake of serum SEC-derived exosomes and their effect on cell 
proliferation and HUVEC spheroid sprouting. 
3. Determine their stability. 
4. Ascertain the suitability of fibrin as a delivery vehicle for exosomes. 
Aim 2: Develop a multi-step purification method for removing lipoproteins from SEC isolated 
exosomes. 
Objectives 
1. Optimise a density gradient for removal of lower density lipoproteins prior to SEC. 
2. Assess the purified exosomes regenerative potential in vitro and in vivo. 
3. Comparatively characterise the proteomes obtained from the single-step and multi-




CHAPTER 2: FUNCTION OF SERUM-DERIVED EXOSOMES 




Numerous methods for isolating and characterising exosomes have emerged over the last 
decade. Purifying exosomes can include UC, precipitation, ultrafiltration, density gradients, 
immunoaffinity purification or SEC (Section 1.3). Immunoblotting, flow cytometry, mass 
spectrometry and imaging methods help to identify isolated exosomes (Section 1.4) (Sahoo and 
Losordo, 2014). The isolation method used depends on the downstream application and the aim 
of the study. If very pure exosomes are required, then the isolation method must have minimal 
co-isolation of proteins and, recently discovered, the co-isolation of lipoproteins (Tkach et al., 
2017). This latter aspect will be further discussed in Chapter 3. Other studies may require a large 
yield of exosomes which come at the cost of a reduction in purity. Exosomes have major potential 
for therapeutic use as they contain miRNA, have regenerative properties as well as being a 
potential delivery vehicle for drug therapy. However, to completely understand their mechanism 
suitable isolation techniques need to be employed. As discussed, current isolation techniques 
have their own advantages and disadvantages, summarised in Table 1.2 (Section 1.3). Blood-
derived exosomes isolated from plasma or serum have shown to have regenerative properties for 
a range of ailments such as myocardial injury, hindlimb ischemia, dysferlinopathy, hepatic fibrosis, 
skin wounds and allergies; discussed in depth in section 1.7.4 and summarised in Table 2.1. The 
exosome isolations for these regenerative studies included UC, ExoQuick and density gradients. 
Most of these serum/plasma-derived exosomes were isolated using UC (Table 2.1). UC is not an 
optimal exosome method as there are numerous disadvantages discussed earlier in section 1.3.1 
and Table 1.2, i.e. protein contamination particularly from blood-derived sources, expensive 
equipment required, long isolation time and high-speed centrifugation could lead to exosome 
damage. In 2014, SEC was suggested to be a successful single-step EV isolation method (Böing 
et al., 2014), discussed earlier in section 1.3.6. The SEC method was found to be a quick and 
simple method to use, briefly, 1.5 ml of platelet-free supernatant from platelet concentrates was 
loaded onto the top of the 10 ml Sepharose CL-2B column and multiple 0.5 ml fractions of the 
eluates were collected. The EVs were detected in SEC fractions 9-12 using NTA and western 
blotting for platelet marker CD61. Furthermore, SEC was found to have minimal protein 
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contamination <1%. Thus, it was considered useful to examine the functionality of serum SEC-
derived exosomes. Due to exosomes showing potential for delivering specific cargo for 
therapeutic use, discussed earlier in section 1.7.1, the stability of exosomes (Section 1.7.1.1) 
require investigation for translation to the clinic as drug products require stability testing (Ammann, 
2011). Hence, the stability of the serum SEC-derived exosomes was also examined.  
 
Table 2.1: Regenerative properties of blood-derived exosomes and their isolation method 
Blood-derived 
source 





Rat plasma Myocardial injury: 
decreased infarct size 
in vivo UC (Vicencio et al., 
2015) 
Mice serum Ischemia/reperfusion 
injury: enhanced 
protective effect 
in vivo ExoQuick 
precipitation 
(Bei et al., 2017) 
Human coronary 
serum 
Hindlimb ischemia model: 
enhanced blood flow 
recovery and 
neovascularisation  
in vivo UC (Li et al., 2018b) 
Human serum Hindlimb ischemia: 
increased vessel number 
and hindlimb perfusion 
in vivo Density gradient (Cavallari et al., 
2017) 
Human serum Dysferlinopathy: assisted 
the repair of human 
dysferlin-/- myotube 
membranes after laser 
injury 
in vitro UC and density 
gradient 
(Dong et al., 
2018) 
Mice serum Hepatic fibrosis: repress 
liver injury 
in vivo UC (Chen et al., 
2018b) 
Human PRP Chronic wound: 
cutaneous healing  
in vivo UC and sucrose 
cushion 
(Guo et al., 2017) 
Mouse serum Full-thickness wound: 
increased healing 






enhanced wound healing 
in vivo UC and 
ultrafiltration 
(Hu et al., 2018) 
Mice serum Allergies: exosomes 
inhibited allergic 
sensitization/inflammation 
in the airway 




2.2 Results and Discussion 
2.2.1 Assessment of the size exclusion chromatography exosome isolation method 
At the start of this study SEC was found to be a promising alternative for exosome isolation when 
compared to UC, due to its cost effectiveness and lack of need for large/expensive equipment. 
Most importantly, SEC was a suitable single-step protocol to isolate a purer population of 
exosomes without damaging the vesicles (Böing et al., 2014, Muller et al., 2014, de Menezes-
Neto et al., 2015). SEC was found to be superior to UC with respect to purity as there was minimal  
albumin contamination (Baranyai et al., 2015).  
Pooled human serum from two individuals was fractionated using SEC on a Sepharose CL-4B 
column (Figure 2.1A). Exosomes are expected to elute first as they will travel within the void 
volume of Sepharose CL-4B. A small peak (max A280 at SEC fraction 9) was observed (inset in 
Figure 2.1B) prior to a large peak which contained the majority of serum proteins (Figure 2.1A). 
TEM showed particles of dimensions expected of exosomes in SEC fractions 8-10 (Figure 2.1D-
F) with average diameters correlating to those of exosomes; 55.3 nm ±21.4, 44.5 nm ±14.5, 38.5 
nm ±12.4 respectively (Figure 2.1I). Similar results were obtained using fresh fasted serum 
(Figure A1, Appendix 1). The spherical properties of the vesicles suggest that they were isolated 
without being lysed by the isolation process or TEM preparation. No vesicles were visible in SEC 
fraction 7 (Figure 2.1C) which correlated with the absence of a A280 reading (Figure 2.1B). SEC 
fraction 11 and 12 had a high background possibly due to the elution of serum proteins (Figure 
2.1G and H). The average diameter decreased in size across the SEC fraction 8-10, as expected, 
as larger vesicles would elute first. The size range of the vesicles in SEC fraction 8 (18.7-125.5 
nm) and SEC fraction 9 (15.3-117.5 nm) (Figure 2.1I), correlated with the reported exosome sizes 
of 20-100 nm (Caradec et al., 2014, Vicencio et al., 2015). The exosome enriched SEC fraction 
will be referred to as SEC exosomes. Fraction 10 was seen to have exosomes as well as vesicles 
smaller than exosomes (≤ 20 nm) (Figure 2.1F), with a size range of 10.4-86.8 nm (Figure 2.1I).  
It is to be considered that these exosome diameters determined by TEM are an underestimation 
of their size due to dehydration and shrinkage. It is estimated that the shrinkage is about 0-21% 
of the real EV diameter as examined by cryo-electron microscopy or resistive pulse sensing 
(Bachurski et al., 2019, Kotrbova et al., 2019). In addition, NTA is seen to overestimate the size 
of serum and L-540 Hodgkin cell-derived EVs compared to TEM due to the inability to detect 
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vesicles below 60 nm; observed with both the NanoSight NS300 and ZetaView (Bachurski et al., 
2019).  
It has been shown that SEC can be used as a stand-alone exosome isolation method from plasma 
(de Menezes-Neto et al., 2015). The vesicles isolated from human serum by SEC fraction 8 and 
9 appeared very similar to that reported by others with vesicles observed in a size range of 20-
100 nm (Caradec et al., 2014, Vicencio et al., 2015, Ibrahim and Marbán, 2016). This suggested 
SEC fraction 8 and 9 may contain exosomes. The presence of smaller vesicles that was more 
prominent on the shoulder of the exosome peak has been reported previously and these particles 






Figure 2.1: SEC of pooled human serum performed on a Sepharose CL-4B column to isolate exosomes. (A) 
Absorbance profile of 1 ml human serum separated using SEC; (B) Absorbance profile of SEC fractions 6-12 to reveal 
the exosome enriched peak. Three independent experiments were performed; (C-H) TEM micrograph of SEC fractions 
7-12 purified from pooled human serum. Scale bar = 100 nm; (I) TEM image analysis of vesicles present in SEC-
derived exosome fractions 8-10. Five technical repeats and standard deviation (SD) shown. 
 
2.2.2 Evaluating the purity of human serum exosomes isolated by three different 
methods 
2.2.2.1 TEM analysis 
SEC was then compared to two other popular exosome isolation methods (UC and ExoQuick 
precipitation). As mentioned in the introduction, PEG is used to precipitate particles by decreasing 
its solubility in a specific environment (salt concentration and 4°C) thereby forcing the particles 
together by excluding space, termed ‘crowding reagents’ (McNamara et al., 2018a). ExoQuick is 
based on PEG precipitation and many researchers have used this technique to isolate exosomes 
from human serum/plasma (Yang et al., 2017, Ye et al., 2017, Li et al., 2018c). UC was originally 
seen as the ‘gold’ standard to isolate exosomes and in 2016, UC was still being used by 81% of 
researchers (Gardiner et al., 2016). Multiple centrifugation steps are used to separate particles 
according to their buoyant density and a final UC step is then used to isolate exosomes at (100 
000 - 200 000 g) for 1-3 hours (Contreras-Naranjo et al., 2017, Konoshenko et al., 2018). The 
identity of the vesicles derived from human serum using three different exosome isolation 
methods (UC, ExoQuick and SEC) were evaluated using TEM imaging (Figure 2.2).  
The negative staining revealed numerous exosome like particles with spherical morphology and 
diameter size ranging from 20-100 nm for all three exosome isolation methods (Figure 2.2). The 
UC-derived exosomes (Figure 2.2A) had a higher background compared to SEC-derived 
exosomes. However, the ExoQuick-derived (Figure 2.2B) exosomes required a 3X dilution to 
image the vesicles, whereas UC and SEC-derived exosomes (Figure 2.2A and C) required no 
dilution.  
The dilution required to image the vesicles for the ExoQuick isolate suggested a high protein 
contamination, even when considering the starting amount of human serum and final exosome 
volume was 6 ml serum and 1.5 ml exosome isolate for UC, 0.5 ml serum and 0.2 ml exosome 
isolate for ExoQuick and 1 ml serum and 0.5 ml exosome isolate for SEC. One limitation of the 
ExoQuick study was that ExoQuick-TC was used due to its availability, which is aimed at isolating 
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exosomes from cell culture media although all ExoQuick products are PEG-based. However, 
there are widely reported issues with using ExoQuick as a stand-alone method to isolate pure 
exosomes. A study reported that commercial kits (ExoQuick and Total Exosome Isolation reagent) 
had the highest yield of serum vesicles detected using NTA; however, they had a lower protein 
purity and were less enriched for exosome markers (CD9, CD63 and TSG101) compared to UC 
(Tang et al., 2017). They suggested the UC damaged the vesicles leading to a decrease in particle 
yield and that ExoQuick was unable to separate exosomes from aggregated high-density serum 
proteins thereby increasing contaminated proteins. In accordance with another report, ExoQuick 
and Total Exosome Isolation reagent precipitation had decreased serum-derived exosome purity; 
however, in this investigation they compared the isolation with Exo-spin which combines 
precipitation and SEC (Soares Martins et al., 2018). The Exo-spin-derived exosomes had 
increased particle number and decreased protein concentration. It has been previously shown 
that commercial qEV SEC columns isolated exosomes of higher purity albeit with low exosome 
recovery from human plasma exosomes compared to ExoQuick and Exo-spin (Lobb et al., 2015). 
They also found Exo-spin achieved significantly higher purification than ExoQuick with respect to 
protein; however, both these techniques had high contamination detected in TEM images and the 
presence of albumin contamination, which was not present in the qEV SEC exosomes. 
Furthermore, exosome marker flotillin-1 was only detected in the SEC exosomes. 
ExoQuick was not specific to isolating only exosomes as SEC performed after ExoQuick revealed 
the presence of a substantial peak eluting after the exosome peak (Figure A2, Appendix 2). This 
confirmed that ExoQuick alone precipitates out contaminating proteins together with exosomes. 
This agrees with another study stating that ExoQuick requires a further isolation step such as UC 
and filtration to remove contaminating proteins when they showed that UC and ExoQuick yield 
the most the exosomes from bovine milk in a rapid amount of time (Yamada et al., 2012). The 
major problem of protein contamination was considered to outweigh the advantages of ExoQuick 




Figure 2.2: TEM micrograph of human serum exosomes isolated using three different isolation techniques. (A) 
UC (120 000 g for 2 hours); (B) ExoQuick-TC; (C) SEC. Scale bar = 100 nm.  
 
2.2.2.2 Protein concentration 
To validate the inference that the ‘dirty’ TEM images of UC and ExoQuick isolates from human 
serum were due to contaminating proteins, the protein concentrations of human serum exosomes 
isolated using the different techniques (UC (based on using centrifugal force), ExoQuick-TC 
(precipitation) and SEC (size separation)) were assessed using a Bradford assay (Table 2.2).  
ExoQuick-TC exhibited the highest resultant protein concentration (38.7 µg/µl ±1.2, 200 µl), 
whereas SEC displayed the lowest (0.2 µg/µl ±0.03, 500 µl). It must be noted that the protein 
concentration for SEC-derived exosomes was at the limit of assay detection suggesting a very 
low level of protein which is likely due in part to the efficacy of the isolation method but may also 
reflect the dilution that occurs during SEC. Attempts were made to try and concentrate the SEC-
derived exosome proteins using either Amicon Ultra 0.5 ml 100 kDa centrifugal filters or 
trichloroacetic acid precipitation (data not shown); however, with lack of success as no evidence 
of an increase in concentration was observed. This suggests that losses during the concentration 
process negated the concomitant concentration achieved.  
Plasma SEC fractions have been concentrated previously using an Amicon® Ultra-4 10 kDa 
device (Lobb et al., 2015). It is possible that an Amicon 10 kDa with regenerated cellulose 
membrane may have improved exosome concentrations rather than 100 kDa, as recent findings 
showed an Amicon 10 kDa filter concentrated and recovered the highest particle and protein yield 
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from human plasma SEC-derived exosomes (Vergauwen et al., 2017). Amicon 100 kDa had 
reduced particle recovery but it was not significantly less. However, other centrifugal filters 
(Vivaspin 10kDa with either hydrosart, polyethersulfone or cellulose triacetate membranes) had 
significant particle loss. It has become apparent that accurately quantifying exosome protein is 
challenging. Previous research investigated the protein concentration of MCF-7 Rab27b-GFP-
derived exosomes using four calorimetric assay (DC Protein, BCA, MicroBCA, Bradford) and 
three fluorometric assays (Qubit, NanoOrange, FluoroProfile) (Vergauwen et al., 2017). The six 
different protein kits had high variability for the exosome protein concentrations, but showed less 
variability with known BSA standards (200-400 µg/ml). They found the Qubit fluorometric assay 
to have the least variance between different experiments and detected 1.5 and 2 times more 
protein than MicroBCA and Bradford. The Bradford assay may underestimate the protein 
concentration of samples containing a membrane (Kirazov et al., 1993). Unfortunately, a Qubit 
assay requires use of a Qubit fluorimeter which is presently not available on our campus. The 
above findings further highlight the type of methodological issues that still plague the exosome 
field (Tkach et al., 2017). 
There are caveats at this point due to dilutions and concentration issues and lack of appropriate 
exosome quantification methods. It was challenging to directly compare the exosome protein 
concentration from the three different isolations. Assuming ExoQuick and UC pellet exosomes 
highly efficiently their use here would have respectively concentrated exosomes at least 2.5 and 
3 times more than SEC. It is challenging to determine the SEC dilution. Furthermore, SEC 
exosome protein concentration was below an accurate reading and outside the quantitative range 
of the Bradford assay. NTA was not available at this stage of the investigation in South Africa; 
hence, particle numbers couldn’t be determined or compared. 
Even with concerns related to relative dilutions and concentrations, ExoQuick-TC showed minimal 
purification (38.7 µg/µl ±1.2) as total serum protein content is 60-80 µg/µl (Merrell et al., 2004). 
Furthermore, in support of our results, Gamez-Velero et al. made use of both protein analysis and 
cryo-electron microscopy to show that SEC was able to remove a large proportion of plasma 
proteins, which PEG and PRotein Organic Solvent Precipitation (PROSPR) could not achieve 
(Gamez-Valero et al., 2016). Another study contrasted with the general consensus as they found 
that UC retained 23% of serum proteins compared to 7.3% using the ExoQuick method (Caradec 
et al., 2014). Tang et al., showed that ExoQuick was found to have higher protein contaminations 
and lower exosome purity when compared to UC when used to isolate exosomes from both serum 
and cell culture media (Tang et al., 2017). The differences could be due to different UC protocols 
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implemented; Caradec et al. used a very small serum volume of 330 µl and with a 30% sucrose 
cushion with one UC step at 100 000 g for 70 min, whereas Tang et al. had a larger serum volume 
(W32Ti rotor which holds 38.5 ml) and they used two UC spins at 110 000 g for 70 min to wash 
the exosome pellet. Precipitation-based isolation methods also co-isolate vesicle-free miRNAs, 
which obscures analysing miRNA cargo of plasma-derived EVs (Karttunen et al., 2018). 
The results do confirm that SEC isolates a protein-poor vesicle enriched fraction from human 
serum, reducing the contribution of plasma proteins towards subsequent functional studies. The 
high background detected in the TEM images of exosomes isolated by UC or ExoQuick (Figure 
2.2) probably reflects the high protein content (Table 2.2); which was further investigated.  
 
Table 2.2: Protein concentration of human serum exosomes isolated using three different isolation 
techniques 
Isolation methods Protein (µg/µl) Basis of technique 
UC 2.8 ±0.04 Centrifugal force 
ExoQuick-TC 38.7 ±1.2 Precipitation 
SEC 0.2 ±0.03 Size separation 
 
2.2.2.3 SDS-PAGE analysis 
Due to the high presence of contaminating protein in the ExoQuick isolates, ExoQuick was not 
further examined. To examine the nature of the SEC and UC isolates more closely equal volumes 
of each preparation were analysed on reducing SDS-PAGE (Figure 2.3).  
This was considered reasonable and appropriate as qualitatively there was not a major difference 
in vesicle number as observed qualitatively by TEM (Figure 2.2). It can be seen that minimal 
protein banding is present in the SEC lane. Only traces of high molecular weight bands are visible 
with the most prominent band above 250 kDa. The UC isolate had a wide range of proteins at 
different molecular weights present. Most prominent was a band at 66 kDa which most likely 
reflects the preponderance of serum albumin (66.5 kDa, represents 57-71% of serum protein) in 
serum (Merrell et al., 2004). There are also prominent bands at around 50 and 25 kDa which are 
probably IgG class γ heavy chains and light chains respectively, thus indicating IgG is at a high 
concentration in the UC isolate. The higher molecular weight bands in SEC are mirrored in the 
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UC lane and it is notable that the serum albumin and IgG bands are absent in the SEC isolate. 
Coomassie blue has detection limits but there appeared to be approximately 18X less protein in 
SEC compared to UC, in relation to the protein amount loaded in the SDS-PAGE (3.8 µg SEC-
derived exosomes and 68.1 µg UC-derived exosomes).  
In light of this finding the high background in the TEM image of UC-derived exosomes (Figure 
2.2) probably reflects high protein content. This is in agreement with previous findings, as plasma 
vesicles are detected in UC isolates after 1 hour or 3 hours; however, they are obscured by a high 
background material which increases after 6 hour and 14 hours UC as detected by TEM (Baranyai 
et al., 2015). The SDS-PAGE revealed significant albumin impurity in the UC isolate which is in 
line with previous studies detecting albumin using western blotting (Baranyai et al., 2015) or mass 
spectrometry (Kalra et al., 2013) in rat or human plasma UC-derived isolates. Further to this, 
various UC conditions (1 hour UC at 4°C, 10-fold dilution, 1 hour UC at 37°C, 3 hour, 6 hour and 
14 hour UC) still result in albumin contamination (Baranyai et al., 2015).  
The SDS-PAGE revealed no detectable presence of albumin in the serum SEC-derived 
exosomes as per Baranyai et al. using Sepharose CL-4B or Sephacryl S-400 columns (Baranyai 
et al., 2015). Due to the abundance of the major soluble plasma protein albumin in UC isolates, 
UC cannot be used to isolate pure exosomes which is important for identifying the composition 
and function of exosomes and for in vivo studies. Overall isolating human serum exosomes using 









Figure 2.3: SDS-PAGE (12%) of proteins present in the exosome samples isolated from human serum using 
SEC or UC. Molecular weight marker (MWM). Equal volume loading of SEC and UC-derived isolates (24 µl) that contain 
3.8 μg and 68.1 μg of protein respectively. n=2 (technical repeats). 
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These results so far demonstrate that the Sepharose CL-4B column efficiently isolated human 
serum vesicles within the exosome size range (20-100 nm) with very low levels of contaminating 
serum proteins. This correlates with a study where researchers compared different SEC columns 
and found that blood plasma exosomes had no significant albumin present when using Sepharose 
CL-4B or Sephacryl S-400 columns (Baranyai et al., 2015). However, these researchers also 
found Sepharose 2B columns to be inferior due to co-elution of exosomes with albumin 
suggesting that this matrix is less suitable for purifying exosomes. Though the authors noted this 
finding as interesting, they did not speculate to why this contamination might occur. It may be 
possible that in Sepharose CL-4B, all variants of exosomes would elute in the void volume and 
not enter the matrix due to the 30 nm Sepharose pores, whilst in the CL-2B with 75 nm pores, 
smaller exosomes would enter the stationary phase and this might result in greater possibility of 
a peak crossover with the large albumin peak. Other studies have assessed Sepharose CL-2B 
and found it to be efficient but have not been focussed on albumin contamination. One study used  
Sepharose 2B SEC prior to UC to remove contaminating plasma proteins from plasma exosomes 
(Muller et al., 2014). The SEC prior to UC was found to isolate plasma or serum exosomes as 
determined by significantly decreased total protein concentrations and improved ‘clearer’ TEM 
images, an observation that correlates with that seen in Figure 2.2. SEC was determined to be 
suitable as a stand-alone isolation method where a Sepharose CL-2B column was shown to 
isolate vesicles larger than 70 nm from platelet-depleted plasma with less than 1% of protein 
present (Böing et al., 2014). The differences in studies could be due to column volume, volume 
of sample loaded, type of SEC column and sample size collected, and these parameters are not 
routinely supplied in the literature. Many studies such as that reported by Böing et al. use short 
columns (diameter of 1.6 cm, height of 6.2 cm and 10 ml of Sepharose CL-2B). Increasing column 
length improves the resolution of SEC as resolution is proportional to column length1/2 according 
to the resolution equation and a large proportion of SEC columns have a 30 cm length for optimal 
resolution (Hong et al., 2012). It has been demonstrated that a longer column length of 30 cm 
with a smaller diameter (~0.5 cm) compared to 10 ml syringes (such as Exo-spin Midi Columns 
or qEV columns) filled with about 12 ml Sepharose CL-2B, has improved resolution and marginal 
better separation of plasma vesicles and albumin (Welton et al., 2016). Here we used diameter 
of 1 cm, height of 12.7 cm and 10 mL of Sepharose CL-4B for SEC. The main advantages of SEC 
are that it is more likely to preserve the biological activity of the exosomes due to is gentle nature, 
is relatively inexpensive, results in minimal protein contamination, and is quick and simple to use. 
However, an important disadvantage to consider is that the exosomes are diluted. UC could be 
used to enrich exosomes from a larger volume of plasma with the combination of SEC to remove 
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the contaminating plasma proteins; as Koh et al. showed that 10 ml plasma can be concentrated 
after 2 hours at 100 000 g and the resuspended 500 µl pellet purified on qEV SEC columns, with 
increased concentration of particles and the detection of exosome markers CD63, flotillin-1 and 
TSG101 (Koh et al., 2018). 
2.2.3 Western blot characterisation of exosomes 
To further determine whether human serum exosomes were isolated using SEC, western blotting 
was used to confirm the presence of proteins enriched in exosomes (Figure 2.4). ISEV 
recommends a minimum of 3 proteins to be detected and they should come from different 
categories (Lötvall et al., 2014), thus transmembrane proteins tetraspanins CD9 (23 kDa) and 
CD81 (26 kDa), as well as cytosolic protein TSG101 (50 kDa) were tested for in the SEC exosome 
enriched fraction. A negative protein marker could not be employed as serum exosomes are 
secreted by a variety of cells such as platelets, erythrocytes, endothelial cells and leukocytes 
(Hunter et al., 2008, Gyorgy et al., 2014).  
CD9 and TSG101 were more readily detected after concentration of SEC fraction 9 using 
Amicon® Ultra-0.5 100 kDa device (Figure 2.4A) indicating achievement of some concentration 
even though no increase in absorbance at 280 nm was not seen (data not shown). A larger volume 
of exosome enriched SEC fraction was required for detection of CD81 and it is likely that this 
caused the spreading of the band. To assess the purity of the SEC fractions, equal protein 
loadings were analysed by western blots for exosomal markers (Figure 2.4B). TSG101 was found 
in fractions 8 and 9, whereas CD9 was only found in fraction 9. This confirms that human serum 
SEC fraction 8 and 9 contained exosomes. However, it can be seen that TSG101 was also 
detected from fraction 12-15 increasing in concentration.  
The human serum SEC exosomes contained exosomal markers from different categories 
(transmembrane proteins (CD9, CD81) and cytosolic protein (TSG101)); further confirming the 
presence of an exosome enriched fraction. The abundance of TSG101 in later SEC fractions has 
been demonstrated previously as well as for CD63 of serum exosome isolations separated using 
SEC using equal volume loading as well as equal protein. Various studies where SEC-based 
isolation of exosomes from blood has been performed have shown this (Sepharose 2B, 
Sepharose CL-4B, Sephacryl S400, qEV size exclusion columns) (Baranyai et al., 2015, Koh et 
al., 2018). However, this phenomenon is not commented on besides Baranyai et al., who 
suggested that the separation efficiency of CD63 and TSG101 from albumin was below 1% as 
they were detected in SEC fractions 6-9 (1 ml fractions) when loading equal volumes (Baranyai 
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et al., 2015). This may indicate SEC has a low separation efficiency due to overloading the SEC 
columns as non-exosome associated TSG101 and CD63 are present in serum which increases 
in concentration in later fractions throughout the isolation. CD9 appears to be more specific for 
exosomes than TSG101 as it was not detected in later SEC fractions. Although there are markers 
that are in high abundance in exosomes such as the transmembrane proteins (CD9, CD63, CD81) 
and cytosolic proteins (TSG101), they only suggest the vesicles are likely exosomes but it is not 
specific enough to characterise them from EVs of different intracellular origins such as 
microvesicles (Kowal et al., 2016, Doyle and Wang, 2019). Again, highlighting the lack of specific 
markers to distinguish exosomes from other vesicles. 
 
 
Figure 2.4: Western blot to confirm presence of human serum exosomes isolated using SEC. (A) Presence of 
the exosome markers CD9, CD81 and TSG101 was determined in SEC fraction 9 (6 µl loaded except for CD81 which 
was 24 µl). n=3-4 (technical repeats); (B) Presence of exosomal markers (CD9 and TSG101) was determined in the 
human serum SEC fractions 7-15 (0.27 µg/fraction). n=2-3 (technical repeats). 
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2.2.4 Functional assessment of exosomes 
2.2.4.1 Exosome uptake into cells 
A further characterisation and functionality study is to test for exosome uptake into cells where 
they release their contents into a recipient cell and uptake is often  employed to indicate presence 
of exosomes (Feng et al., 2010). A common technique used to test for exosome uptake into cells 
is to label the exosomes with fluorescent dyes. These include lipophilic membrane dyes PKH26 
(Feng et al., 2010), BODIPY™ TR Ceramide (Cianciaruso et al., 2016),  PKH67 (Nakata et al., 
2017) and DiD or DiO (Beit‐Yannai et al., 2018); cell-permeant nucleic acid stain SYTO™ 
RNASelect™ green fluorescent cell stain (Singh et al., 2015) and a dye that labels EV proteins 
green ExoGlow™-protein EV labelling kit (green) (Gutkin et al., 2016). In this exosome uptake 
experiment a variety of stains were examined (nucleic acid stain (SYTO RNASelect), membrane 
stain (BODIPY TR Ceramide), dual staining of the membrane and nucleic dye and a dye that 
labels EV proteins green (ExoGlow)). The cytoskeleton of the cells was stained red or green with 
Phalloidin to examine the location of the labelled exosomes and the cells nuclei were stained blue 
with DAPI.  
To ensure that the excess fluorescent stain was removed, specialised columns (exosome spin 
column) were used to remove the unbound dye from the exosome sample. Another study used 
this column to remove free dye from ceramide-conjugated red fluorescent dye which labels the 
membrane, to show 293T cell-derived EVs entered U87 cells and not due to free stain labelled 
the cells (Balaj et al., 2015). This is in alignment with our results in which we showed that exosome 
spin column removed the free fluorescent dye (Figure 2.5).  
When no column was used for the SYTO RNASelect stain, the RNA stain labelled the HT1080 
cellular RNA as seen by the green fluorescence within the cells (Figure 2.5A). The exosome spin 
columns removed the excess SYTO RNASelect stain as no green fluorescence was detected; 
hence, there was no labelling of the cellular RNA (Figure 2.5B). The level of fluorescence after 















Figure 2.5: Exosome spin column removes unbound SYTO RNASelect as no cellular HT1080 RNA fluoresces. 
(A) Dye-only sample SYTO RNASelect (green); (B) PBS mixed with SYTO RNASelect and centrifuged through the 
exosome spin column to remove unbound SYTO RNASelect dye; (C) PBS control. HT1080 cells were cultured for 3 
hours with the treatments. After treatment fluorescent images were obtained using a fluorescent microscope (Nikon 
Eclipse 90i DS-Ri1). Nuclei stained with DAPI (blue) and cytoskeleton stained with Alexa Fluor® 594 Phalloidin (red). 
Scale bar = 20 µm. n=2 (technical repeats, 5 random fields of view per n). 
 
Various volumes of human serum SEC-derived exosomes labelled with SYTO RNASelect (green) 
were incubated with HT1080 cells to test the dosage effect on the amount of transfection (Figure 
2.6).  
Both 25% (v/v) SEC exosomes (Figure 2.6D) and 12.5% (v/v) (Figure 2.6C) gave 100% labelling 
of the cells with a drop in intensity observed at 12.5% and 6.25% (v/v) (Figure 2.6B) did not label 
all cells. Therefore, 12.5% (v/v) human serum SEC-derived exosomes was the concentration 
















Figure 2.6: Dosage effect of exosome uptake of fluorescently labelled SEC-derived exosomes by HT1080 cells 
in vitro. (A) PBS control; (B-D) Uptake of exosome sample labelled with SYTO RNASelect (green) at various dosages 
(6.25, 12.5, 25% (v/v)). HT1080 cells were cultured for 3 hours with the treatments. After treatment fluorescent images 
were obtained using a fluorescent microscope (Nikon Eclipse 90i DS-Ri1). Nuclei stained with DAPI (blue) and 
cytoskeleton stained with Alexa Fluor® 594 Phalloidin (red). Scale bar = 250 µm. n=2 (technical repeats). 
 
The SEC exosomes were labelled with nucleic acid stain (SYTO RNASelect) which labelled the 
RNA within the exosomes (green) (Figure 2.7B-C), membrane stain (BODIPY TR Ceramide) 
which labelled the lipid membrane of the exosomes (red) (Figure 2.7E-F), dual staining of the 
membrane and nucleic dye (red and green) (Figure 2.7H-I) and a dye that labels EV proteins 
green (ExoGlow) (Figure 2.7K-L).  
It was shown using all dyes that after incubation with HT1080 cells, SEC exosomes entered the 
cells (Figure 2.7). The PBS controls showed no auto fluorescence of the HT1080 cells labelled 
with DAPI or Phalloidin (Figure 2.7A and D). Zoomed in images of SEC exosome uptake 
determined localisation of the exosomes into HT1080 cells using the various stains (Figure 2.7C, 
F, I and L). The SYTO RNASelect labelled exosomes were detected by green diffuse fluorescence 
throughout the cell (Figure 2.7C), BODIPY TR Ceramide labelled exosomes were detected by red 
fluorescence around the cells nuclei (Figure 2.7F), the double staining revealed red punctuation 
around the cells nuclei and parts of the cytosol and green diffuse labelling throughout the 
cytoplasm (Figure 2.7I) and ExoGlow labelled exosomes were detected by green punctate 
fluorescence which accumulated along the cell membranes and there was cytoplasm labelling. 
All of which indicated exosome uptake into the cells and the release of exosome contents within 
the cytoplasm (Figure 2.7C, F, I and L).  
Reports on exosome uptake efficiency are variable as they range from 1 hour to 24 hours. These 
experiments showed SEC exosomes entered HT1080 cells after 3 hours, using a variety of stains. 
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A previous study showed that EVs derived from human embryonic kidney cells 293 were 
internalised by Uppsala 87 malignant glioma cells after 60 minutes of incubation (Balaj et al., 
2015). Numerous studies have used SYTO RNASelect or BODIPY TR Ceramide to test for 
exosomal uptake into cells (Harp et al., 2016), such as SYTO RNASelect labelled adipose stem 
cell-derived exosomes were taken up by neuron cells after 3 hours (Ching et al., 2018). ExoGlow 
has also been used for investigating exosomal uptake into cells (Mead and Tomarev, 2017, Sun 
et al., 2017), such as human menstrual blood-derived stem cell exosomes labelled with ExoGlow 
are taken up by AML12 cells after 24 hours (Chen et al., 2017).  
All three stains which as indicated above work on very different basis: nucleic acid stain, lipid 
membrane stain and a dye that labels EV proteins green. The labelled exosomes were found 
located within the cytoplasm which is in agreement with the literature (Mutschelknaus et al., 2016, 
Rosenberger et al., 2019). The internalisation of the exosomes suggests that the exosomes break 
apart to release their contents into the recipient cell, which was seen previously by membrane-
labelled cancer cell-derived exosomes gathering along the cell membrane after 3 hours and after 
24 hours the exosomes had been taken up by the cells causing cytoplasm labelling 
(Mutschelknaus et al., 2016). Exosome uptake was dose dependent, as there was as a brighter 
green fluorescence with increasing exosome concentration (6.25%, 12% and 25% (v/v)). Another 
study also showed this effect, SW780 cell-derived exosomes were taken up by bladder cancer 
cells within 4 hours and fluorescent intensity increased with a dose-dependent increase in 
exosomes (64, 320, 640, 1280x106 exosomes) (Franzen et al., 2014). It has also been found that 
exosome uptake can be time-dependent, menstrual MSC-derived exosomes were taken up by 
HUVEC and HMEC in increasing quantities over 4, 8 and 16 hours detected via FACS 
(Rosenberger et al., 2019). They further confirmed the labelled MSC-derived exosomes were 
localised in the cytoplasm by confocal microscopy. The incubation time for exosome uptake can 
be cell-dependent, head and neck cancer cell-derived exosomes were taken up by dendritic cells 
within 30 minutes, whereas T cells required 24 hours to internalise the exosomes as detected by 
confocal microscopy (Ludwig et al., 2018). The HT1080 cells readily internalised the human 
serum SEC-derived exosomes. This is of course functionally important as it shows the exosomes 
can readily deliver their therapeutic benefit or be a delivery vehicle to cells. However, caution 
must be taken in interpreting exosome uptake studies. Research had shown that serum and pure 
protein samples stained with lipophilic dyes (CellMask, PKH67, DiD) transfer the dye into cells 
(Takov et al., 2017). Hence, a slight contamination of proteins in the exosome preparation can 




Figure 2.7: Uptake of fluorescently labelled human serum SEC-derived exosomes by HT1080 cells in vitro. (B-
C) Exosome samples labelled with SYTO RNASelect (green), 12.5% (v/v); (E-F) Exosome samples labelled with 
BODIPY TR Ceramide (red), 12.5% (v/v); (H-I) Exosome samples double labelled with BODIPY TR Ceramide (red) 
and SYTO RNASelect (green), 12.5% (v/v); (K, L) Exosome samples labelled with ExoGlow (green), 25% (v/v); (A, D, 
G, J) PBS control; (C, F, I, L) Zoomed in image of SEC exosome uptake. HT1080 cells were cultured for 3 hours with 
the treatments. After treatment fluorescent images were obtained using a fluorescent microscope. Nuclei stained with 
DAPI (blue) and cytoskeleton stained with Alexa Fluor® 594 Phalloidin (red) (A-C) or Alexa Fluor® 488 Phalloidin 
(green) (D-F). Scale bar = 20 µm. n=3 (technical repeats). 
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2.2.4.2 The effect of exosomes on fibroblast growth 
Serum exosomes have functional properties as removing exosomes from FBS using UC 
decreases muscle cell proliferation and differentiation (Aswad et al., 2016). Furthermore, human 
serum exosome isolated using UC and density gradient have been shown to increase HMEC 
proliferation and tube formation (Cavallari et al., 2017) and coronary serum exosomes from 
myocardial ischemia patients isolated using UC improved HUVEC proliferation, migration and 
tube formation (Li et al., 2018b). Most of the functional studies testing the therapeutic effects of 
serum exosomes use UC isolations which contain non-exosome contaminants that could cause 
the biological effects detected (Takov et al., 2017, Menard et al., 2018). There are limited studies 
that investigate the function of serum/plasma-derived exosomes isolated using SEC (Takov et al., 
2019). The following experiment was done to determine the optimal storage conditions for 
assaying the functional effects of serum-derived exosome enriched SEC fraction with low protein 
content (Figure 2.8). Favourable storage conditions for exosomes have been reported to be below 
-70°C to preserve isolated exosomes for clinical application and scientific research (Lee et al., 
2016). Here various storage conditions of SEC-derived exosome were tested: SEC exosomes 
used immediately after isolation, stored at -80°C for 2 hours or snap frozen in liquid nitrogen and 
subsequently stored at -80°C for 2 hours. Due to exosomes having a potential to be used for 
therapeutic purposes, it is important to determine the stability of the exosomes after freezing.  
To determine the effects of exosome enriched fraction on HdFb proliferation, fibroblasts were 
incubated with SEC exosomes for 72 hours (Figure 2.8). As 12.5% (v/v) were internalised by all 
cells in the uptake experiment (Figure 2.6), 10% (v/v) of the exosome enriched SEC fraction (SEC 
exosomes) was considered sufficient for the cell proliferation assay. Treatment with 10% (v/v) 
SEC-derived exosomes had a significant increase in cell proliferation (p < 0.05) compared to 
fibroblasts treated with PBS control containing no serum. There was no significant difference in 
proliferation induced by SEC-derived exosome used immediately after isolation, stored at -80°C 
for 2 hours or snap frozen in liquid nitrogen and subsequently stored at -80°C for 2 hours. Although 
10% exosomes significantly promoted the proliferation of HdFb cells, proliferation was 
significantly more with 5% human serum (set at 100%). This indicates that exosomes play a role 
in cell proliferation; however, there are other components in serum that can also promote cell 
proliferation.  
The majority of serum exosomes have been found to be derived from platelets (Brisson et al., 
2017). Blood is suggested to contain components that have regenerative potential function 
(Villeda et al., 2014, Wyss-Coray, 2016, Sun et al., 2019). A further broad indication of this 
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potential is the extensive research into the use of PRP in regenerative approaches in ulcer 
wounds, tendon injuries, cosmetic purposes, scar healing and hair loss, discussed in section 
1.6.2.1 (Alves and Grimalt, 2018). PRP has a higher concentration of platelets than in plasma and 
once the platelets are activated they release a pool of bioactive agents including proteins, growth 
factors, cytokines and exosomes (Anitua et al., 2015). Studies have shown that PRP exosomes 
promote cutaneous healing of chronic wounds in a diabetic rat model (Guo et al., 2017) and 
plasma/serum exosomes are cardioprotective (Vicencio et al., 2015, Bei et al., 2017). Hence, 
PRP exosomes could be beneficial for regenerative purposes. It should be noted that at this early 
stage in this field of research, there are no studies comparing the difference in angiogenic 
potential of PRP exosomes to serum exosomes. The data suggests that serum exosomes isolated 
using SEC have bioactivity, as shown by previous researchers. One study found that 14 out of 18 
serum-derived exosome samples caused proliferation of HMEC (averaging 5x104 
exosomes/target cell) (Cavallari et al., 2017). Further research has shown that human umbilical 
cord blood-derived exosomes accelerate wound healing by transfer of miR-21-3p into HdFbs and 
HMEC (Hu et al., 2018). Plasma exosomes have been shown to be cardioprotective and potential 
mechanisms include HSP70 present on the surface of exosomes communicate with TLR4 
resulting in a signalling pathway in cardiomyocytes which activated cardioprotective HSP27 
(Vicencio et al., 2015), serum exosomes activate an ERK1/2 and HSP27 signalling cascade to 
prevent apoptosis of H9C2 cardiomyocytes (Bei et al., 2017, Li et al., 2018c) or serum exosomes 
are regulating miR-17-3p/TIMP3 to increase the proliferation of  H9C2 cardiomyocytes (Liu et al., 
2018b). However, three of these reports used ExoQuick to isolate the serum exosomes (Bei et 
al., 2017, Li et al., 2018c, Liu et al., 2018b). This isolation method is potentially compromised due 
to the high serum protein contamination as previously discussed which may mislead the 
conclusion of how the plasma exosomes are cardioprotective. The lack of plasma proteins, 
especially albumin, in the SEC exosome result in better quality exosomes. The fact that these low 
protein SEC exosomes significantly increase cell proliferation of fibroblasts suggests that serum 
exosomes do play a role in cell proliferation.  
It was further demonstrated that exosomes are suitable for cryopreservation. In support of this, 
previous studies have shown that exosomes derived from fresh and frozen plasma cause equal 
immune suppression by the down-regulation of CD69 expression on activated human CD4+ T 
cells (Muller et al., 2014). Though few studies testing the functionality of serum-derived exosomes 
isolated using SEC are available, our results are consistent with a study by Takov et al., who 
found that plasma-derived EVs isolated using SEC are bioactive as they found they stimulated 
migration of HUVEC (Takov et al., 2019). Serum provides an accessible and promising source of 
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Figure 2.8: In vitro effects of human serum SEC-derived exosomes on HdFb proliferation. Human fibroblasts 
were grown in MCDB media for 72 hours with various treatments shown. Data was normalised to cells cultured in 5% 
human serum. Proliferation was detected with the XTT assay. Combination of four independent experiments with four 
technical repeats. * p < 0.05 compared to no serum.  
 
2.2.4.3 The effect of exosomes on endothelial cell-derived spheroid sprouting 
Most exosome functionality studies test for cellular uptake, proliferation and migration (tube 
formation assay or transwell assay) (Guo et al., 2017, Tao et al., 2017b, Chen et al., 2018b). The 
spheroid sprouting assay designed in 1999 (Korff and Augustin, 1999), allows for studying the 
therapeutic effect of biological components on sprouting angiogenesis in a 3D in vitro model 
(Heiss et al., 2015). The 3D spheroid assay represents in vivo angiogenesis better than 2D 
angiogenesis assays (tube formation on Matrigel) as it illuminates the communication between 
endothelial cells under various treatments (Nowak-Sliwinska et al., 2018). Angiogenic potential is 
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analysed by sprout number and length. The minority of exosome functionality studies that do use 
the spheroid assay, investigate the therapeutic effect of exosomes against cancer growth (Khalyfa 
et al., 2016, Murgoci et al., 2018, Wang et al., 2018a). Hepatic stellate cell-derived exosomes (5 
µg) have been previously shown to deliver miR-335 (tumour suppressor) to cancer spheroids, 
inhibiting cancer cell invasion in vitro which correlated with their inhibition of tumour growth in vivo 
(Wang et al., 2018a). Microglia cell-derived exosomes (isolated from LPS stimulated cells) have 
shown to inhibit tumour invasion by 50% over 6 days using 3D glioma cell culture spheroids 
(Murgoci et al., 2018). To test for potential angiogenic properties of human serum SEC exosomes 
(30% (v/v)), exosomes were incubated with HUVEC spheroids embedded in a fibrin hydrogel 
(3.25 mg/ml) for 48 hours (Figure 2.9).  
Phase contrast images of the spheroids showed more sprout activity when treated with SEC 
exosomes compared to the PBS control after 48 hours (Figure 2.9A). The sprout number was 
analysed after 48 hours (Figure 2.9B). The serum SEC exosomes significantly increased the 
HUVEC sprout number (23 ±0.3) (p < 0.05) compared to the PBS control (16 ±2.1). There was 
no difference in sprout length (data not shown).  
Endothelial cell proliferation is located within the stalk cells during sprout elongation and the onset 
of angiogenesis is tip cell activation and loosening of cell to cell contact for migration (Ausprunk 
and Folkman, 1977, Gerhardt, 2008). Depending on the microenvironment, pro-angiogenic 
paracrine signals will initiate endothelial cell sprouting. The spheroid assay is a useful in vitro 
technique to test for migration in a 3D setting. There are limited studies that investigate the effect 
of exosomes on spheroids. Our data is novel in identifying serum SEC exosomes cause an 
increase in endothelial sprout number. Other studies have found that conditioned media from 
MSCs induced significantly longer HUVEC sprout length after 16 hours (Gong et al., 2017). They 
went on to investigate whether the paracrine mechanism was involved, and they showed 
exosomes derived from MSCs mediated the transfer of miRs from MSCs to HUVECs and 
promoted angiogenesis. Their results suggested the exosomes delivered pro-angiogenic 
miRNAs; albeit they did not directly investigate the effect of MSC exosomes on spheroid 
sprouting. We did not see an increase in sprout length, but our source of exosomes was from 
serum and not MSCs. Plasma-derived exosomes, isolated using precipitating Total Exosome 
Isolation reagent, from patients with sleep apnea stimulate proliferation and migration of lung 
cancer cells (Khalyfa et al., 2016). However, the plasma-derived exosomes from patients with 
sleep apnea caused no significant difference in invasion using a 3D spheroid assay with lung 
cells. As described above, spheroid assays have also been used to test for the role of cancer-
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derived exosomes. A study showed that exosomes (100 µg/ml) derived from cancer cell lines 
(LNCaP and DU145) caused prostate epithelial cell line (RWPE-1) spheroids to disseminate after 
48 hours (Hosseini-Beheshti et al., 2016). Two cell types are within the bud of the sprout, tip cells 
(migration) and stalk cells (elongation) (Irvin et al., 2014) that may provide a reason for the 
spheroid observations. It is possible the serum SEC exosomes activate the tip cells for migration 
leading to an increase in sprout number, but they don’t activate the stalk cells; hence, no increase 
in sprout length. As the serum SEC exosomes showed bioactivity through cellular uptake, 
enhancing fibroblast proliferation and increasing spheroid sprout numbers in vitro; the stability of 
the SEC exosomes stored at 37°C for 3 weeks was further investigated. 
 
 
Figure 2.9: In vitro effects of human serum SEC-derived exosomes on sprouting of HUVEC spheroids in fibrin 
hydrogels. (A) Fibrin hydrogels were treated with either 30% PBS or 30% serum SEC-derived exosomes in 2% FBS 
MCDB media and sprouting was imaged using a phase-contrast microscope at 48 hours. Scale bar = 100 µm; (B) 
Analysis of sprout number (30% PBS and 30% serum SEC-derived exosomes) after 48 hours. Combination of three 
independent experiments with four technical repeats. * p < 0.05 compared to 30% PBS control.  
 
2.2.5 Stability of exosomes 
Pharmaceutical companies have an obligation to prevent loss of therapeutic properties during 
delivery of drugs. Hence, a temperature-controlled environment is required by certain therapeutic 
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products. It is good practice for drug products to be tested for stability (Ammann, 2011). Due to 
exosomes having a potential to be used for therapeutic purposes, it is important to determine the 
temperature stability of the exosomes. These experiments tested the bioactivity of human serum 
SEC exosomes that were stored at either -80°C or 37°C. Even though UC-derived exosomes 
were shown to have high protein contamination, their stability was also tested. The SEC and UC-
derived exosomes morphological stability was determined by TEM and their functionality stability 
by their retention of their ability to stimulate cell proliferation and be taken up by cells.  
2.2.5.1 TEM analysis 
To determine the stability of the SEC and UC-derived exosomes, they were stored at 37°C for 3 
weeks with gentle agitation and their physical properties assessed by TEM (Figure 2.10). 
The TEM revealed that SEC-derived exosomes retained their spherical shape and diameter size 
ranging between 20-100 nm when stored at 37°C for 3 weeks compared to the -80°C storage 
(Figure 2.10A). The average diameter of SEC exosomes stored at -80°C (41.2 nm ±16.4) 
decreased in size when stored at 37°C for 3 weeks (36.1 nm ±15.2), which is a 12.4% decrease 
in average vesicle diameter (Figure 2.10B). The size range of the vesicles in SEC exosomes 
stored at -80°C (21.0-128.2 nm) and stored at 37°C for 3 weeks (15.5-155.1 nm) (Figure 2.10B), 
were not significantly different. The TEM revealed that vesicles were isolated using UC as could 
be seen by the presence of spherical or cup-shaped particles (Figure 2.10A). The average vesicle 
diameters were difficult to accurately quantify for the UC-derived exosomes due to the high 
background present on the TEM grid, whereas the SEC-derived exosomes had a cleaner TEM 
background. The TEM background is higher on the UC-derived exosomes stored at 37°C for 3 
weeks compared to being stored at -80°C, likely due to contaminating proteins aggregating. This 
high background confirms the previous result that UC isolated contaminating proteins which 







Figure 2.10: TEM micrograph of human serum exosomes isolated using SEC or UC and stored at either -80°C 
or 37°C for 3 weeks. (A) TEM micrographs. Scale bar = 100 nm; (B) TEM image analysis of vesicles present in SEC-
derived exosome and stored at either -80°C or 37°C for 3 weeks. Five technical repeats and SD shown.  
 
2.2.5.2 Uptake analysis 
The stability of the exosomes after storage at 37°C for 3 weeks was then further assessed with 
respect to both their uptake by cells and their efficacy in stimulating cellular proliferation.  
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To examine exosome uptake, the exosomes were labelled green with SYTO RNASelect which 
labelled RNA contained within the exosomes (Figure 2.11). The PBS controls showed no auto 
fluorescence of the HT1080 cells stained with DAPI and ActinRed™ ReadyProbes® (Figure 
2.11A and D). Exosome uptake occurred for the SEC-derived and UC-derived exosomes that 
were stored at -80°C (Figure 2.11B and E). Both the SEC-derived and UC-derived exosomes 
retained their functionality as they were taken up by HT1080 cells after being stored at 37°C for 
3 weeks as detected by green fluorescence with all cells showing the presence of RNA within 
their cytoplasmic regions (Figure 2.11C and F). Therefore, the exosomes were still functional and 
able to enter the HT1080 cells. 
 
 
Figure 2.11: Functional stability of human serum SEC or UC-derived exosomes stored at either -80°C or 37°C 
for 3 weeks. Uptake of SYTO RNASelect (green) labelled exosomes by HT1080 cells in vitro. (A) PBS control for SEC-
derived exosomes; (B) SEC-derived exosomes stored at -80°C, 12.5% (v/v); (C) SEC-derived exosomes stored at 37°C 
for 3 weeks, 12.5% (v/v); (D) PBS control for UC-derived exosomes; (E) UC-derived exosomes stored at -80°C, 4.18% 
(v/v); (F) UC-derived exosomes stored at 37°C for 3 weeks, 4.18% (v/v). HT1080 cells were cultured for 3 hours with 
the treatments. After treatment fluorescent images were obtained using a fluorescent microscope. Nuclei stained with 
DAPI (blue) and cytoskeleton stained with ActinRed™ ReadyProbes® (red). Scale bar = 20 µm. Two independent 




2.2.5.3 Proliferation analysis 
To study whether human serum exosomes retained their biological activity after being stored at 
37°C for 3 weeks, fibroblasts were incubated with SEC or UC-derived exosomes for 72 hours 
before analysing cell proliferation (Figure 2.12). It was calculated that 3.33% of UC exosomes 
was roughly equivalent to 10% SEC exosomes isolated, as determined from initial serum volumes 
and final isolate volumes. UC was concentrated 3.6X from 5.4 ml human serum and SEC had a 
final isolate volume of 0.5 ml from 1 ml human serum; hence, it was estimated that there were 3X 
more EVs in UC-derived than SEC-derived exosomes. 
Treatment with 10% SEC-derived exosomes showed a significant increase in cell proliferation (p 
< 0.05) compared to fibroblasts treated with no serum. There was no statistical difference between 
SEC-derived exosomes stored at -80°C and 37°C for 3 weeks (Figure 2.12A). Treatment with 
3.33% UC-derived exosomes stored at -80°C and 37°C trended towards increased cell 
proliferation; however, it was not statistically significant compared to fibroblasts treated with no 
serum (Figure 2.12B). 
 
 
Figure 2.12: In vitro effects of human serum SEC or UC-derived exosomes stored at either -80°C or 37°C for 3 
weeks on HdFb cell proliferation. (A) Serum SEC-derived exosomes; (B) Serum UC-derived exosomes. Human 
fibroblasts were grown in MCDB media for 72 hours with various treatments shown. Data was normalised to cells 
cultured in 5% human serum. Proliferation was detected with the XTT assay. Combination of four independent 
experiments with four technical repeats. * p < 0.05 compared to no serum.  
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In this study UC was also used to isolate exosomes from human serum as this is still the most 
common exosome isolation technique (Gardiner et al., 2016). Exosomes were seemingly 
confirmed to be isolated as determined by electron microscopy that showed vesicles ranging 
between the sizes of 20-100 nm. It was not possible to detect the exosome markers in the UC 
exosomes using western blotting (data not shown) as there were prominent bands at around 50 
and 25 kDa. These are probably IgG class y heavy chains and light chains as prominent bands 
could be observed in the SDS-PAGE gel (Figure 2.3). It was shown that UC was a less optimal 
isolation method as large levels of contaminating proteins were isolated as seen by the electron 
micrograph and SDS-PAGE (Figure 2.3). As discussed in section 2.2.2, UC isolations have been 
shown by us and others (Kalra et al., 2013, Baranyai et al., 2015) to be contaminated with albumin 
and other proteins such as IgG. 
Human serum exosomes in PBS isolated using SEC or UC and stored at 37°C for 3 weeks with 
gentle agitation were shown to retain their morphological characteristics. Their spherical shape 
was still intact as evident on the electron micrographs (Figure 2.10). A previous study stored 
plasma exosomes spiked with LIM 1863 exosomes for 30 days at 37°C and suggested some 
stability as they detected undamaged TSG101 on a western blot; however, they suggested high 
levels of protein disrupted the microscopic analysis due to isolation with UC (Kalra et al., 2013). 
This is in agreement with the observation of a substantial precipitate with exosomes isolated by 
UC (Figure 2.10). The SEC-derived exosome size decreased by 12.4% when stored at 37°C for 
3 weeks compared to storage at -80°C. In another study the exosome size was found to decrease 
by 60% when stored at 37°C for 2 days as determined by NTA (Sokolova et al., 2011). This 
difference could arise from their differing characterisation method or the use of exosomes from 
human embryonic kidney 293 cells, endothelial colony forming cells and MSCs and not human 
serum exosomes. This potential difference between tissue culture and serum-derived exosomes 
will need further investigation. In another study, superparamagnetic nanoparticles (SPMNs) were 
anchored onto exosomes and isolated the reticulocyte-derived exosome-based 
superparamagnetic nanoparticle cluster (SMNC-Exos) from mice serum using magnetic 
separation (Qi et al., 2016). The stability of the SMNC-Exos at 4°C in PBS buffer and 37°C in 
serum was assessed by changes in exosome diameter using dynamic light scattering at various 
time intervals. The SMNC-Exos did not aggregate in PBS buffer at 4°C and 37°C after 7 days 
once magnetically separated and redispersed. This indicates the exosomes were stable which 
agrees with our results for SEC exosomes. A shorter storage of 18 hours at 37°C, as well as at 
4°C, 27°C, 42°C and changes in pH (6.6, 7.1 and 7.4) have been reported for cardiac myocyte 
exosomes in PBS isolated using ultrafiltration and UC and they retained HSP60 (membrane 
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bound) as well as GAPDH (cytosol) indicating exosome stability (Malik et al., 2013). Urine has 
been stored at 37°C for 24 hours and the exosomes remained stable in size (Lv et al., 2013). 
Thus, several studies indicate morphological stability.   
The SEC-derived exosomes and UC-derived exosomes stored at -80°C and 37°C for 3 weeks 
were internalised by HT1080 cells indicating exosome functionality. A similar type of study stored 
35 µg of LIM 1863 exosomes spiked into 1 ml plasma at -20°C for 30 days and the reisolated 
exosomes were taken up by LIM 1215 colorectal cancer cells revealing functionality (Kalra et al., 
2013). Furthermore, the SEC-derived exosomes stored at -80°C and 37°C for 3 weeks both 
similarly and significantly increased cellular proliferation of HdFb compared to no serum. Human 
serum SEC-derived exosomes stored at 37°C are functionally stable as there was no statistical 
difference between -80°C and 37°C stored exosomes. The 12.4% decrease in SEC exosome 
diameter size stored at 37°C for 3 weeks size had no apparent influence on their bioactivity. The 
UC-derived exosomes trended towards increasing cellular proliferation; however, they did not 
significantly increase proliferation of HdFb when stored at either -80°C or 37°C. The results had 
a high degree of variability, and this could have been caused by the contamination of serum 
proteins and aggregation which was evident on the TEM micrographs which co-isolated with the 
exosomes. Though in this study dose from equivalent starting volumes were used, it is possible 
a higher dose of UC exosomes might have induced a significant proliferation effect. However, it 
is also perhaps likely that the variability observed may have worsened by the greater absolute 
levels of contaminating protein. It has been previously shown that human induced pluripotent 
stem cell-derived MSC exosomes substantially increased the proliferation of HUVEC and 
fibroblasts in a dose-dependent manner over a period of 5 days (Zhang et al., 2015) but as of yet 
this type of functional assay has not been used to assess stability of exosomes stored at 37°C. 
These experiments showed that human serum SEC-derived exosomes in PBS are stable and 
functional when stored at 37°C for 3 weeks. However, the presence of smaller vesicles that was 
more prominent on the shoulder of the exosome peak has been reported previously and these 
vesicles were identified as HDL (Böing et al., 2014). The isolation of pure exosome preparations 
is still a challenging area that requires intensive investigation (Baranyai et al., 2015), which will 
be discussed and investigated in the following chapter. Long term survival of exosomes is an 
advantage for further pharmaceutical therapeutic applications using exosomes. From these 
results it could be assumed that exosomes are stable at RT for up to 3 weeks perhaps due to 
their membrane stability which is advantageous for transporting and storing exosomes for 
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potential clinical use. The stability of the exosomes could assist in their exploitation for drug or 
RNA delivery.  
2.2.6 Exosomes embedded in hydrogels 
Hydrogels have a similar structure to that of the ECM, making them suitable for delivery to a 
variety of tissues. Hydrogels can be designed such that their release rate can be controlled by 
environmental conditions such as pH and cellular degradation (Hoffman, 2002, Zisch et al., 2003, 
Wang et al., 2012). They are suitable for the controlled localised release of various bioactive 
factors such as stem cells, plasmid DNA and growth factors to promote regeneration in damaged 
tissue (Lei et al., 2010, Farhat et al., 2018). For example, it has been shown that adipose stem 
cells delivered in a chitosan/gelatin hydrogel significantly increased capillary density in a mice 
wound healing model compared to hydrogel or stem cell only treatment (Cheng et al., 2017). 
Another study showed that a multiarmed PEG and heparin hydrogel increased cell proliferation in 
an acute mice kidney injury when loaded with bFGF or murine EGF (Tsurkan et al., 2013).  
The delivery of bioactive molecules from hydrogels has been widely studied over the last decade 
due to their ability to localise and sustain the delivery of the factors. It is reasonable to predict that 
these characteristics of delivery may be desirable for exosome delivery. The use of hydrogels for 
exosome delivery has very recently begun to be reported on in recent years. Hydrogels tested for 
exosome delivery include chitosan (Xu et al., 2018), chitosan/silk (Shi et al., 2017), hyaluronic 
acid (Chen et al., 2018a), hydroxyapatite/chitosan (Li et al., 2016b), poly(vinyl alcohol) (Fuhrmann 
et al., 2018), silk fibroin (Han et al., 2019) and sodium alginate (Guo et al., 2017). As detailed in 
section 1.7.2.3, a range of pathologies have begun to be targeted with exosomes encapsulated 
in hydrogels. Hydrogels have been investigated for their ability to deliver exosomes for therapeutic 
purposes such as in wound healing (Guo et al., 2017, Tao et al., 2017c, Xu et al., 2018), MI (Chen 
et al., 2018a) and hindlimb ischemia (Zhang et al., 2018, Han et al., 2019). PRP-derived 
exosomes embedded in a sodium alginate hydrogel promoted cutaneous healing of chronic 
wounds in a diabetic rat model (Guo et al., 2017). In another example silk fibroin hydrogel 
improved the retention of miR-675 loaded MSC-derived exosomes and significantly enhanced 
blood perfusion (Han et al., 2019). Due to the therapeutic potential of sustained delivery of 
exosomes from hydrogels, serum SEC-derived exosomes were investigated for their delivery from 
a naturally derived fibrin hydrogel. 
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2.2.6.1 Exosomes embedded in a fibrin hydrogel 
A fibrin hydrogel is a naturally derived gel which functions as a haemostatic plug and a matrix for 
cell migration and wound healing. Fibrin glue has been used instead of sutures or staples to 
enhance healing and minimise scarring (Janmey et al., 2009) and is FDA approved. Fibrin has 
also been shown to be directly protective after injection into an infarcted heart (Christman and 
Lee, 2006) as well as to deliver bioactive components such as bone marrow mononuclear cells 
resulting in increased tissue regeneration and significantly higher microvessel density (Ryu et al., 
2005). Fibrin hydrogels are suitable as a delivery mechanism as they gel in situ, degrade naturally 
in the body and show controlled release. Currently there are no studies that we are aware of that 
have tested the use of serum exosomes in a fibrin hydrogel.  
2.2.6.1.1 Distribution 
To assess the distribution of the exosomes within the fibrin hydrogel, BODIPY TR Ceramide 
labelled SEC-derived exosomes were entrapped at a 30% (v/v) in a 3 mg/ml fibrin hydrogel. The 
exosomes were seen to be entrapped and distributed throughout the depth of hydrogel with 
confocal microscopy. A maximum intensity projection Z-stacked confocal image is shown (Figure 











Figure 2.13: Distribution of human serum SEC-derived exosomes in a fibrin hydrogel. Maximum intensity 
projection of BODIPY TR Ceramide (red) labelled SEC-derived exosomes suspended within a fibrin hydrogel (3 mg/ml). 




2.2.6.1.2 Release rate 
A standard dilution curve was obtained for BODIPY TR Ceramide labelled SEC-derived 
exosomes (Figure 2.14A) to establish a means of quantifying released exosomes from a fibrin 
hydrogel (Figure 2.14B). The exosomes were diluted with PBS and the exosome concentrations 
ranged from 0.8 µl to 10 µl/100 µl. A cumulative percentage release of BODIPY TR Ceramide 
labelled exosomes from a 3 mg/ml fibrin hydrogel over 96 hours is shown (Figure 2.14B). There 
was a burst release of approximately half of the label in the first 24 hours followed by a sustained 
release until completion at 96 hours.  
A release study on PRP-derived exosomes from sodium alginate hydrogels, detected with CD63-
based ELISA, saw complete release by 12 hours which suggests that fibrin may have more 
favourable release characteristics with sustained release over 96 hours. This release rate 
presumably reflects steric hindrance of the diffusion of the exosomes out of the hydrogel and/or 
the degradation of the hydrogel. It was observed that the fluorometer signal was found to increase 
over the 24 hours prior to stabilising (Figure A3, Appendix 3). It is not clear why this increase in 
signal occurred but the linearity of the standard curve indicated that delaying fluorescent 
measurements for 24 hours was suitable. 
 
 
Figure 2.14: Release rate of exosomes from a fibrin hydrogel. (A) Standard curve generated from dilutions of 
BODIPY TR Ceramide labelled SEC-derived exosomes. Four technical repeats; (B) Cumulative percentage release of 




2.2.6.1.3 Uptake of exosomes embedded in a fibrin hydrogel 
The transwell migration assay, also known as the Boyden chamber assay, was developed in 1962 
to analyse cell migration in response to a chemotactic agent (Boyden, 1962). The assay uses a 
cell culture insert with a porous membrane to separate the upper and bottom compartment. Cells 
are seeded on the upper layer of the insert and the chemotactic agent is placed in the bottom 
compartment. To test for invasion, the membrane is coated with a gel comprised of ECM. After 
the chamber is incubated (3-18 hours), the cells that have migrated through the membrane are 
fixed and stained. The cells on the bottom compartment are counted to quantify migration induced 
by chemotactic agents (Marshall, 2011). Transwell assays have also been used to test exosomes 
for chemoattractant properties; however, there is variation in the concentration of exosomes 
required for a response. MSC-derived exosomes promote migration of cardiac stem cells in a 
dose-dependent manner (100, 200, 400 and 800 µg/ml) with significance from 400 µg/ml (Zhang 
et al., 2016). Whereas, a lower concentration of PRP-derived exosomes (5 and 50 µg/ml) have 
been shown to significantly increase migration of fibroblasts and HMEC compared to control and 
supernatant of activated PRP (Guo et al., 2017). Differences could be attributed to the different 
source of exosomes, exosome isolation method or cell types tested. 
A novel modified transwell assay was used to assay for uptake of SEC-derived exosomes 
embedded in a fibrin hydrogel by invading HT1080 cells that migrated down through the hydrogel 
to the bottom of the transwell insert (Figure 2.15). HT1080 cells (20 000) were seeded on top of 
a 50 µl 3 mg/ml fibrin hydrogel polymerised in the insert. The hydrogel contained 63.6% SYTO 
RNASelect labelled SEC-derived exosomes (Figure 2.15A). The chemoattractant consisted of 
10% FBS and 10 ng/ml bFGF in MCDB media. The cells were left for 24 hours to allow for 
migration through the fibrin gel and for uptake of the RNA labelled exosomes (Figure 2.15B). The 
cells potentially containing the green RNA labelled exosomes migrated to the bottom of the 
polycarbonate insert membrane (Figure 2.15C). The bottom of the insert was cut out, fixed and 





Figure 2.15: Transwell assay using SYTO RNASelect labelled human serum SEC-derived exosomes embedded 
in a fibrin hydrogel. Diagram showing the modified transwell experiment to test for uptake of exosomes when HT1080 
cells migrate through a fibrin hydrogel. (A) HT1080 cells seeded on top of fibrin hydrogel (3 mg/ml) containing SYTO 
RNASelect labelled serum SEC exosomes (green) (63.6%); (B) Cells allowed to migrate for 24 hours; (C) Cells migrated 
through the fibrin hydrogel to the bottom of the polycarbonate insert membrane; (D) Bottom of the insert is cut out, fixed 
and imaged using a fluorescent microscope. 
 
After 5.5 hours HT1080 cells did not migrate through the fibrin gel as no cells were detected at 
the bottom of the polycarbonated transwell cell culture inserts (Figure 2.16A). This control also 
indicated that any cells that remained above the cell culture insert membrane were completely 
removed. Hence, only the cells that would have migrated through the fibrin gel and the 
polycarbonated pores would be detected. After 24 hours HT1080 cell migrated through the 3 
mg/ml fibrin hydrogel; with the majority of cells fluorescing green indicating effective ingress of 
the exosomes as the HT1080 cells invaded and moved through the hydrogel (Figure 2.16A).  
To investigate the stability of exosomes over time, the fibrin hydrogels containing exosomes were 
incubated in excess media (36X hydrogel volume) for various time periods prior to cells being 
added. HT1080 cells were again seen to be transfected effectively by exosomes embedded in 
the fibrin hydrogel (3 mg/ml) for 1 day as well as for 3 days as detected by green fluorescence 
though there was a not unexpected reduction in intensity at day 3 (Figure 2.16B). Exosomal 
uptake was not detected when the exosomes were previously embedded in the fibrin hydrogel (3 
mg/ml) for 7 days as no green fluorescence was detected. This correlates with the release profile 
(Figure 2.14B) as by day 4 all exosomes are released from a 3 mg/ml fibrin hydrogel. It was 
considered that a 10 mg/ml fibrin hydrogel might reduce the release rate due to increased steric 
88 
 
hinderance. There was substantial transfection when cells were allowed to migrate through an 




















Figure 2.16: HT1080 uptake of human serum SEC-derived exosomes embedded in fibrin hydrogels using 
transwell cell culture inserts. (A) Treatments: 5.5 hours of migration through fibrin hydrogel with 63.6% SYTO 
RNASelect labelled exosomes (green), 24 hours of migration through fibrin hydrogel PBS control, 24 hours of migration 
through fibrin hydrogel with 63.6% green exosomes; (B) HT1080 uptake of exosomes embedded in a 3 or 10 mg/ml 
fibrin hydrogel over 1, 3 or 7 days in 20% FBS MCDB media. After migration the transwells were processed for 
fluorescent imaging. Nuclei stained with DAPI (blue) and cytoskeleton stained with ActinRed™ ReadyProbes® (red). 
Scale bar = 20 µm. Three independent assays with two technical repeats.  
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A concern was that dye from disrupted exosomes might persist in the fibrin and label cells in an 
artefactual manner. To reduce the concern that such artefactual dye transfer was occurring, RNA 
labelled SEC-derived exosomes were sonicated and tested for dye transfer in the 2D transfection 
assay (Figure 2.17A). If free SYTO RNASelect was present after sonication of exosomes, cells 
would be expected to be labelled.  
Examination with TEM indicated that sonication of the SEC-exosomes severely disrupted their 
morphology (Figure 2.17B). There was a marked decrease in fluorescent intensity in cells 
incubated with sonicated exosomes (Figure 2.17A). This indicates that it is unlikely that dye 



















Figure 2.17: Controls to ensure the transwell experiment was not an artefact of released fluorescent dye. (A) 
Uptake experiment to test if sonicated fluorescently labelled (SYTO RNASelect dye) exosomes affected their uptake 
into cells. Nuclei stained with DAPI (blue) and cytoskeleton with Alexa Fluor® 594 Phalloidin (red). Scale bar = 20 µm. 
Two independent experiments with four technical repeats; (B) TEM image of 12.5% exosomes and of 12.5% sonicated 
exosomes to ensure sonication worked. Scale bar = 100 nm.  
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The morphological stability of the encapsulated vesicles was then assessed by digesting the 
hydrogels with proteinase K to allow for their release. The physical effect of proteinase K on 
exosomes and exosomes in the fibrin hydrogel was assessed first using TEM (Figure 2.18). 
Exosomes incubated with proteinase K at 500 µg/ml (Figure 2.18A) were visible and had a circular 
shape. A control fibrin hydrogel without exosomes was digested with proteinase K (500 µg/ml) 
showed minimal background (Figure 2.18B). Exosomes were detected and retained their circular 
shape when digested from the fibrin hydrogel (50 µl) with proteinase K at 500 µg/ml (Figure 2.18C) 
and when incubated for 1 day at 37°C prior to being digested with proteinase K (Figure 2.18D).  
Overall, the SEC-derived exosomes seemed to retain their physical properties when embedded 
in a fibrin hydrogel. This result and that after sonication indicate that uptake observed for HT1080 
cells was a result of uptake of vesicle encapsulated dye. Serum SEC-derived exosomes retained 
their shape within a fibrin hydrogel and if any of the exosomes had lysed it would have led to a 
decrease in exosome uptake. Together, these results show that fibrin hydrogels are a good 









Figure 2.18: TEM micrograph of fibrin hydrogels and fibrin hydrogels containing SEC-derived exosomes 
digested with proteinase K. (A) SEC exosomes digested with proteinase K (500 µg/ml); (B) 50 µl fibrin gel (10 mg/ml) 
digested with proteinase K (500 µg/ml); (C) 50 µl fibrin gel (10 mg/ml) containing 31.8 µl SEC exosomes digested with 
proteinase K (500 µg/ml); (D) 50 µl fibrin gel (10 mg/ml) containing 31.8 µl SEC exosomes incubated for 1 day at 37°C 






2.3 Summary  
Blood is another source of exosomes and it is advantageous over cell culture sources due to its 
simple collection and processing. Furthermore, there is growing research that blood may contain 
bioactive biomolecules that have regenerative potential (Villeda et al., 2014, Wyss-Coray, 2016, 
Sun et al., 2019). PRP has been shown to be a potential therapy for ulcer wounds, tendon injuries, 
cosmetic purposes, scar healing and hair loss (Alves and Grimalt, 2018) and once the platelets 
in PRP are activated they release bioactive components (Anitua et al., 2015), discussed in section 
1.6.2.1. Indeed, exosomes from PRP have been found to have regenerative potential as in 
stimulating neovascularisation (Guo et al., 2017). Furthermore, over the recent years the interest 
in understanding the function of serum or plasma exosomes has grown. They have potential to 
be biomarkers for diseases such as cancer (Krafft et al., 2017), cardiovascular problems (Wu et 
al., 2018) and liver disease (Suehiro et al., 2018). Serum or plasma exosomes have also been 
determined to have anti-fibrotic properties (Chen et al., 2018b), be cardioprotective (Vicencio et 
al., 2015) and improve blood flow recovery and neovascularisation in a mouse hindlimb ischemia 
model (Li et al., 2018b) (Section 1.7.4).  
However, there are issues in standardising exosome isolations with a variety of methods being 
utilised that include UC, precipitation, ultrafiltration, density gradients, immunoaffinity purification 
or SEC (Section 1.3). The choice of exosome isolation method largely depends on the application 
of the exosomes such as analysing the proteome of exosomes requires minimal co-isolation of 
contaminating proteins. As shown in these experiments ExoQuick precipitation and UC isolate 
human serum exosomes with contaminating proteins; verified with SDS-PAGE, TEM and protein 
concentration. This has been found to be a major issue in the exosome field, where other 
researchers confirmed that ExoQuick as well as UC isolate contaminating serum proteins 
(Baranyai et al., 2015, Lobb et al., 2015, Tang et al., 2017). In recent years SEC has provided a 
simple, and efficient method to isolate exosomes with minimal protein contamination (Böing et al., 
2014, Baranyai et al., 2015). Hence, the present study was carried out to determine the presence 
of protein-based contaminants in isolated human serum exosomes using Sepharose CL-4B 
chromatography, assess their function and additionally assess the efficacy of exosome-releasing 
fibrin hydrogels.  
The outcome of the present study verified that SEC using Sepharose CL-4B isolated a fraction 
enriched with 20-100 nm vesicles and exosomal markers CD9, CD81 and TSG101 and was able 
to label HT1080 cells with a range of fluorescent labels targeting different aspects of exosome-
92 
 
based uptake. Furthermore, they were devoid of significant contaminating serum proteins 
particularly albumin. This correlates with previous findings that Sepharose CL-4B isolates plasma 
exosomes without significant albumin content and they further found that Sepharose CL-2B 
columns isolated exosomes with albumin contamination (Baranyai et al., 2015).  
Our studies further showed that SEC exosomes promoted proliferation of fibroblasts and 
increased HUVEC sprout numbers. Currently there are no prior studies that have used serum 
SEC-derived exosomes and shown them causing cell proliferation of fibroblasts and initiating 
HUVEC sprouting in vitro. However, plasma exosomes (20 µg) derived from qEV SEC columns 
have shown to be enriched for pro-angiogenic factor endothelin-1 and promoted migration of 
HUVECs (Takov et al., 2019). Another study found that maternal and umbilical cord serum-
derived exosomes increased HUVEC proliferation and migration, with maternal exosomes 
showing greater migration (Jia et al., 2018). However, they isolated their exosomes using 
ExoQuick which isolates contaminating proteins potentially clouding the finding (Lobb et al., 
2015). Another group isolated PRP-derived exosomes (5 and 50 µg/ml) using UC, and found 
them to increase proliferation and migration of fibroblasts and HMEC-1 and increased tubule 
formation of HMEC-1 (Guo et al., 2017). Overall, the literature and this data suggest that serum 
exosomes do have regenerative properties to treat various ailments.  
To use exosomes in a clinical setting, knowledge of their stability is important. These experiments 
showed that human serum SEC exosomes in PBS are stable and retain function when stored at 
37°C for 3 weeks. Long term survival of exosomes is an advantage for further pharmaceutical 
therapeutic applications using exosomes. From these results it would be reasonable to 
extrapolate that exosomes are stable at RT for up to 3 weeks, which is advantageous for 
transportation of exosomes for potential clinical use. Furthermore our findings in conjunctions with 
others, with observation of preservation of the internal exosomal marker TSG101 after 30 days in 
plasma (Kalra et al., 2013) and maintenance of size in serum (Qi et al., 2016) for 7 days at 37°C, 
suggest that exosomes would endure in the circulation and tissue increasing their potential as 
therapeutic delivery vehicles. 
Controlled release of exosomes will likely become increasingly utilised as has occurred in the past 
for the delivery of other bioactive reagents such as growth factors (Ehrbar et al., 2004) and MSCs 
(Ciuffreda et al., 2018). We showed that the FDA approved fibrin hydrogel could control the 
release of exosomes over 96 hours. Further, using a novel modified transwell assay, with human 
serum exosomes encapsulated in a fibrin hydrogel showed uptake of label by HT1080 cells 
migrating and invading through the gel. There was no uptake when a 3 mg/ml fibrin hydrogel 
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containing labelled exosomes was preincubated for 7 days prior to cellular invasion. A 10 mg/ml 
fibrin hydrogel appeared to retain exosomes better than 3 mg/ml as labelling still occurred when 
cells invaded the higher concentration hydrogel after it had been preincubated for 7 days. To our 
knowledge, this is a novel means of showing exosomal bioactivity in 3D. One limitation could be 
that the exosomes have burst open allowing the RNA dye to be released staining the RNA within 
the HT1080 cells. Thus, further control experiments were performed to indicate that this 
artefactual outcome was unlikely. It is important to highlight the fact that exosomes can be used 
as a delivery mechanism as they are readily engulfed by cells even when embedded in a hydrogel 
simulating a 3D environment. The human serum SEC exosomes seem to be functional when 
entrapped in hydrogel which will also be useful for therapeutic effect for a local and prolonged 
exposure. In correlation, literature has also seen regenerative results when exosomes are 
delivered in hydrogels. One study showed that PRP exosomes loaded in a sodium alginate 
hydrogel promoted chronic wounds in diabetic rats to heal faster with improved angiogenesis and 
re-epithelialisation (Guo et al., 2017). They promoted the proliferation and migration of endothelial 
cells and fibroblasts. 
Overall, the human serum SEC fraction 8 and 9 contained vesicles within the exosome size range, 
had very minimal serum protein contamination, contained exosomal markers, was able to 
transport lipid and RNA stains and vesicle entrapped dyes into cells collectively suggesting that 
SEC fraction 8 and 9 contained exosomes. Furthermore, the SEC exosomes had functional 
properties including increasing fibroblast proliferation and promoting HUVEC sprouting. The 
exosomes appeared stable which is beneficial for therapeutic application. They appear to be 
functional when entrapped in a fibrin hydrogel which is valuable for a local and prolonged 
therapeutic effect. 
A possible limitation with the above findings is the recently acquired knowledge that there is a 
potential problem with lipoprotein contamination when isolating exosomes from bodily fluids such 
as serum or plasma (Yuana et al., 2014, Sódar et al., 2016, Karimi et al., 2018). At the start of 
this investigation there was no significant concern about lipoprotein contamination as it was 
considered that apolipoprotein B (ApoB) present in isolates was thought to be a component of 
exosomes (Looze et al., 2009, Liang et al., 2013, Welton et al., 2016). However, in 2016 it was 
suggested that low-density lipoprotein (LDL) co-isolated with plasma EVs (Sódar et al., 2016). 
Lipoprotein content can affect lipophilic dye staining experiments (Takov et al., 2017). Due to this 
potential limitation, it remains unclear whether lipoproteins could also be contributing to the uptake 
into cells. It has been suggested a 2-step purification involving a density gradient UC and SEC 
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should be used (Simonsen, 2017). Apolipoprotein B100 (ApoB100) (very low-density lipoprotein 
(VLDL), intermediate-density lipoprotein (IDL), LDL) and apolipoprotein A1 (ApoA1) (HDL) 
lipoproteins may be removed from human serum exosomes respectively. The next Chapter 3 





















CHAPTER 3: ANALYSIS OF LIPOPROTEINS IN SERUM-





3.1.1 Lipoproteins co-isolate with exosomes 
An example of the state of flux in the exosome field (Bhome et al., 2018) is that the presence of 
ApoB in exosome containing fractions was postulated to derive from the exosomes themselves 
(Looze et al., 2009, Liang et al., 2013, Welton et al., 2016). Reports in the literature where 
exosomes have been isolated from serum, blood and plasma with SEC, UC etc. are still frequently 
published (Bei et al., 2017, Cavallari et al., 2017, Li et al., 2018b, Ghai et al., 2019). However, it 
has recently become apparent that density gradient, PEG precipitation, SEC and UC of human 
serum or plasma co-isolates lipoproteins with the exosomes (Deregibus et al., 2016, Sódar et al., 
2016, Grigor’eva et al., 2017, Foers et al., 2018, Karimi et al., 2018, Takov et al., 2019). 
Several publications in 2014-2015 indicated that SEC purification of blood-derived exosomes was 
optimal (Böing et al., 2014, Baranyai et al., 2015, de Menezes-Neto et al., 2015). More recently 
(Sódar et al., 2016) showed that lipoproteins are found co-isolating with EVs isolated from platelet 
concentrates using qEV SEC columns as well as in plasma EVs isolated using an OptiPrep 
density gradient. These findings were confirmed by other researchers as plasma and serum SEC-
derived exosomes were seen to be contaminated with ApoB lipoproteins, as detected using mass 
spectrometry (Karimi et al., 2018) and an immunoassay (Takov et al., 2019), after isolation using 
Sepharose CL-2B and qEV SEC columns respectively. The co-isolated ApoB lipoproteins would 
be expected to be VLDL and IDL due to their larger size, whereas the smaller sized LDL would 
elute in later SEC fractions (Takov et al., 2017). It should be emphasised that other methods of 
isolation such as UC were also found to be contaminated (Deregibus et al., 2016). Particularly 
contamination of HDL still occurs when using UC and density gradient, which was seen when 
isolating exosomes from human synovial fluid and plasma (Yuana et al., 2014, Foers et al., 2018). 
There are roughly 107-109 exosomes/ml plasma, whereas lipoproteins are in abundance at 1016 
(Simonsen, 2017) and thus co-isolation of only a very small proportion of the lipoproteins present 
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can result in significant contamination. This makes it difficult to interpret data as lipoproteins can 
attach non-specifically to antibodies as well as transfer lyophilic fluorescent dyes into cells which 
are used to test for exosomal uptake (Takov et al., 2017, van der Pol et al., 2018). It is difficult to 
determine what is transporting miRNA when there is co-isolation of lipoproteins and exosomes, 
discussed below (Vickers et al., 2011, Yuana et al., 2014). It is important that researchers 
understand the limitations and issues in exosome research to avoid drawing incorrect 
conclusions.   
3.1.1.1 Lipoproteins 
Lipoproteins are also nanoparticles which transport cholesterol, triacylglycerols and 
phospholipids. After consuming fat-containing meals chylomicrons (75-1200 nm) are generated. 
They travel through the blood plasma to deliver lipids and cholesterol to the liver (German et al., 
2006). Lipoproteins are divided into classes according to their ratio of triglycerides, cholesterol 
and apolipoproteins. The fat in chylomicrons is converted by the liver into VLDL (30-80 nm) 
followed by conversion into lipoproteins of smaller diameter. These include IDL (25-35 nm), LDL 
(21-27 nm) and HDL (7-13 nm); which also transport lipids and cholesterol to surrounding tissues. 
There are various apolipoprotein markers for different lipoproteins. ApoA1 is predominantly 
associated with HDL, ApoB100 is associated with IDL, LDL and VLDL and apolipoprotein B48 
(ApoB48) is affiliated with chylomicrons (Ramasamy, 2014). 
Lipoproteins may have functions beyond the transport of lipids as recent papers have shown that 
they also carry miRNA. Vickers et al. showed that HDL contained miRNA, the most abundant 
being miR-223 followed by miR-105 and miR-106a and their concentration increased with humans 
having atherosclerosis (Vickers et al., 2011). The HDL miRNA was shown to be transferred to 
recipient hepatocyte cells. Furthermore, they detected LDL to contain miRNA. However, a density 
gradient was used to isolate HDL which contained about 1% of EVs. Due to EVs having a larger 
diameter than HDL (100 nm versus 10 nm), the EVs will have greater volume for miRNA cargo; 
hence, potentially influencing HDL studies too (Yuana et al., 2014). 
3.1.1.2 Co-isolation of lipoproteins and exosomes  
There is potential for co-isolation of lipoproteins and exosomes apart from the extreme mismatch 
in number of particles as they overlap in size and density (Figure 3.1). Chylomicrons, IDL and 
VLDL overlap in size with exosomes, whereas HDL overlaps in density. Another issue is that LDL 
may attach to exosomes which would make it difficult to separate them using current isolation 
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techniques (Sódar et al., 2016). TEM has also identified contaminating particles such as IDL (25-
35 nm), LDL (21-27 nm) and VLDL (30-80 nm) in exosome preparations from plasma, urine and 
conditioned cell culture media (10% depleted serum) when using UC (Grigor’eva et al., 2017). 
VLDL can interfere with determining the concentration of exosomes using NTA (Jamaly et al., 
2018) and IDL are also likely to be an issue due to their size. One bio distributive difference is 
that exosomes are circulated quickly away from the point of an injection and accumulate in the 
liver, lungs and spleen, whereas VLDL and HDL can remain for hours and LDL for 4 days before 


















Figure 3.1 Outline of the overlap of size and density of exosomes/microvesicles and lipoproteins. High-density 
lipoproteins (HDL) overlap in density, whereas low-density lipoproteins (LDL), intermediate-density lipoproteins (IDL), 
very low-density lipoproteins (VLDL) and chylomicrons overlap with the size of exosomes. Figure from (Simonsen, 
2017) with permission.  
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There are still a substantial number of blood-derived exosome publications that do not 
acknowledge the potential for interference from lipoproteins, but awareness is increasing. For 
example, when looking for biomarkers for metastatic breast cancer through isolating exosomes 
from plasma, 2 possible biomarkers were identified (Tucker and Pedro, 2018). However, they 
noted the limitation that lipoproteins were precipitated using their UC method and that their NTA 
results (12.3-298.4 nm) also corresponded with some of the sizes of lipoproteins. In this chapter, 
the purity of exosomes isolated with Sepharose CL-4B in Chapter 2 with respect to lipoproteins 
was determined and characterised with a lipoprofiling method, western blotting and ELISA. 
Furthermore, the potential for interference of lipoproteins with fluorophore staining used for uptake 



















3.2 Results and discussion 
3.2.1 Assessment of lipoprotein contamination 
As a consequence of the reported lipoprotein, described above, it was considered necessary to 
assay their presence in our SEC isolates. 
3.2.1.1 SDS-PAGE, ELISA and western blot analysis 
An initial estimate of the quantity of lipoprotein contamination in the human serum SEC fractions 
(Figure 3.2) was carried out on SDS-PAGE. An equal volume of SEC fractions 7-14 was loaded 
on a 4-15% SDS-polyacrylamide gradient gel to separate out high molecular weight proteins 
(Figure 3.2A). A band corresponding to the molecular weight of ApoB100 lipoproteins (512 kDa) 
was detected in SEC fraction 8 and increased in intensity to SEC fraction 12, thereafter a slight 
decrease in intensity in SEC fraction 13-14. As previously observed (Section 2.2.2), minimal 
overall protein was detected in SEC fractions 8-9 corresponding to the exosome fraction. 
However, the most prominent band above 250 kDa can now be seen to correlate with the 
ApoB100 lipoproteins.  
The above was then confirmed and quantified with an ApoB ELISA. SEC exosome fraction 8 and 
9 contained ApoB lipoprotein at 6.12 µg/ml and 15.03 µg/ml respectively (Figure 3.2B). The ApoB 
lipoprotein concentration continued to increase across SEC fraction 10-14 (21.59-155.74 µg/ml). 
The gradient of the increase was larger between SEC fraction 11-14 than 7-10 suggestive of a 
shoulder prior to a major peak for ApoB. ELISA analysis of ApoB content of the starting human 
serum gave a concentration of 968.67 µg/ml ±17.7. This falls within values reported for normal 
plasma and serum (Ridker et al., 2005, Holme et al., 2009, Patel et al., 2017) of 650-1500 µg/ml. 
This indicates that less than 1% of ApoB loaded is contained in peaks 8 and 9 combined. As there 
was an indication of a shoulder, an analysis of the proportions of the various LDL classes (VLDL, 
IDL and LDL) was carried out (see below). 
Western blot analysis of the HDL marker, ApoA1 lipoprotein was performed. ApoA1 was not 
detected in exosome SEC fraction 8-10 (Figure 3.2C). ApoA1 was detected at 25 kDa in SEC 
fraction 12 and increased in intensity to SEC fraction 20. Thereafter intensity dropped in SEC 





Figure 3.2: Assessment of lipoprotein contamination in human serum exosomes isolated using SEC. One ml 
of serum was loaded onto 10 ml Sepharose CL-4B columns and fractions of 500 μl were collected. (A) 4-15% SDS-
polyacrylamide gradient gel of SEC fractions 7-14 stained with Coomassie Brilliant Blue R-250 (15 µl sample loaded). 
n=2 (technical repeats); (B) ELISA to quantify ApoB lipoprotein content in SEC fractions 7-14. n=2 (technical repeats); 
(C) Western blot to identity HDL marker ApoA1 in SEC fractions 7-10, 12, 14, 16, 18, 20, 22, 24 (10 µl loaded). n=2 
(technical repeats). Figure 3.2A (gradient gel) and Figure 3.2C (ApoA1) were from the same SEC isolate as Figure 
2.4B (EV markers). The exosome markers for other repeated SEC isolates always had EV markers in fraction 9 and 





3.2.1.2 Lipoprint analysis 
The Lipoprint® System, is a commercial polyacrylamide gel tube electrophoresis system used to 
resolve subfractions of either HDL or LDL (Hoefner et al., 2001). Minimal sample volume is 
required (25 µl) and analysis time is only 3 hours. A densitometric scanning system is used to 
quantify the relative distributions of HDL subclasses (large, intermediate and small) or LDL 
subclasses (VLDL, IDL (Mid) and small LDL) after electrophoretic separation. The Lipoprint® HDL 
System and Lipoprint® LDL System were used to assess the distribution of the lipoprotein 
subclasses in the serum SEC exosome enriched fractions 8 and 9.  
Lipoprint gels (Figure 3.3A) were quantified to identify HDL subclass profiles in the Liposure 
control, serum and serum SEC exosome fraction 8 and 9 (Figure 3.3B-E). The Liposure control 
was used for quality control to monitor the performance in terms of accuracy and precision of the 
Lipoprint. Albumin was present in the Liposure control and serum detected by the wide peak 
(Figure 3.3B and C). As the Lipoprint® System expects to detect albumin in serum samples and 
SEC exosome fractions had been shown above to have no detectable albumin (Figure 2.3), an 
artificial line had to be inserted for the serum SEC exosome fractions 8 and 9 (Figure 3.3D and 
E), which was an approximation based on the leading front of the Liposure loading control 
containing an albumin peak but this does not influence the quantification. The Liposure control 
contained 69% large HDL, 29% intermediate HDL and 1% small HDL (Figure 3.3F). The HDL 
subclass distribution was slightly different for the serum, with less large HDL (26%) and more 
intermediate HDL (52%) and small HDL (23%). There was no detectable distribution of HDL 
subclasses for the serum SEC exosome fractions 8 and 9 (Figure 3.3F). 
The Liposure control verified that the Lipoprint® System was working; therefore, relative ratios of 
HDL could be analysed for the remaining samples. The lack of detectable HDL subclasses in the 
serum SEC exosomes agrees with the western blot results that also didn’t detect HDL marker, 
ApoA1 (Figure 3.2). The detection limit of the HDL Lipoprint® System is around 7.5% of normal 
levels in human serum. Western blots using the detection system used here can detect a minimum 
of 0.05 ng of protein (Diagnostics, 2011). This of course is highly antibody dependent but suggests 
that there is at least less than 0.5% of ApoA1 in serum present (1100-1500 µg/ml in normal 
plasma) (Ridker et al., 2005, Holme et al., 2009). Both methods confirm the lack of detectable 










Figure 3.3: Distribution of HDL subclasses in human serum SEC exosome fraction 8 and 9. The fractions were 
analysed using a Lipoprint® System and Lipoware software. (A) Representative Lipoprint gels; (B) Scan result of 
Liposure control showing the HDL subclasses; (C) Scan result of serum; (D-E) Scan results of serum SEC exosome 
fraction 8 and 9; (F) Table of percentages of large, intermediate and small HDL subclasses. 
 
A Lipoprint® System was then used to detect distribution of VLDL, IDL and LDL subclasses in 
serum SEC exosome fractions 8 and 9 (Figure 3.4). Lipoprint gels (Figure 3.4A) were quantified 
to identify any LDL subclass profiles (Figure 3.4B-E). HDL was present in the Liposure control 
and serum as detected by the wide green peak (Figure 3.4B and C). Again, as the Lipoprint® 
System expects to detect HDL in serum samples and these were absent as expected in the serum 
SEC exosome fractions 8 and 9, an artificial HDL line had to be inserted (Figure 3.4D and E) in 
reference to the Liposure loading control which contains a HDL peak. The Liposure control 
contained 19% large VLDL, 21.6% IDL and 34.8% small LDL (Figure 3.4F). The serum contained 
similar ratios of LDL subclasses to the Liposure control, 19.1% large VLDL, 25% IDL and 36.4% 
small LDL (Figure 3.4F). The serum SEC exosome fractions 8 and 9 contained increased VLDL 
(41.5% and 27.8%) compared to serum (19.1%), as well as increased IDL (Mid) (58.1% and 
67.5%) compared to serum (25%). Serum SEC exosome fraction 8 contained more VLDL (41.5%) 
compared to fraction 9 (27.8%) (Figure 3.4F). The IDL profile was slightly higher in fraction 9 
(67.5%) compared to in fraction 8 (58.1%). There was no detectable distribution of LDL subclass 
for the serum SEC exosome fractions 8 and 9 (Figure 3.4F). 
Compared to serum, the SEC exosomes were enriched for the VLDL and IDL (Mid) subclasses 
with relatively increased percentages. This might be predicted due to the isolation method, SEC, 
used as the void volume for Sepharose CL-4B should contain particles greater in size than 30 nm 
and thus should preferably contain VLDL (30-80 nm) and IDL (25-35 nm) rather than LDL (21-27 
nm) together with the exosomes present (German et al., 2006). As VLDL (30-80 nm) are larger 
than IDL (25-35 nm) they might be expected to be at the front of the void volume fractions as seen 
by the relatively higher distribution of VLDL in SEC fraction 8 compared to fraction 9. The detection 
limit of the Lipoprint® System for LDL-cholesterol (LDL-C) is ≥ 8.30 mg/dL (Quantimetrix, 2005). 
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This indicates that the minimal amount of LDL present in fraction 9 is less than 5% of the LDL-C 
loaded (150 mg/dL LDL-C in normal human plasma (Ridker et al., 2005)). This also suggests the 





Figure 3.4: Distribution of LDL subclasses in human serum SEC exosome fraction 8 and 9. The fractions were 
analysed using a Lipoprint® System and Lipoware software. (A) Representative Lipoprint gels; (B) Scan result of 
Liposure control showing the LDL subclasses; (C) Scan result of serum; (D-E) Scan results of serum SEC exosome 
fraction 8 and 9; (F) Table of percentages of VLDL, Mid and LDL subclasses. 
 
Using an ELISA, Lipoprint® System and SDS-PAGE the results show that ApoB containing 
lipoproteins do contaminate SEC-derived exosome containing fractions. This agrees with recent 
literature (Sódar et al., 2016, Karimi et al., 2018, Takov et al., 2019). One study isolated plasma 
EVs from 1 ml of plasma loaded on a qEV SEC column and detected ApoB within the exosome 
fractions enriched for CD81 and HSP70 (SEC fraction 5.5 ml) (Takov et al., 2019). Furthermore, 
their ApoB concentration increased to SEC fraction 6 ml, equivalent to our fraction 12, and 
thereafter decreasing. Whereas our results show a continuous increase up to fraction 14. This 
difference could be due to the different SEC columns used. Increasing column length improves 
the resolution of separating molecules (Ricker and Sandoval, 1996); Takov et al. separated 1 ml 
of rat plasma on commercial qEV columns where these columns are shorter, wider (3.2 cm bed 
volume height and 2 cm column width) and contain Sepharose CL-2B as compared to the longer 
Sepharose CL-4B column used here (12.7 cm bed volume height and 1 cm column width). Their 
shorter column and different Sepharose may have resulted in less efficient separation of ApoB 
(see section 2.2.2). The ApoB concentrations reported here are quantitative, whereas Takov et 
al. reported arbitrary units derived from a dissociation-enhanced lanthanide fluorescence 
immunoassay (DELFIA). The DELFIA assay is designed to capture samples and detect the 
presence of a compound which was ApoB lipoproteins in this case using lanthanide chelate 
labelled reagents (Takov et al., 2019). Takov et al. used 1 µg/ml of biotin-conjugated goat anti-
rabbit IgG for ApoB to measure the relative degree of ApoB contamination in SEC fractions; 
however, their ApoB was represented as arbitrary fluorescent units and not exact ApoB 
concentrations.  It is also not clear what the detection limit for their modified DELFIA assay. The 
commercial ELISA used in this study has a limit of 39.1 ng/ml. 
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Reports also predominantly detected plasma protein ApoB in human plasma SEC fractions 8 and 
9 (1 ml plasma separated on 10 ml Sepharose CL-2B) (Karimi et al., 2018) and in human serum 
SEC fraction 8 (0.5 ml diluted serum separated on qEV columns) (An et al., 2018) using mass 
spectrometry; however, they also detected ApoA1. This conflicts with these results that SEC 
removes HDL from exosomal fraction 8 and 9 but could reflect a greater sensitivity of mass 
spectrometry than the immunoblotting used here. Though again, this might reflect the longer and 
narrower column filled with Sepharose CL-4B in this study, whereas they used shorter and wider 
in house-made columns with Sepharose CL-2B or qEV commercial columns. Our findings are in 
line with those of (Böing et al., 2014, Baranyai et al., 2015). Böing et al. used a 10 ml Sepharose 
CL-2B with a column diameter of 1.6 cm and height of 6.2 cm and found that SEC removes more 
than 95% of HDL in SEC exosome containing fractions 9-12 of platelet-derived exosomes (from 
supernatant of platelet concentrates) (Böing et al., 2014). The total recovered HDL cholesterol 
was 4.8% in SEC fractions 9-11 using the colorimetric reagent HDL-Cholesterol Plus third 
generation (Roche Diagnostics) on a Cobas C8000 analyser (Roche). However, the ApoA1 
protein marker for HDL was below the detection limit (0.01 g/L) measured on an Architect.   
Fractions 9-12 contained the majority of vesicles and additionally contained 4.8% ±1 of total 
recovered HDL cholesterol, whereas HDL ApoA1 was below the detection limit (0.01 g/L) in those 
fractions. Karimi et al. based their Sepharose SEC column on Böing et al. method; however, they 
detected ApoA1 in SEC fractions in human plasma 7-12 using a more sensitive method (western 
blotting). This likely represents the 5% of HDL that the SEC column couldn’t resolve. Again our 
longer column might be expected to elute the HDL in later fractions and the Sepharose pore size 
may have also had an influence (30 nm for Sepharose CL-4B and 75 nm for Sepharose CL-2B) 
due to the small diameter (7-13 nm) of HDL (German et al., 2006). Our Sepharose CL-4B matrix 
may have allowed for better separation of HDL than Sepharose CL-2B as was observed for serum 
albumin (Baranyai et al., 2015).  
Others have predicted that the lipoprotein contamination would be expected to be VLDL and IDL 
due to their size (Simonsen, 2017) but we are the first to our knowledge to show this directly. 
Whereas, another study suggested them to originate from LDL copurifying with plasma derived-
EVs and microvesicles (Sódar et al., 2016). They showed using flow cytometry and western 
blotting, plasma or platelet concentrate-derived microvesicles or exosomes isolated using either 
UC, OptiPrep density gradient or SEC contain contaminating ApoB, even when isolated from 
donors under fasting conditions. Mass spectrometry and western blot analysis identified ApoB100 
to be the most abundant protein. Sódar et al. hypothesised that the ApoB100 represented LDL, 
as ApoB100 in blood plasma is mainly found on LDL compared to less than 10% for IDL and 
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VLDL. To investigate this hypothesis further, they mixed commercial LDL with cell-derived 
exosomes and microvesicles and found the LDL to bind to the EVs as determined by TEM. TRPS 
analysis revealed the commercial LDL average diameter to be 110 nm indicating aggregation as 
LDL are 21-27 nm. However, it must be emphasised that the suggestion that the ApoB100 was 
derived from LDL was speculative and not supported by direct evidence. Furthermore, they used 
a short commercial qEV column (5 cm height, 2 cm width, 10 ml volume, 70 nm beads, Sepharose 
CL-2B) for their SEC isolation, which as indicated above is not ideal for isolation of exosomes.  
Though this present study focuses on serum-derived exosomes, it should be noted that caution 
also needs to be taken when using exosome depleted serum for isolating cell culture exosomes. 
ApoB was detected in both peaks when isolating EVs from HEK293 cell culture conditioned media 
using anion exchange chromatography (Heath et al., 2018). They used a step gradient of 335 mM 
NaCl and 890 mM NaCl over 10 column volumes each to isolate EVs from 1 litre of HEK293T-
conditioned media using a flow rate of 10 ml/minute. The cell-derived exosomes were enriched in 
peak 2 as determined by NTA and western blotting confirmed the presence of exosomal markers 
CD63, CD81 and Alix and cryo-electron microscopy showed vesicles. Western blotting revealed 
ApoB in the conditioned media and in equal concentrations in peak 1 and 2 after the anion 
exchange. As in this study, ApoA1 was undetectable in peak 1 and peak 2. To eliminate 
lipoprotein contamination, one may have to use serum-free cell culture media with the downside 
of altering cellular function. For example,  N2a neuroblastoma cells grown in serum-free media 
for 48 hours had increased EV release and were enriched for specific proteins such as G-proteins, 
small GTPases and kinases, compared to cells cultured in serum-containing media (Li et al., 
2015). 
Identifying the contribution of each bioactive component in serum is vital to understand the 
mechanisms of regeneration that has been observed after delivery of exosomes. Lipoproteins 
also have potential regenerative roles and the co-isolation of lipoproteins is therefore not desirable 
when trying to determine the functional aspects of blood-derived exosomes nor when assessing 
their cargo. HDL transports miRNA such as miRNA-223 to recipient cells. Endothelial cells 
incubated with HDL have been found to have increased mature miR-223 which resulted in 
decreased adhesion molecule expression (Tabet et al., 2014). They demonstrated that HDL 
transferred miR-223 to the endothelial cells and was not a result of miR-223 being transcribed 
within the cell. The presence of miR-233 also contributed to the anti-inflammatory properties of 
HDL. In vivo anti-inflammatory effects of HDL has also been shown, increasing ApoA1 levels 
using human ApoA1 transgenic mice (lacking mouse ApoA1) demonstrated atheroprotective 
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properties such as a decrease in plaque size compared to the mice expressing normal amounts 
of mouse ApoA1 or mice lacking mouse ApoA1 (Valenta et al., 2006). Furthermore HDL has 
antithrombotic properties shown by inhibition of thrombin induced platelet aggregation caused by 
thrombin and fibrinogen binding (Nofer et al., 1998). The function of HDL has been previously 
reviewed in (Murphy, 2013). There is evidence that LDL can inhibit, promote or have no effect on 
endothelial cells; however, it also depends on the whether the LDL is oxidised (harmful 
cholesterol) or native. One study showed that 100 µg/ml of oxidised LDL decreased bFGF 
expression by 40-50% within 24-48 hours; hence, inhibiting bovine aortic endothelial cell 
proliferation (Chen et al., 2000). Whereas, native LDL and mildly oxidised LDL had no effect on 
bFGF expression. In contrast Zhang et al. showed that 50 µg/ml of oxidised LDL significantly 
increased proliferation of human aortic endothelial cells after 24 hours compared to untreated 
cells; native LDL (50 µg/ml) also significantly increased endothelial cell proliferation albeit not as 
effective as oxidised LDL (Zhang et al., 2017). Exosomal miRNA appears to more closely 
resemble LDL miRNA than HDL miRNA, as the miRNA signature of LDL have a closer alignment 
with human plasma exosomes isolated using UC and fast protein liquid chromatography (FPLC) 
(correlation = 0.72) compared to HDL-miRNA signature (correlation = 0.54) (Vickers et al., 2011). 
Furthermore, there was no correlation with the HDL-miRNA profile compared to the exosome-
miRNA profile from the same plasma, due to differences in miRNA signature, concentration and 
the top-ranked miRNA. Due to FPLC being used, the possibility of VLDL co-isolating with the 
exosomes in the above study may have influenced their exosome-miRNA profile.  
3.2.2 Lipoproteins a confounding factor for exosome uptake studies 
As described in detail above (Section 2.2.4.1), fluorescent label uptake studies are widely used 
to identify exosome containing samples (Feng et al., 2010, Nakata et al., 2017) and to highlight 
or indicate their cell delivery function (Tian et al., 2014, Hu et al., 2018). As lipoprotein 
contamination had been identified in our SEC purified exosome isolates, their potential 
interference with the fluorescent label uptake studies with the isolates (Figure 2.7) was assessed 
with the canonical lipoprotein LDL (Figure 3.5). Though significant contamination with this 
lipoprotein was not identified above, it was thought reasonable that its behaviour would be similar 
to that of the higher molecular weight variants and we had access to purified LDL from the 
Lipidology Unit, University of Cape Town. The purified LDL was isolated from human plasma 
using a potassium bromide (KBr) gradient (0.5 g/ml) centrifuged at 100 000 g for 17 hours, after 
which the LDL was removed and dialysed to remove the KBr. TEM confirmed the LDL were 
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uniform in size 21.7 nm ±2.5 (Table A4, Appendix 4). The aim was to examine whether LDL can 
transport fluorescent dyes commonly used in exosome uptake studies into recipient cells.  
The uptake assays with BODIPY TR Ceramide, SYTO RNASelect and ExoGlow-protein label (as 
discussed in section 2.2.4.1) were repeated with LDL (Figure 3.5A). There was no cytoskeleton 
stain for BODIPY TR Ceramide and ExoGlow. As can be seen the concentration of LDL particles 
used was substantially higher than those previously seen in the exosome containing isolate 
uptake studies as determined by TEM (Figure 3.5B). It was felt that this was appropriate so as to 
identify any potential for interference. The LDL were readily taken up by HT1080 cells as all labels 
utilised were present within cells with a particularly bright signal for the SYTO RNASelect dye 
(Figure 3.5A). The transfer of BODIPY TR Ceramide label when using LDL might have been 
expected as it is a lipid dye. The SYTO RNASelect dye appears to have bound to the RNA present 
in LDL (Vickers et al., 2011, Tabet et al., 2014) and upon entry into the cells allowed them to 
intensely fluoresce green. There are previous findings that show that lipoproteins such as VLDL 
(Hussain et al., 1991), LDL (Sawamura et al., 1997) and HDL (Ahmed et al., 2003) may be labelled 
by lipophilic dyes, e.g. Dil-labelled oxidised HDL and DiO-labelled oxidised LDL (25 μg protein/ml) 
were internalised into THP-1 machrophages after 2 hours at 37°C (Ahmed et al., 2003). Though 
as detailed, others have seen evidence of transfer by LDL of the lipophilic “exosome labels”, we 
have not seen previous evidence that this can also occur with RNA label and ExoGlow-protein 
label. The ExoGlow-protein label should be more specific as it relies on an enzymatic conversion 
of the native, non-fluorescent dye to an activated fluorescent moiety when taken up by EVs and 
this might not be expected to occur in lipoproteins. This is either not the case or there is non-
specific transport of the dye into the cell that then allows for labelling of intracellular proteins. 
Functional studies testing for exosome uptake require special evaluation for contamination with 





Figure 3.5: Uptake of lipophilic, RNA and protease dye-labelled LDL, a confounding factor for exosome uptake 
studies. (A) LDL were labelled red with BODIPY TR Ceramide, green with SYTO RNASelect and green with ExoGlow. 
HT1080 cells were cultured with either fluorescently labelled LDL (12.5% (v/v) LDL diluted to the same concentration 
as SEC exosomes) or PBS (control) for 3 hours. After treatment fluorescent images were obtained using a fluorescent 
microscope. Nuclei stained with DAPI (blue) and cytoskeleton stained with Alexa Fluor® 594 Phalloidin (red) for SYTO 






3.2.3 Attempt to isolate platelet exosomes from PRP with calcium activation  
Platelets are considered to be the major contributor of mitogenic activity in serum. Further 
investigation revealed that platelets contained various growth factors including PDGF-BB (Kaplan 
et al., 1979), TGF-β (Assoian et al., 1983), IGF-1 (Karey and Sirbasku, 1989), bFGF (Brunner et 
al., 1993) and VEGF (Banks et al., 1998), located in the platelet alpha granules. Protein synthesis 
by platelets has also been discovered (Schwertz et al., 2012). In the 1980s and 1990s PRP started 
being administered in a clinical setting for its regenerative potential in a range of acute and chronic 
conditions, as discussed previously in section 1.6.2.1. Recently exosomes have also been found 
to be derived from platelets (Aatonen et al., 2014, Tan et al., 2016). This raises the possibility of 
obtaining a more concentrated and defined bioactive component from plasma for potential use in 
regenerative therapies. Torreggiani et al. showed that platelet-derived exosomes significantly 
promoted bone marrow stromal cell growth, migration and osteogenesis (Torreggiani et al., 2014). 
Furthermore, the exosomes were enriched for bFGF, VEGF, PDGF-BB and TGF-β1 and non-
coding RNA as compared to platelet lysate. In further validation for platelets as a source for 
regenerative exosomes, PRP-derived exosomes improved proliferation and migration of 
endothelial cells and fibroblasts similar to PRP suggesting exosomes are the functional cause 
(Guo et al., 2017).  
In light of the lipoprotein contamination identified above, it was considered whether lipoprotein 
contamination could be reduced by isolating exosomes directly from platelets. The aim was to 
isolate platelets from PRP followed by exosome isolation and assess for lipoprotein 
contamination. 
3.2.3.1 Scanning electron microscope, TEM and western blot analysis 
Platelet exosome isolation was based on carefully pelleting platelets from PRP using a low 
centrifugation (900 g) (Tan et al., 2016) and activating the platelets with 1 mM CaCl2 (Goetzl et 
al., 2016), instead of thrombin to avoid clot formation potentially trapping released exosomes. 
ExoQuick-TC was used to precipitate the exosomes after the platelets were activated (Goetzl et 
al., 2016) (Figure 3.6). Goetzl et al. further showed that CaCl2 activated platelets further activated 
with 30 nm thrombin or 0.3 µm collagen did not influence the concentration of secreted exosomes.  
The shape of the isolated platelets needed to be assessed to ensure that the platelets remained 
inactivated, to prevent platelet releasate being lost through washes, prior to the activation step. 
To assess the level of activation of the platelets, scanning electron microscope (SEM) analysis 
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was performed on platelets before and after activation (Figure 3.6A). The majority of the platelets 
before activation were round and not activated. However, there were some single pseudopods 
indicating early activation prior to the chemical activation was initiated. This may be an issue as 
the platelets could have started activating before the pellet was spun down which might have 
result in loss of exosomes. Once the platelet pellet was resuspended this caused more activation 
as platelet aggregation was detected and more pseudopods were detected and spheroid stage 
platelets. The platelets were extensively activated after incubation with CaCl2. The platelets were 
in late stage activation as seen by their spheroid shape and aggregation. The SEM images of the 
activated platelets agreed with previous studies that the platelets after activation had a spheroid 
shape with aggregation (Hantgan et al., 1985, Pleines et al., 2010). 
Platelet exosome isolation was proceeded using ExoQuick-TC (Goetzl et al., 2016). Vesicles with 
a diameter range of 18.5-52.1 nm and average diameter of 29.5 nm were detected using TEM 
(Figure 3.6B). The sample had to be diluted 50X to image the vesicles, which could mean that 
ExoQuick-TC isolated contaminating proteins, lipoproteins or there were many vesicles present. 
Exosome like vesicles were present as the markers CD9 (24 kDa) and TSG101 (50 kDa) were 
detected using western blotting (Figure 3.6C) and there were vesicles that had diameters of 52.1 
nm, that of exosomes.  
A major concern was the co-isolation of lipoproteins as spherical white vesicles with diameters 
comparable to that of IDL (25-35 nm) were detected on the TEM micrograph. Analysis for 





Figure 3.6: Isolation of human platelets and platelet exosomes using calcium activation of the platelets and 
exosomes isolated using ExoQuick-TC. (A) SEM of platelets before activation immobilised on 3-
aminopropyltriethoxysilane (APES) coated coverslips, platelets after the platelet pellet was completely resuspended 
and platelets after activation with 1 mM CaCl2. Observations made using Nova NanoSEM 230. Scale bar indicated on 
each figure. n=2 (technical repeats); (B) TEM micrograph of platelet exosomes from activated platelets using ExoQuick-
TC (50X diluted). Scale bar = 100 nm; (C) Western blot of CD9 and TSG101 to confirm exosome markers are present 
in the platelet exosome isolation (6 µl platelet exosomes loaded). n=2 (technical repeats).  
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3.2.3.2 Lipoprint analysis 
The Lipoprint® HDL System and Lipoprint® LDL System was used to assess for any distribution 
of the lipoprotein subclasses in the platelet exosomes isolated using calcium activation of the 
platelets. 
 
A Lipoprint® System was used to detect any distribution of large, intermediate and small HDL 
subclasses in platelet exosomes isolate using calcium activation of platelets (Figure 3.7). Lipoprint 
gels (Figure 3.7A) were quantified to identify any HDL subclass profiles in the Liposure control, 
plasma and platelet exosomes (Figure 3.7B-D). The Liposure control contained 67% large HDL, 
30% intermediate HDL and 1% small HDL (Figure 3.7E). The plasma control contained 32% large 
HDL, 56% intermediate HDL and 12% small HDL, a slightly different profile to the Liposure control. 
However, these data indicated the lipoprotein system was working. Surprisingly the platelet 
exosomes co-isolated 70% large HDL, 31% intermediate HDL and 0% small HDL (Figure 3.7E). 
This agrees with the TEM image as small round white vesicles were detected (Figure 3.6), 
correlating to HDL. However, the minimum diameter of vesicles from the platelet exosome 
isolation was 18.7 nm and HDL are 7-13 nm. The HDL may have been obscured from vision in 
the TEM image due to high background (Figure 3.6B).   
The relative ratios of HDL could be analysed for the plasma and platelet exosomes due to the 
Liposure control working. The platelet exosomes were contaminated with HDL, and they had a 
higher percentage of large HDL and less intermediate HDL compared to the plasma control. There 
was no detectable presence of small HDL in the platelet exosomes which may be attributed to 
the sensitivity limit of the Lipoprint HDL analysis which is ≥ 3.65 mg/dL (Quantimetrix, 2005). 





Figure 3.7: Distribution of HDL subclasses in platelet exosomes isolated using calcium activation of the 
platelets. The fractions were analysed using a Lipoprint® System and Lipoware software. (A) Representative Lipoprint 
gels; (B) Scan result of Liposure control showing the HDL subclasses; (C) Scan result of plasma; (D) Scan result of 






A Lipoprint® System was also used to detect presence of VLDL, IDL (Mid) and small LDL 
subclasses in platelet exosomes isolated using calcium activation of the platelets (Figure 3.8). 
Lipoprint gels (Figure 3.8A) were quantified to identify any LDL subclass profiles in the Liposure 
control, plasma and platelet exosomes (Figure 3.8B-D). The Liposure control contained 16.7% 
large VLDL, 25.7% IDL and 35.8% small LDL (Figure 3.8E). The plasma control contained similar 
ratios, 21.8% large VLDL, 36.7% IDL and 21.2% small LDL. The platelet exosomes also contained 
LDL lipoproteins. The platelet exosomes contained 18% large VLDL, 65.3% IDL and 12.3% small 
LDL. This agrees with the TEM image as round white vesicles were detected, comparable to 
lipoproteins. The platelet exosomes were enriched for the IDL and contained 3.8% less VLDL and 
8.9% less small LDL compared to the plasma control.  
The Lipoprint® LDL System confirmed the suspicion that IDL was present in the platelet 
exosomes as observed from the TEM analysis (Figure 3.6B). The platelet exosomes were 
enriched for IDL (25-35 nm) which correlates with the observed diameters of the vesicles present 
in the platelet exosomes isolation 18.5-52.1 nm and average diameter of 29.5 nm.   
The CaCl2 activation method seemed promising and the platelet exosome isolation contained 
exosome markers (CD9 and TSG101) as previously reported (Tan et al., 2016). The morphology 
of the platelet exosomes were slightly smaller in diameter compared to another study where they 
had a range from 30-150 nm (Tan et al., 2016). However, the same research group published 
another paper in which their TEM image resembled ours having a high background with small 
rounded white vesicles (Li et al., 2017a). They did not test for lipoprotein contamination. The white 
rounded appearance of the vesicles was concerning, and the data showed that the platelet-
derived exosomes co-isolated HDL, VLDL, IDL and LDL. It was considered that the contamination 
observed precluded progress to further purification with SEC. A protocol was then developed to 







Figure 3.8: Distribution of LDL subclasses in platelet exosomes isolated using calcium activation of the 
platelets. The fractions were analysed using a Lipoprint® System and Lipoware software. (A) Representative Lipoprint 
gels; (B) Scan result of Liposure control showing the LDL subclasses; (C) Scan result of plasma; (D) Scan result of 







As shown with ELISA, the Lipoprint® System and gradient SDS-PAGE, SEC using Sepharose 
CL-4B isolates contaminating ApoB lipoproteins with human serum-derived exosomes. This 
purification issue has recently become a concern in the exosome research field (Sódar et al., 
2016, Karimi et al., 2018, Takov et al., 2019). Here we went further to show that the ApoB 
lipoprotein contaminants were almost exclusively VLDL and IDL. As these are lipoproteins that 
have equivalent sizes to the exosomes, their predominance might be expected. The platelet 
exosome isolation method seemed promising as the isolate contained exosome markers (CD9 
and TSG101) as previously reported (Tan et al., 2016). The initial approach used was to target a 
more defined population of exosomes from blood, namely platelet-derived exosomes to discern 
whether lipoprotein contamination could be avoided. However, there were also contaminating 
lipoproteins present. Further highlighting the immense challenge of isolating EVs from blood 
including platelets.  
Exosome activity is often tested by detecting uptake of exosomes into recipient cells. Various 
fluorescent dyes which stain lyophilic membranes, RNA or proteins are employed to label the 
exosomes for uptake experiments (Singh et al., 2015, Cianciaruso et al., 2016, Gutkin et al., 
2016). Proteins and lipoproteins have also been seen to transfer membrane dyes (CellMask, 
PKH67, DiD) to recipient cells (Takov et al., 2017) in agreement with our finding that LDL carried 
the lipophilic dye BODIPY TR Ceramide into the HT1080 cells. The issue in exosome uptake 
studies are that the contaminating lipoproteins are directly competing with and can overrepresent 
the effect of the exosomes present  or the lipid dye forming dye aggregates (Simonsen, 2019). 
More surprisingly there was substantial uptake of SYTO RNASelect (RNA dye) which might have 
been due to nonspecific transfer of the dye by LDL or perhaps more likely due to staining of LDL 
RNA. Literature has shown LDL can transport and deliver miRNA to cells (Vickers et al., 2011). 
Further studies also show that lipoproteins may contribute towards exosome uptake studies, 
fasted rats had less lipophilic dye transfer with the exosome enriched plasma SEC fractions 4.5 
ml and 5 ml (Takov et al., 2017).  
The ExoGlow-protein EV labelling kit is understood to label internal exosome proteins green to 
allow detection of uptake into cells, through the use of carboxyfluorescein succinimidyl diacetate 
ester (CFSE) chemistry (Parish, 1999). Esterases within exosomes would hydrolyse the CFSE 
which activates to fluoresce green once bound to the amino ends of proteins (Konadu et al., 2016, 
McNamara et al., 2018b). ExoGlow-protein label is indicated to be specific for exosome proteins; 
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however, LDL incubated with the ExoGlow stain resulted in some unexpected green fluorescence 
within cells. It is perhaps most likely that LDL non-specifically transported the stain into the cell 
whereby cellular esterases then labelled intracellular proteins; however, the punctate pattern is 
curious. This study together with other literature highlights the importance of interpreting cellular 
uptake of exosomes from biological fluid as co-isolated lipoproteins could obscure the findings. 
There is an issue with lipophilic dyes (Takov et al., 2017) and as discovered here also with RNA 
and exosome protein fluorescent dyes. 
A major caveat for many of these studies is the absolute purity of exosomes utilised (Simonsen, 
2017, Tkach et al., 2017). The numerous exosome isolation methods were discussed in section 
1.3 and the issue of purity is highlighted here in Chapter 3. Therefore, there is a major need for 
an optimised exosome isolation technique from both cell culture and biofluids and standardised 
exosome analyses. It was considered optimal to further purify blood-derived exosomes in a 

















CHAPTER 4: PURIFICATION OF SERUM-DERIVED 




4.1.1 Removing the contaminating lipoproteins 
As the significant issue of contamination of exosome isolations with lipoproteins, which is more 
pronounced but not limited to blood-derived exosomes (due to the huge preponderance of 
lipoproteins) has become more apparent, increasing effort has been devoted to improved isolation 
methods. Overall, the literature highlights the issue of contaminating ApoB and ApoA1 
lipoproteins. UC isolates contaminating ApoB as seen for plasma-derived EVs (Sódar et al., 2016) 
and urine-derived EVs (Andreu et al., 2017). Other single-step isolations such as PEG 
precipitation and SEC of human serum or plasma also co-isolate lipoproteins with the exosomes 
(Deregibus et al., 2016, Sódar et al., 2016, Grigor’eva et al., 2017, Foers et al., 2018, Karimi et 
al., 2018, Takov et al., 2019). However, density gradients have been used to separate ApoB from 
serum exosomes, one study used this method to prove that serum exosomes had a strong 
procoagulant activity devoid of ApoB lipoproteins (Verbree-Willemsen et al., 2018, Wang et al., 
2018b). It should be noted that in addition to identifying transmembrane or GPI-anchored proteins 
and cytosolic proteins recovered in EVs, the current minimal information for studies of EVs as 
detailed (MISEV2018) now advises that non-EV contaminants such as lipoproteins, protein and 
protein/nucleic acid aggregates must be determined to assess purity of the EVs (Théry et al., 
2018). 
As SEC has become increasingly popular as an isolation technique due to ease of use; low protein 
contamination and preservation of exosomal morphology, researchers have begun to investigate 
the lipoprotein content in SEC-derived exosomes. As described above, Chapter 3, plasma and 
serum SEC-derived exosomes co-isolate with ApoB lipoproteins (Karimi et al., 2018, Takov et al., 
2019). Our results were in agreement and showed that SEC using Sepharose CL-4B isolates 
contaminating ApoB lipoproteins with human serum-derived exosomes, with increasing ApoB 
concentrations in later SEC fractions as detected using an ApoB ELISA (Chapter 3). The co-
isolated ApoB lipoproteins were the larger lipoproteins namely VLDL and IDL. It has been 
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predicted that LDL would elute later in the SEC fractions due to its smaller size (Takov et al., 
2017), in agreement with the results shown in Chapter 3. Researchers using cell culture-derived 
exosomes should also take caution as trace amounts of ApoB have seen to be present in 
exosome isolations using anion exchange chromatography of cell culture media (Heath et al., 
2018). A solution to ensure no lipoprotein contamination, is to grow the cells in serum-free media; 
however, this comes at the cost of altering the cells properties.  
Due to exosomes having a similar size and density to lipoproteins (Figure 3.1), recently it was 
suggested to combine density gradient with SEC to remove the lipoproteins from the exosomes 
(Simonsen, 2017). OptiPrep™, a density gradient medium used for the isolation of cells, cell 
organelles, virus particles and lipoproteins, is a 60% (w/v) solution of iodixanol in water with a 
density of 1.32 g/ml. It has been found that OptiPrep purification of HIV-1 virion preserved the 
shape of the virus compared to sucrose purification which may have caused damage due to the 
high osmotic pressure of sucrose, whereas OptiPrep is iso-osmotic (Kol et al., 2010). OptiPrep 
has been used as a discontinuous gradient for the isolation of exosomes (Greening et al., 2015, 
Sung et al., 2015). As VLDL, IDL, LDL and chylomicrons (<1.06 g/ml) have a lower density than 
exosomes (>1.10 g/ml), a density gradient can be used to separate these lipoproteins from 
exosomes. SEC can remove HDL as their diameter (7-13 nm) is smaller than the Sepharose 
pores (35 nm for Sepharose CL-4B and 75 nm for Sepharose CL-2B) (Section 3.2.1.1). Therefore, 
we and others (Karimi et al., 2018, Onódi et al., 2018) have begun to investigate this approach. 
In this following chapter, various density gradients in combination with SEC were assessed for 










4.2 Results and discussion 
4.2.1 Determining optimal density gradient conditions 
The aim here was to develop a simple OptiPrep step gradient that would function as a flotation 
gradient for lower density lipoprotein particles (chylomicrons, VLDL, IDL and LDL) and would also 
allow for the sedimentation of exosomes. The layering of density gradients is relatively technically 
difficult and thus for reproducibility, simplicity is advantageous. The density gradient isolates were 
then to be further purified with a Sepharose CL-4B SEC column to remove HDL and plasma 
proteins.  
The initial approach was to assess the efficacy of a minimal 2-step gradient that consisted of a 
40% iodixanol high-density cushion overlayed with serum that was adjusted to 18% iodixanol. 
Density was assessed by weighing precise volumes (Table 4.1), it would be predicted that the 
lower density lipoprotein particles would float to the top of the 18% step and the exosomes would 
sediment towards the bottom. The cushion is there to potentially reduce loss due to sticking of 
exosomes via non-specific adsorption to the tube polymer. The 18% OptiPrep diluted in human 
serum had a density of 1.069 g/ml. This should allow sedimentation of the exosomes and HDL as 
they have a higher density. Technically the chylomicrons, VLDL, IDL and LDL would move above 
this layer of 18% OptiPrep and serum, due to them having a lower density. Though this is a 
desirably simple gradient, concern was that separation would be insufficient and a 3-step gradient 
was also considered where a low-density overlay onto the 18% iodixanol:serum step was 
incorporated. It was believed that a 4% or 6% overlay would allow for greater separation as they 
both have a higher density than chylomicrons, VLDL and IDL. Proportion of LDL would be 
expected to remain in the 4% or 6% density layer as their density goes as high as 1.063 g/ml 
(Vance and Vance, 2008). Therefore, both 4% and 6% OptiPrep was investigated to find the most 
suitable top density layer. The aim was to create a simple density gradient with only 2-3 layers to 








Table 4.1: Densities of gradient components, lipoproteins and exosomes 
 
Density (g/ml)  Reference 
40% OptiPrep and sucrose buffer 1.164  Our analysis (Section 7.9.1) 
18% OptiPrep in serum 1.069  “ 
4% OptiPrep and sucrose buffer 1.023  “ 
6% OptiPrep and sucrose buffer 1.029  “ 
Chylomicrons <0.95  (Vance and Vance, 2008) 
VLDL 0.95-1.006  “ 
IDL 1.006-1.019  “ 






(Colombo et al., 2014) 
 
4.2.2 Determining the efficiency of a simple 2-step gradient 
It was determined whether the 2-step gradient (Figure 4.1) could achieve separation with a short 
centrifugation period as the use of a swing out SW 60 Ti allowed for high centrifugal force. Thus, 
the gradients were spun at 200 000 g for 3 hours. However, visual examination of the gradients 
showed no visible evidence of separation such as a layer at the top. Most significantly, there was 
no evidence of sedimentation of exosomes away from the top of the gradient. TSG101 was found 
to be present at equal concentration throughout the gradient. Thus, though the simplicity of the 







Figure 4.1: Determining the efficiency of the floatation density gradient conditions to separate lipoproteins 
from exosomes. (A) Gradient consisted of 0.5 ml 40% iodixanol and 3 ml 18% iodixanol in serum. Gradient spun at 
200 000 g, 3 hours, 4°C; (B) After centrifuging 0.5 ml fractions were collected from the top of the gradient; (C) Western 
blot to detect exosome marker TSG101 in DG fractions 1-6 (25 µl) of the gradient. 
 
4.2.3 Determining the efficiency of a 3-step gradient using 4% or 6% iodixanol 
The efficiency of the new density gradient was tested when centrifuged for an extended time of 
20 hours (Figure 4.2). This gradient consisted of 3 layers, 0.5 ml 40% iodixanol, 1 ml 18% 
iodixanol in serum and 2 ml 4% or 6% iodixanol (Figure 4.2A). Gradients were spun at 265 000 g 
for 20 hours at 4°C in a SW 60 Ti rotor.  
After 20 hours of centrifugation, a separation was visible as the yellow serum was seen to 
decrease in height compared to before the centrifugation (Figure 4.2B). The yellow colour in 
serum is due to beta-carotene present in human LDL and HDL (Knipping et al., 1990). The 
gradient that had a 6% iodixanol step also had a faint yellow band at the top of the gradient that 
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was assumed to result from LDL, which was an indication that the 6% iodixanol step might more 
efficiently float lower density lipoprotein particles than the 4% iodixanol step. The 6% iodixanol 
with its slightly higher density than 4% iodixanol, would be predicted to drive a higher proportion 
of LDL upwards due the greater buoyant force generated. The 0.5 ml density gradient fractions 
were separated on a 4-15% SDS-polyacrylamide gradient gel to assess the ApoB lipoprotein 
separation (Figure 4.2C and D). Equal volumes (10 µl) were loaded for density gradient fractions 
1-4. Serum proteins were likely to be present in in the lower fractions and due to high protein 
content, 3.3 µl were loaded for fractions 5-7. A band corresponding to the molecular weight of 
ApoB100 lipoproteins (512 kDa) was detected in density gradient fraction 1-4 (Figure 4.2C) using 
the 4% iodixanol. Using the 6% iodixanol there was a higher concentration of ApoB100 in density 
gradient fraction 1-2 as detected by the increased intensity compared to fraction 3-4 (Figure 4.2D). 
This correlates with the presence of the upper beta-carotene containing band in this gradient. 
Thus, the 6% iodixanol step separated the ApoB lipoproteins from serum better than 4% iodixanol 
and it considered likely that this was due to more efficient flotation of LDL, the most prevalent 
lower density lipoprotein particle in blood (Feingold and Grunfeld, 2018). Therefore, for future 
purifications the gradient consisting of 18% iodixanol in serum and 6% iodixanol was chosen. One 
limitation of this method is the small volumes of the gradient which could lead to a low yield of 
exosomes isolated. Hence, the volume of the gradient was increased prior to detailed analysis of 
lipoprotein and exosome markers. As the vast majority of the serum proteins were present in 
fraction 5-7 and predominately in fraction 6-7, the 40% iodixanol density cushion at the bottom 
was replaced with 60% iodixanol instead to create a higher density cushion to more effectively 
prevent the exosomes sedimenting to the bottom of the UC tube so as to reduce any potential 




Figure 4.2: Optimising the density gradient conditions to separate lipoproteins from exosomes. (A) Gradients 
consisted of 0.5 ml 40% iodixanol, 1 ml 18% iodixanol in serum, 2 ml 4% or 6% iodixanol. Gradients were spun at 265 
000 g, 20 hours, 4°C; (B) After centrifuging the gradient using 6% iodixanol contained a faint yellow band. 0.5 ml 
fractions were collected from the top of the gradient; (C and D) 4-15% SDS-polyacrylamide gradient gel of DG fractions 
1-7 stained with Coomassie Brilliant Blue R-250 (10 µl sample loaded for fractions 1-4 and 3.3 µl for fractions 5-7); (C) 




4.2.4 Assessment of lipoprotein separation in a larger scale density gradient 
The scaled up and refined iodixanol density gradient was assessed for its ability to remove ApoB 
lipoprotein contamination in serum (Figure 4.3). The gradient consisted of 0.5 ml 60% iodixanol, 
6 ml 18% iodixanol in serum and 6.5 ml 6% iodixanol (Figure 4.3A) and the gradient was 
centrifuged using a SW 40 Ti rotor for 24 hours at 195 000 g at 4°C. The time was increased to 
partially compensate for the reduced centrifugal force. 
After centrifuging for 24 hours, a faint yellow band was again visible at the top of the gradient and 
an intense yellow band sitting above the 60% iodixanol cushion (Figure 4.3A). The density 
gradient was fractionated into 2 ml fractions collected from the top, except fraction 6 was 1 ml, 
adding up to the total volume loaded. The density gradient fractions were separated on a 4-15% 
SDS-polyacrylamide gradient gel to assess the ApoB lipoprotein separation (Figure 4.3B). Equal 
volumes (10 µl) were loaded for density gradient fractions 1-4 and again due to high protein 
content, 3.3 µl were loaded for fractions 5-7. A band corresponding to the molecular weight of 
ApoB100 lipoproteins (512 kDa) was detected in density gradient fraction 1-4. There was possibly 
a higher concentration of ApoB100 in density gradient fraction 2 as detected by the increased 
intensity compared to fraction 1, 3 and 4. The ApoB lipoproteins were distributed in the upper 
fractions 1-4, whereas the serum proteins started to appear in fraction 4 and had condensed into 
lower fractions 5-7. Fraction 7 appeared overloaded which might reflect sedimentation of the 
serum proteins and/or the presence of a higher concentration of iodixanol (Figure 4.3B).  An ApoB 
ELISA was used to quantify the concentration of ApoB in the density gradient fractions 1-7, to 
assess the efficiency of ApoB lipoprotein separation from serum (Figure 4.3C). The ApoB 
concentration was the highest in fraction 1 (594.7 µg/ml) and decreased in concentration to 
fraction 6 (10.4 µg/ml). Fraction 7 (19.8 µg/ml) had a slightly higher ApoB concentration than 
fraction 6; however, it was lower than fraction 5 (29.6 µg/ml). Thus, the gradient was able to 
separate 62% of ApoB on the gradient into the top two fractions. 
Western blots were used to detect HDL marker ApoA1 in the density gradient fractions 1-7 (Figure 
4.3D). A faint trace of ApoA1 was detected in fractions 1-3 with the majority of the ApoA1 found 
in fraction 4-7. This indicates that the majority of ApoA1 loaded onto the gradient was contained 
in HDL and not chylomicrons suggesting that the pre-gradient chylomicron removal from unfasted 
serum was highly effective (13 000 g for 10 min). The exosomal markers CD9 (25 kDa) and 
TSG101 (50 kDa) were detected in density gradient fractions 5-7 (Figure 4.3E) with the majority 
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in fraction 7. CD9 was more clearly sedimented into fraction 7 than TSG101, suggestive of 
different exosome subtypes.  
Here it can be seen that the longer centrifugation period had concentrated the exosomes markers 
towards the bottom of the step gradient with some separation from ApoA1. This is in line with the 
known density ranges for HDL and exosomes (Table 4.1). Additionally, the two fractions that 
contained the bulk of the exosome markers (6 and 7) only contained 1.6% of the ApoB on the 
gradient. 
UC was used after the density gradient (DG UC) to concentrate fractions 6 and 7 from four repeats 
as these fractions contained most of the exosome markers and had the least contaminating ApoB 
present. The resulting pellet was resuspended in a final volume of 1 ml which resulted in 1.8 µg/ml 
ApoB lipoprotein being present (Figure 4.3F). Thus, UC resulted in removal of a further 98% of 
ApoB that was present after the density gradient in agreement with a recent analysis of UC-based 
removal of ApoB (Takov et al., 2019).  
As the step gradient separated the ApoB lipoproteins from the exosome fractions, the exosome 








Figure 4.3: Assessment of removing ApoB lipoprotein contamination in human serum using an iodixanol 
density gradient. (A) Gradient consisted of 0.5 ml 60% iodixanol, 6 ml 18% iodixanol in serum and 6.5 ml 6% iodixanol. 
After centrifuging a faint yellow band is visible at the top and a dense yellow band condensing at the bottom; (B) 4-15% 
SDS-polyacrylamide gradient gel of DG fractions 1-7 stained with Coomassie Brilliant Blue R-250 (10 µl sample loaded 
for fractions 1-4 and 3.3 µl for fractions 5-7); (C) ELISA of ApoB lipoproteins in DG fractions 1-7. n=2 (technical repeats); 
(D) Western blot to identity HDL marker ApoA1 in DG fractions 1-7 (3.3 µl loaded). n=3 (technical repeats); (E) Western 
blot to detect exosomal markers (CD9 and TSG101) in DG fractions 2-7 (6.7 µl loaded). n=2 (technical repeats); (F) 
ELISA of ApoB lipoproteins in DG UC pellet (1 ml). n=2 (technical repeats). 
 
4.2.4.1 Assessment of lipoprotein separation after density gradient followed by size 
exclusion chromatography 
Density gradient fraction 6 and 7 from four tubes were concentrated using UC (fractions diluted 
in PBS and concentrated by centrifuging at 100 000 g for 3 hours at 4°C with a Type 40 Ti rotor). 
The pellet was resuspended in 1 ml which was subsequently loaded on SEC to further purify the 
exosomes (Figure 4.4). This method of density gradient followed by SEC will be referred to as 
DG SEC. 
The A280 profile of DG SEC performed on a Sepharose CL-4B column displayed a shoulder peak 
in fraction 8-10 (Figure 4.4A). Western blot showed that CD9 was present, in two forms 25 kDa 
and 22 kDa, in DG SEC fraction 10 (Figure 4.4B). TSG101 was present in DG SEC fraction 9-10 
at 50 kDa. TSG101 was also detected in DG SEC fraction 13-15 with increasing intensity as had 
been observed previously for single-step SEC. Electron microscopy revealed exosome like 
structures in DG SEC fractions 8-10 ranging from 30-100 nm (Figure 4.4C) though the fractions 
had to be diluted 5X due to a high background. Even accounting for this dilution, there appeared 
to be a lower number of particles per field than seen in the single-step SEC (Figure 2.1). There 
was a higher portion of cup-shaped particles than previously observed for SEC (Figure 2.1). This 
is accepted now as the classical appearance of exosome as viewed in TEM (Sluijter et al., 2017). 
ApoA1 was detected in DG SEC fractions 12 and 14 at 25 kDa and majority of the HDL was in 
fraction 14 (Figure 4.4E). An ApoB ELISA was used to quantify the concentration of ApoB in the 
DG SEC fractions 7-14, to assess ApoB lipoprotein separation from serum exosomes (Figure 
4.4F). There was no detectable ApoB lipoproteins in DG SEC fraction 7-11. Hence, less than 39.1 
ng/ml of ApoB lipoproteins were present in DG SEC exosome fraction 9-10. ApoB started to 
appear from DG SEC fraction 12 (0.07 µg/ml) and continued to increase until at least DG SEC 
fraction 14 (0.16 µg/ml). This indicates that Sepharose CL-4B separates LDL from exosomes as 
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that is the most likely ApoB particle to elute after to the void volume as the particle size cut off for 
Sepharose CL-4B is 35 nm. Additionally, LDL was considered the most likely ApoB containing 
particle to sediment with the exosomes on the density gradient. NTA became available in Cape 
Town, South Africa, during the time of the establishment of these density gradients. NTA results 
revealed no clear evidence of peaks across DG SEC fractions 8-15 (Figure 4.4D). 
SDS-PAGE gradient gel analysis indicated that density gradient fraction 2 contained the highest 
ApoB100 concentration; however, density gradient fraction 1 contained the highest overall ApoB 
lipoprotein as determined by ELISA. Thus, it is possible that chylomicrons also contributed to the 
ApoB lipoprotein concentration (ELISA detects ApoB100 and ApoB48) as ApoB100 is  associated 
with IDL, LDL and VLDL and ApoB48 with chylomicrons (Ramasamy, 2014). Although exosomes 
were present in density gradient fraction 5, there was a slightly higher level of ApoB lipoprotein 
present than in the last two fractions. Thus, only fraction 6 and 7 was used to obtain a purer 
population of exosomes. After SEC, it appeared most to all of the HDL was removed from the 
serum exosomes using DG SEC and they were enriched for exosomal markers CD9 and TSG101. 
Furthermore, the DG SEC exosomes contained no detectable ApoB lipoproteins. The ApoB 
detected in later DG SEC fraction 12-14 suggests it derives from LDL.  
NTA was unable to detect a peak of particles for the DG SEC exosome fraction 9 and 10. As TEM 
had a high background, perhaps due to aggregation caused by UC of the density gradient 
fractions prior to SEC, this could have obscured the signal due to the presence of exosomes. 
Though good separation of exosome markers from ApoB and ApoA1 was achieved by DG SEC, 
the lack of a clear peak on NTA, the presence of aggregates and the apparent low yield as 
determined by TEM indicated that the procedure should be further modified. It was considered 
perhaps more optimal to concentrate exosomes prior to DG and SEC as the sedimentation might 
be more gentle and reduce adhesion to tube polymer in the presence of an excess of serum 




Figure 4.4: Assessment of removing ApoA1 and ApoB lipoprotein contamination in human serum using an 
iodixanol density gradient followed by SEC. (A) A280 profile of DG SEC performed on a Sepharose CL-4B column. 
1 ml of UC concentrated DG fractions 6&7 was loaded onto the column; (B) Western blot to detect exosomal markers 
(CD9 and TSG101) in DG SEC fractions 7-15 (equal protein loading 0.16 µg). n=3 (technical repeats); (C) TEM 
micrograph of DG SEC fractions 7-11 (5X diluted). Scale bar = 100 nm; (D) NTA of particles/ml vs the fraction number 
of human serum DG SEC fractions 8-15; (E) Western blot to identity HDL marker ApoA1 in DG SEC fractions 7-14 (3.3 




4.2.5 Assessment of lipoprotein separation by first concentrating exosomes using 
ultracentrifugation followed by density gradient 
Human serum (31 ml) was concentrated using UC thereafter the UC pellet was resuspended in 2 
ml 18% iodixanol. The gradient consisted of 0.25 ml 60% iodixanol, 1 ml 18% iodixanol UC pellet 
(from 15.5 ml serum) and 2.6 ml 6% iodixanol (Figure 4.5A). The gradient was centrifuged in a 
SW 60 Ti rotor for 24 hours at 195 000 g at 4°C. The UC and density gradient step will be referred 
to as UC DG.  
An ApoB ELISA was used to quantify the concentration of ApoB in the UC pellet (Figure 4.5C). 
The ApoB concentration was 44.1 µg/ml, showing that 95% of ApoB in serum was removed in 
this instance. This confirms the finding that was observed for UC after DG (see above) and shows 
that UC though not removing all ApoB can contribute significantly to purification. After centrifuging 
the density gradient for 24 hours, even though the concentration of ApoB loaded was significantly 
reduced relative to on the density gradient of the DG SEC procedure, a faint yellow band was still 
visible at the top of the gradient and a condensed cloudy yellow band at the bottom (Figure 4.5A). 
This is suggestive that the main lipoprotein particles present after UC are LDL and HDL. Four 
fractions were collected from top to bottom (1 ml, 1 ml, 0.5 ml and 1.1 ml). Western blot only 
detected HDL marker ApoA1 in UC DG fraction 4 (Figure 4.5B). The ApoB concentration was the 
highest in UC DG fraction 1 (22.7 µg/ml) and decreased in fraction 2 (3.3 µg/ml) and fraction 3 
(2.6 µg/ml) (Figure 4.5D). There was a slight increase in fraction 4 (5.3 µg/ml) compared to fraction 
2 and 3. This pattern of decreasing ApoB concentration till there is a slight increase in the last 
fraction of the density gradient is as was observed for the DG SEC approach though with much 
reduced ApoB on the UC DG gradient due to the prior removal of ApoB by UC. The exosomal 
markers CD9 (25 kDa) and TSG101 (50 kDa) were only detected in UC DG fraction 4 (Figure 
4.5E). Thus, HDL and exosomes co-isolated as expected. This does show that though 83% of 
ApoB on the gradient was separated away from exosome marker containing fractions, there was 
a higher proportion present in these fractions than seen in the DG SEC approach at this stage. 
This perhaps reflects the enrichment of higher density LDL particles by UC. 
As the UC and step gradient separated the majority of the ApoB lipoproteins from the exosome 






Figure 4.5: Assessment of removing ApoB lipoprotein contamination in human serum using UC followed by 
an iodixanol density gradient. (A) Gradient consisted of 0.25 ml 60% iodixanol, 1 ml 18% iodixanol UC pellet and 2.6 
ml 6% iodixanol. After centrifuging the LDL were visible by a faint yellow band at the top and HDL condensing at the 
bottom. Isolations were performed on three independent pooled human sera batches with two technical repeats for two 
of the batches; (B) Western blot to identity HDL marker ApoA1 in UC DG fractions 1-4 (3.3 µl loaded); (C) ELISA to 
identify ApoB lipoproteins in UC pellet. n=2 (technical repeats); (D) ELISA to identify ApoB lipoproteins in UC DG 
fractions 1-4. n=2 (technical repeats); (E) Western blot to detect exosomal markers (CD9 and TSG101) in UC DG 
fractions 1-4 (6.7 µl loaded).  
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4.2.5.1 Assessment of lipoprotein separation after ultracentrifugation, density gradient 
followed by size exclusion chromatography 
The 1 ml UC density gradient fraction 4 was loaded directly onto the SEC column to isolate the 
purified human serum exosomes (Figure 4.6). The UC, density gradient followed by SEC method 
will be referred to as UC DG SEC.  
The A280 profile of UC DG SEC performed on a Sepharose CL-4B column displayed a peak in 
fraction 8-10 (Figure 4.6A) unlike the shoulder observed for DG SEC. Western blot detected CD9 
present in UC DG SEC fraction 9 and slightly less in fraction 10 (Figure 4.6B). TSG101 was 
present in UC DG SEC fraction 9 and was again also detected in UC DG SEC fraction 13-15 
increasing in intensity. Thus, UC DG SEC fraction 9 contained majority of the exosomal markers 
as well as having the highest absorbance reading in the peak. The lowest magnification TEM (0.5 
µm scale bar) revealed numerous vesicles (Figure 4.6C). When observed at higher magnifications 
the vast majority of vesicles are seen to be cup-shaped with a few spherical particles that more 
resembled lipoprotein particles. TEM showed particles of dimensions expected of exosomes in 
UC DG SEC fraction 9 with average diameters correlating to those of exosomes (71.7 nm ±22.3). 
The size range of the vesicles in UC DG SEC fraction 9 (40.3-121.3 nm) correlated with the 
reported exosome sizes of 30-100 nm (Caradec et al., 2014, Vicencio et al., 2015). The UC DG 
SEC fraction 9 had a larger average diameter (71.7 nm ±22.3) and larger minimum vesicle size 
(40.3 nm) compared to SEC fraction 9 (44.5 nm ±14.5 and 15.3 nm respectively, Figure 2.1), 
further evidence that more exosomes and less lipoproteins were isolated particularly since LDL 
are 21-27 nm. The marker ApoA1 was mainly detected in UC DG SEC fraction 14 (Figure 4.6D). 
A faint band of ApoA1 was detected in fraction 12 with a very slight trace in fraction 10. UC DG 
SEC fraction 9 did not contain a detectable amount of ApoA1. ApoB concentration was detected 
from UC DG SEC fraction 11 (0.05 µg/ml) and continued to increase after (UC DG SEC fraction 
14 (0.535 µg/ml)) (Figure 4.6E). As UC DG fraction 4 contained ApoB (Figure 4.5D) these later 
UC DG SEC fractions containing ApoB are suggested to be LDL of 21-27 nm as the Sepharose 
CL-4B have 35 nm pores. There were no detectable ApoB lipoproteins in UC DG SEC fraction 
7,8, 9 and 10. Thus, there was no or minimal ApoB lipoproteins in UC DG SEC exosome fraction 
9-10. 
NTA was then used to compare the particle number in serum SEC-derived fractions and purified 
UC DG SEC-derived exosome fractions (Figure 4.6F). The NTA results showed an initial rise in 
particle number in SEC fraction 8 (7.28x1010 particles/ml) and a peak in fraction 9 (1.24x1011 
particles/ml). The particle number continued to decrease from fraction 10 (7.66x1010 particles/ml) 
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through to fraction 12 (1.10x1010 particles/ml). The peak particle count in SEC fraction 9 coincides 
with the A280 peak and exosome marker reported previously (Figure 2.1 and 2.4). A clear peak 
was visible for the UC DG SEC isolation unlike that observed for DG SEC further indicating that 
the aggregates observed on TEM may have obscured the particle count in DG SEC or that there 
were less particles present. There was an initial increase in particle number in UC DG SEC 
fraction 8 (1.80x109 particles/ml) and a shared peak in fraction 9 (4.47x109) and 10 (4.72x109 
particles/ml). The particle concentration decreased in fraction 11 (2.77x109 particles/ml) and 12 
(2.05x109 particles/ml). The shared peak particle concentration in UC DG SEC fraction 9 and 10 
coincided with the A280 peak and exosome marker densities (Figure 4.6A and B). The purified UC 
DG SEC serum fractions contained ~100 times less particles than SEC strongly indicating that 
lipoproteins like VLDL and IDL contributed the majority of particles observed on TEM for SEC 
isolations. The representative graph of particles/ml vs particle diameter (nm) from the NTA report, 




















Figure 4.6: Assessment of removing ApoA1 and ApoB lipoprotein contamination in human serum using UC 
followed by an iodixanol density gradient and SEC. (A) A280 profile of UC DG SEC performed on a Sepharose CL-
4B column. 1 ml concentrated UC DG fraction 4 was loaded onto the column; (B) Western blot to detect exosomal 
markers (CD9 and TSG101) in UC DG SEC fractions 7-15 (equal protein 0.4 µg). n=2 (technical repeats); (C) TEM 
micrograph of UC DG SEC exosome fraction 9 at different magnifications. Scale bars indicated on figures; (D) Western 
blot to identity HDL marker ApoA1 in UC DG SEC fractions 7-14 (3.3 µl loaded); (E) ELISA to identify ApoB lipoproteins 
in UC DG SEC fractions 7-14. n=2 (technical repeats); (F) NTA of particles/ml vs the fraction number of serum 
exosomes isolated using SEC or UC DG SEC. 
 
As blood is a very complex medium, the co-isolation of lipoproteins and exosomes is an issue 
when using a single-step purification. In 2017, it was proposed that a combination of density 
gradient and size exclusion techniques would obtain a purer population of EVs (Simonsen, 2017). 
This should be expected to reduce incorrect interpretations regarding exosome bioactivity and 
composition. Even though the issue of co-isolation is more prominent in EV isolations due to the 
higher concentration of lipoproteins in blood, a minor contamination of EVs in lipoprotein isolations 
can also significantly influence the protein and RNA composition when detected using mass 
spectrometry or qPCR respectively (Simonsen, 2017). We are presently aware of only two studies 
that have explored the utility of density gradient isolation followed by further downstream SEC 
purification (Karimi et al., 2018, Onódi et al., 2018). Both these studies used identical iodixanol 
gradients (equal volumes of 10, 30 and 50% iodixanol) overlayed with plasma. In the earlier 
publication, Karimi et al. loaded onto the density gradient 6 ml of human plasma (equal to total 
density gradient volume) or a 6 ml resuspension of an UC pellet of 40-80 ml plasma (large scale). 
For the latter, though microvesicles were pelleted at 16 500 g (20 min) and exosomes at 118 000 
g (2.5 hour), the two pellets were combined prior to being loaded on the density gradient. Onódi 
et al. modified the approach of Karimi et al. in several ways. They loaded 0.5 ml rat plasma (1/8th 
139 
 
total density gradient volume, small scale) or 2 ml (1/4 total density gradient volume, large scale). 
They also, as we did for serum (UC DG SEC), centrifuged the plasma to remove microvesicles 
prior to addition to the density gradient. Furthermore, unlike Karimi et al. who centrifuged their 
gradient at 178 000 g for 2 hours, Onódi et al. spun their gradients at 120 000 g for 24 hours. Both 
studies investigated the utility of SEC as a post-purification procedure (Sepharose CL-2B) with 
Onódi et al. additionally examining the efficiency of UC (100 000 g, 3 hours) or bind-elute SEC 
(Hiscreen Captocore700). 
The major differences in our approach to the above are the use of human serum as a source for 
exosomes, the construction of a technically simpler gradient that only requires three loadings of 
components rather the four used in both above studies. The separation of lipoprotein particles 
from exosomes on the density gradients was reliant on sedimentation of exosomes in the above 
whilst our approach focused more on buoyant force driven flotation of the lipoprotein particles. 
Furthermore, we used Sepharose CL-4B in a longer column (all SEC columns were 10 ml volume) 
for post density gradient purification. As detailed above (Chapter 2), we used this matrix as it had 
been reported to optimally separate exosomal sized vesicles (Baranyai et al., 2015). Analysis of 
lipoprotein content also differed, our study employed a highly quantitative and sensitive sandwich 
ELISA to detect ApoB (100 and 48) while Onódi et al. used western blotting to relatively quantify 
ApoB (100 and 48). Interestingly, Karimi et al. did not directly assay for ApoB contamination but 
did assay ApoA1 via western blotting as did we and Onódi et al.  
From the results, the gradient was efficient at removing majority of the ApoB lipoproteins from the 
serum exosomes and it was very simple to construct as it only contained three layers. The density 
layers were underlayed which is much easier than overlaying, especially with the denser 60% 
cushion (Pandya and N, 2015). Our approach allowed for underlaying the gradient as the serum 
was within the 18% iodixanol layer. 
The majority of ApoB content was present in density gradient fraction 1-4 (DG SEC method) and 
UC DG fraction 1 (UC DG SEC method) with low levels of ApoB (5-20 µg/ml) present in exosome 
marker containing fractions. Though difficult to directly compare as their analysis was a relative 
measure (western blotting), our data is in accordance with Onódi et al. who also found ApoB100 
and ApoB48 in upper density fractions (1-4 and 1-3 for small and large scale respectively) and 
exosome markers (Alix, CD81 and TSG101) into denser fraction 5-7, detected by western blotting 
(Onódi et al., 2018). They had a trail of ApoB100 in density fractions 5-7, coinciding with the 
exosome markers. This further correlates with the minor detection of ApoB in density fraction 6 
and 7 (DG SEC method) and UC DG fraction 4 (UC DG SEC method). Hence, the co-isolation of 
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the minor LDL using the density gradient was shown to be separated into the later DG SEC and 
UC DG SEC fractions 12-14. The minimal LDL detected in the lower gradient fractions may have 
not separated efficiently to the top of the gradient due to their higher density than the other ApoB 
lipoproteins.  
In both our density gradients, ApoA1 was not seen to co-isolate with low-density lipoproteins 
unlike as observed by Karimi et al. They detected the majority of ApoA1 present in a low-density 
band (<1.025 g/ml). This suggests the possibility of a significant amount of early stage 
chylomicrons associated with ApoA1 and further that as indicated above, that our pre-gradient 
removal of chylomicrons was effective. In our UC DG SEC approach, we did not observe any 
separation of ApoA1 from exosome markers in the density gradient but did see some on the 
density gradient in the DG SEC study as was observed by both Karimi et al. and Onódi et al. 
Though this separation is desirable, it was not considered a serious concern as Sepharose CL-
4B SEC effectively separated ApoA1.  
Sepharose CL-4B SEC of density fractions from either DG SEC or UC DG SEC resulted in 
exosome marker (CD9, TSG101) enriched fractions having no detectable ApoB or ApoA1. 
However, it was noted that in the UC DG SEC approach, ApoB and ApoA1 (very faint trace) were 
detected one fraction earlier and closer (11 and 10 respectively) to the exosome marker fraction 
than that seen in DG SEC (12 and 11 respectively). Though indicating a possible reduction in 
purification for UC DG SEC relative to DG SEC, this needs to be contextualised with the 
morphological and quantitative analysis of the particles obtained. 
Our UC DG SEC exosome fraction 9 did not contain a detectable amount of ApoA1, whereas 
Karimi et al. did detect some ApoA1 contamination in their exosome fraction 8 and 9 using both 
their small and large scale DG SEC methods. Onódi et al. DG SEC method using a commercial 
column also agreed with our results as they detected ApoB100 in later fractions 12-17. However, 
they also detected ApoB48 in fractions 9-11 and a slight trail in fractions 12-17. This could be due 
to that they didn’t use a UC step between the DG and SEC, which would have further removed 
low-density ApoB48 as was shown in these studies in which no detectable ApoB was found in 
exosome DG SEC fractions or UC DG SEC fractions. 
The morphology and concentration of exosomes isolated improved using the UC DG SEC method 
compared to DG SEC even though the UC DG SEC method used slightly less starting serum (UC 
DG SEC: 15.5 ml serum; DG SEC: 16.8 ml serum). It must be noted that density gradient fraction 
5 containing exosome markers was sacrificed for the DG SEC method due to a relatively higher 
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level of ApoB. The A280 absorbance was less for the DG SEC fraction 9 exosome shoulder (0.123 
AU) compared to UC DG SEC method fraction 9 exosome peak (0.145 AU). Electron micrography 
showed the particles to be cleaner and containing a high percentage of exosome like particles. It 
is difficult to compare the NTA data for both preparations as there was not a clear peak for the 
DG SEC, suggestive of the presence of aggregates that were also detected by TEM. However, 
even with the assumption of no aggregates, there were 1.6 times more particles present in the 
UC DG SEC exosome sample. It is possible as indicated above that with concentration by UC at 
the start, exosomes were protected by the presence of excess particles and other serum 
components and that less exosomes were lost due to adhesion to the centrifuge tube in UC DG 
SEC. Sódar et al. suggested that commercial LDL attached to 5/4E8 Th1 T hybridoma cell-derived 
exosomes isolated using differential UC (Sódar et al., 2016). However, we did not see evidence 
of LDL attaching to the serum UC DG SEC-derived exosomes in our TEM analysis. 
We also saw as expected that NTA failed to distinguish between exosomes and lipoproteins, as 
reported by other authors (Karimi et al., 2018, Takov et al., 2019). The particle number was 100-
fold more in SEC-derived exosomes compared to purified UC DG SEC-derived exosomes, even 
though only 1 ml of serum was used for SEC compared to 15.5 ml for the UC DG SEC method. 
Karimi et al. found 30-100 times more particles in the low-density band as compared to their high-
density band isolated off their 4-step density gradient (Karimi et al., 2018). These results highlight 
the issue of quantification in the exosome field when working with blood-derived components such 
as serum, as exosomes are alike in shape and size to lipoproteins. Thus, using the UC DG SEC 
method, provides a more suitable method to estimate particles concentration with NTA.  
The repeated detection of TSG101 in western blots of later SEC, DG SEC and UC DG SEC 
fractions 13-15 suggests the presence of substantial amounts of free TSG101 or that TSG101 
may be bound to other much smaller vesicles. As mentioned and discussed previously other 
researchers using SEC to isolate plasma/serum exosomes observed the same pattern for 
TSG101 and CD63 (Baranyai et al., 2015, Koh et al., 2018). Karimi et al. also observed flotillin-1 
and TSG101 in their downstream fractions on SEC (Karimi et al., 2018). This requires further 
analysis though it should be noted that CD9 in our isolations did not have the same distribution 
being detected only in the void volume peak. Interestingly, when Karimi et al. separated the low-
density band from their DG on SEC columns, TSG101 was detected in fractions 10-14 and flotillin-
1 in fractions 7-9 suggesting there are particles with a density <1.025 g/cm3 containing exosome 
markers. It might also indicate a too brief centrifugation period 2 hours versus 24 hours for Onódi 
et al. (Onódi et al., 2018). When we centrifuged for 3 hours at 200 000 g relative to their 2 hours 
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at 178 000 g, though at a higher iodixanol density, we observed no sedimentation of exosomal 
markers. 
A few other purification approaches directed towards purifying exosomes away from lipoprotein 
particles in blood-derived samples have been reported recently. 
As mentioned above, Onódi et al., assessed the utility of bind-elute SEC after density gradient 
isolation. They further purified density gradient fraction 6-8 from the large scale (1.5 ml) using 
bind-elute SEC using a 4.7 ml CaptoCore 700 column. They did not detect ApoB100 in their DG 
bind-elute SEC fractions 1-12; however, they had minor levels of ApoB48 in fractions 6-7 
coinciding with exosome markers TSG101, CD81 and Alix. It is to be noted they used western 
blotting to quantify ApoB which may not be as sensitive as the ELISA used here. Furthermore, 
their Capto Core 700 column was shown to retain a significant amount of exosomal markers which 
would have reduced their exosome yield.  
One study investigated the efficiency of SEC, heparin-Sepharose, lipopolysaccharide-Sepharose, 
(2-hydroxypropyl)-β-cyclodextrin-Sepharose, and concanavalin A-Sepharose in separating 
serum EVs and lipoproteins (Wang and Turko, 2018). They found that SEC followed by heparin-
Sepharose isolated purer exosomes; however, it still recovered 0.6% ApoA1 and 0.4% ApoB100. 
It should be noted that our approach of utilising a density gradient followed by SEC reduced ApoB 
to at least 0.002% of serum levels. 
The use of anti-ApoB antibody magnetic beads have also been used to remove contaminating 
lipoproteins from plasma or cell culture exosomes; however, a substantial loss of exosomes and 
NTA artefacts were noted as issues (Mørk et al., 2017).  
An approach whereby 5 UC steps were used to remove more than 95% of serum proteins and to 
remove ApoB and ApoA1 lipoprotein contamination from exosome samples with minimal loss in 
yield is promising in its simplicity (An et al., 2018). There are discrepancies in the literature though, 
another report suggested two UC steps removes ApoB as determined detected by western blot 
but the concentration of exosomal marker CD9 dropped 50% with the second UC step (Nielsen 
et al., 2018). It should be noted with respect to the latter finding that detection of ApoB by western 
blot is challenging (Sódar et al., 2016).  
Acoustofluidic technology has also been suggested to separate exosomes and lipoproteins, with 
the advantage of a simple, fast (25 min), only 100 µl undiluted human blood required and 
continuous-flow isolation. Acoustofluidics employs a continuous acoustic streaming, and the 
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device separated the EVs and lipoproteins according to their acoustic properties. Yet, the UC DG 
SEC method was superior in removing more lipoproteins as only 70% of VLDL was reduced using 
the acoustofluidic method (Wu et al., 2019a). A further possibility would be to combine SEC with 
immunoaffinity. This has been performed previously to isolate tumour-derived exosomes from 
plasma using SEC and immunoaffinity capture with a unique melanoma cell epitope (Sharma et 
al., 2018). However, the lack of a specific exosome marker (Théry et al., 2018) limits the potential 
to isolate all exosomes using immunoaffinity capture.  
As our UC DG SEC method isolated exosome like particles, enriched for exosomal markers with 
non-detectable levels of ApoB and ApoA1, the exosome fraction protein content was assayed by 
liquid chromatography with tandem mass spectrometry (LC-MS/MS) and compared to the 
proteomic data gained by Karimi et al.  
4.2.6 Proteomic analysis of SEC and UC DG SEC isolates 
An initial proteomic pilot study was carried out to determine whether mass spectrometry of 
proteins from the two isolates was feasible. Runs with UC DG SEC isolates satisfied quality 
control of the LC-MS/MS core facility, which was running a complex reference sample (human 
neuroblastoma cell line) with the calibration of the mass spectrometer to benchmark the 
instrument. The samples were initially overloaded, but after dilution these too passed the relevant 
quality control. The mass spectrometry data was obtained using label-free discovery proteomics 
which uses a data-dependent Top 10 method that picks the most abundant peptides from the 
survey scan which does allow for quantification. However, as this was a pilot study several 
caveats with respect to quantification must be noted. The inherent random nature of complex 
biological samples means that peptides can appear to be absent in a sample when they are 
present but at very low amounts. To achieve better quantitative accuracy in label-free proteomics, 
biological and technical replicates are recommended. Furthermore, it is common practice to 
quantify total proteins prior to tryptic digest so that the amount of protein in each sample is equal. 
However, due to the concern that there might be a very low amount of starting material in this 
exploratory study, it was decided to proceed with tryptic digest without performing protein 
quantitation. Thus, the amount of total protein in these samples was not normalised. Though 
comparison of the total ion intensity of these samples, to that of a known reference sample, 
determined that this method provides sufficient starting material to allow for protein quantitation 




Bearing the above limitations in mind, the readouts of the LC-MS/MS were further analysed and 
it was noted that the level of ApoA1, as determined by LFQ intensity, was similar between the 
two. CD9 was similarly elevated approximately 3-fold for UC DG SEC relative to SEC (Appendix 
6) as had been observed with western blotting (Figure 5.1 - Data shown in section 5.2.1). It was 
thus suggestive that the readouts obtained were probably reasonably representative of the pattern 
of protein levels in the two isolates. It can be seen that 224 proteins were identified in UC DG 
SEC exosomes and 135 proteins in SEC exosomes (Figure 4.7 and 4.8) using the MaxQuant 
search engine, Andromeda. This is perhaps not unexpected as the very high level of lipoproteins 
might have impeded detection of lower level proteins. If one looks at the top 10 proteins in SEC 
(LFQ levels in SEC) (Table 4.2), four were lipoproteins with ApoB having the highest LFQ intensity 
(2.56x1011). Thus, the high levels of lipoproteins overwhelmed the mass spectrometry data as 
was also observed by Karimi et al. who found a lower number of proteins identified in their plasma 
SEC exosomes with the majority being lipoproteins, predominately ApoB with only minimal EV 
proteins identified.  
The Funrich analysis of cellular components, based on their GO identification numbers, indicated 
that 81% and 85% of GO identified proteins within UC DG SEC and SEC samples, respectively, 
are exosome associated (p < 0.001) (Figure 4.7). This reflects 182 and 115 proteins for UC DG 
SEC and SEC respectively. When the SEC and UC DG SEC isolated proteins were compared to 
each other (Figure 4.8) there was an overlap of 117 proteins with the UC DG SEC proteome 





Figure 4.7: Enrichment of cellular components in SEC and UC DG SEC exosomes. LC-MS/MS was performed on 
the exosomes isolated from fraction 9 using either SEC or UC DG SEC. In total, 224 proteins were identified in UC DG 
SEC exosomes and 135 proteins in SEC exosomes and were analysed with MaxQuant version 1.3.1.12 followed by 




Figure 4.8: Venn diagram comparing the proteins in SEC and UC DG SEC exosome fraction 9. 
 
Table 4.2: Top ten proteins in SEC exosomes 
 Protein IDs Proteins LFQ intensity 
1 P04114 ApoB 100 2.56E+11 
2 P01871 Immunoglobulin heavy constant mu 1.26E+11 
3 P02649 Apolipoprotein E 7.19E+10 
4 P04275 von Willebrand factor 4.09E+10 
5 P02656 Apolipoprotein C-III 3.79E+10 
6 P02655 APOC4-APOC2 readthrough 3.76E+10 
7 P00738 Haptoglobin 3.76E+10 
8 P68871 Hemoglobin subunit beta 3.43E+10 
9 P01834 Immunoglobulin kappa constant 3.18E+10 





Analysis of biological functions showed significant association with the immune response for both 
SEC and UC DG SEC. Among the top 10 most abundant proteins identified in UC DG SEC 
exosomes, the amount of immunoglobulin and complement-related proteins were substantially 
elevated higher (Table 4.3), than in the corresponding SEC exosome proteins. The complement 
system is part of the innate immune system and has an array of plasma proteins that when 
activated function to eliminate pathogens through a biological cascade (Sarma and Ward, 2011). 
It assists the antibodies and phagocytic cells to clear microbes and damaged cells, increase 
inflammation and attack the pathogen’s cell membrane. Numerous publications have reported the 
association of complement factors and immunoglobulins with exosomes and EV from blood 
(Radons and Multhoff, 2005, Wei et al., 2016a, Buzás et al., 2018). It has recently been suggested 
that immunoglobulin associated exosomes may be due to a primary secretion of immunoglobulin 
packed within B-cell derived exosomes (Huang et al., 2018). Thus, the elevated presence of 
immune components further indicates the enrichment and purification of exosomes in UC DG 
SEC. 
Alix and flotillin were only present in UC DG SEC exosomes and CD9 LFQ intensity was 3.7-fold 
higher relative to in SEC exosomes (Appendix 6), again indicating the removal of lipoproteins by 
UC DG SEC and the probable enrichment of exosomes. Interestingly, the common exosome 
protein markers TSG101, CD81 and CD63 were absent in the total protein sets even though the 
former two were positively detected by western blotting in our isolates (Figure 2.4 and Figure 4.6). 
This probably reflects the nature of mass spectrometry whereby very low-level proteins may not 
be captured by the detectors. Similarly, Karimi et al. did not detect TSG101, with CD81 identified 
only by the presence of a single peptide and CD63 by two peptides, which does not indicate a 
very confident identification for either protein by mass spectrometry. Molecular and Cellular 
Proteomics guidelines discourages the use of identifying proteins by a single unique peptide 
(Biology, 2019). A peptide-count level assessment of protein quantity is not a suitable quantitative 
measurement as protein-level inferences based on pure peptide counts cannot be made. Proteins 
identified on basis of a single unique peptide are discouraged, but if included, the ability to view 
annotated spectra for these identifications must be made available. It should be noted that 
proteins were only assigned to our data sets using LFQ which is a stringent way of quantifying 
proteins based on peptide-level signals that takes intra-sample peptide variation into account, 
normalises for small technical differences between samples, and its quantitative accuracy is not 
affected by the size of the protein. Our LC-MS/MS analytical approach was more quantitative in 
nature than Karimi et al., as it was based on LFQ analysis rather than peptide counting.  
148 
 
There were several UC DG SEC exosome proteins not previously associated with exosomes that 
were confidently identified in our mass spectrometry dataset. Two of the most prominent were 
platelet factor 4 variant (released from activated platelets and linked to immune and inflammatory 
responses, and leukocyte and neutrophil chemotaxis) and properdin (positive regular of 
complement activation, linked to immune response and neutrophil degranulation). It is noteworthy 
that these are both immune response linked proteins. Interestingly, at the time of drafting this 
manuscript, platelet factor 4 itself was identified as a novel exosome marker for human serum 
exosomes (Nguyen et al., 2019). 
 
Table 4.3: Top ten proteins in UC DG SEC exosomes 
 Protein IDs Proteins LFQ intensity 
1 P68871 Hemoglobin subunit beta 1.99E+11 
2 P01871 Immunoglobulin heavy constant mu 1.50E+11 
3 P69905 Hemoglobin subunit alpha 1.11E+11 
4 P01024 Complement C3 4.79E+10 
5 P01834 Immunoglobulin kappa constant 3.97E+10 
6 P01857 Immunoglobulin heavy constant gamma 1 3.47E+10 
7 P00738 Haptoglobin 2.16E+10 
8 P0CG04 Immunoglobulin lambda-like polypeptide 5 1.86E+10 
9 P04114 ApoB 100 1.80E+10 
10 P01023 Alpha-2-macroglobulin  1.34E+10 
 
Furthermore, as would be predicted of the 10 proteins most reduced in UC DG SEC, relative to 
in SEC, eight were apolipoproteins (Table 4.4). This again indicates effective removal of 
apolipoproteins by density gradient isolation. ApoB100 was reduced by 14-fold and was the 11th 
most reduced proteins in UC DG SEC. However, ELISA indicated, if the assumption is made that 
ApoB100 levels were around 39.1 ng/ml (minimum detection), that at least 156.5-fold reduction 
was achieved. As the ELISA recognises both ApoB100 and ApoB48, this might suggest the 
presence of significant levels of chylomicrons in SEC samples that might have been missed by 
LC-MS/MS which would require the analysis of specific peptides to allow the levels of the two 
variants to be determined. This type of analysis was not possible during this pilot. However, no 
prominent band was observed in SDS-PAGE at ~250 kDa (ApoB48) for SEC but only at ~512 
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kDa which was most likely ApoB100. Most of the apolipoproteins that were reduced or absent 
were components of VLDL and IDL (Table 4.4). ApoE, ApoC-II and ApoD which are associated 
with LDL (according to UniProt) were also reduced in the UC DG SEC sample, highlighting the 
depletion of LDL in the UC DG SEC exosomes. Perhaps a more likely explanation for the 
discrepancy noted for ApoB100 removal between ELISA and mass spectrometry is that the 
intensity of ApoB in the SEC isolate was above the maximum threshold for the detector of the 
mass spectrometer, which is accurate to about 1010, possibly resulting in an underestimation of 
ApoB levels in SEC exosomes by mass spectrometry analysis. Additionally, the ELISA results 
reflect data from two repeats and at present ELISA is considered the more quantitative approach 
(Cross and Hornshaw, 2016). 
 
Table 4.4: Top ten proteins reduced in UC DG SEC exosomes compared to SEC exosomes 
 Protein IDs Proteins Fold reduction 
1 P55056 Apolipoprotein C-IV 46 
2 P02656 Apolipoprotein C-III 39 
3 P02649 Apolipoprotein E 33 
4 P02654 Apolipoprotein C-I 29 
5 O95445 Angiotensinogen 29 
6 P08519 Apolipoprotein(a) 26 
7 P04275 von Willebrand factor 20 
8 P02655 Apolipoprotein C-II 17 
9 P05090 Apolipoprotein D 16 
10 P35542 SAA2-SAA4 readthrough 14 
 
The 2 proteomes were compared to that of Karimi et al. (Figure 4.9). It was decided to exclude all 
proteins from the Karimi et al. data set that were only identified by a single peptide as Molecular 
and Cellular Proteomics guidelines discourages identifying proteins in this manner (Biology, 
2019). About 47% of the proteins identified in UC DG SEC overlapped with those in Karimi et al. 
It is not clear at this stage why the other 53% did not overlap but it probably reflects inherent 
variability in LC-MS/MS (Øverbye et al., 2015, Parker et al., 2015), variability in the serum source 
or differences in the isolation technique (e.g. Sepharose CL-4B vs Sepharose CL-2B). ApoB100 
was present in their database as the protein with the sixth highest number of peptides present. 
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Though their LC-MS/MS analytical approach was less quantitative in nature than ours, this does 
suggest that a density gradient that relies on sedimentation (Karimi et al., 2018) is of the same or 



























Figure 4.9: Venn diagram comparing the proteins in SEC and UC DG SEC exosome fraction 9, and the 





Our UC DG SEC isolates were enriched for exosomal markers, immunoglobulin and complement 
related proteins with a reduction in lipoproteins as assayed by LC-MS/MS. Subsequent to that as 
none of these recent studies investigating the removal of contaminating lipoproteins from 
exosomes have performed functionality tests on the purified exosomes, cellular and in vivo 


























It is particularly challenging to isolate exosomes from biofluids such as plasma or serum due to 
their complex composition. This study provides an isolation method that combines a density 
gradient separation followed by SEC to isolate exosomes from human serum resulting in 
substantial reduction in lipoprotein contamination. Due to the DG SEC method containing a high 
precipitant background, low vesicle concentration and variable NTA data, the exosome 
concentration was increased by first concentrating them from serum using UC followed by a 
density gradient and SEC. This gradient is an advance over other findings as it is a simpler 3-
layer gradient compared to 4 layers (Karimi et al., 2018, Onódi et al., 2018). No ApoB lipoprotein 
was detectable in UC DG SEC exosome fraction using the ELISA, which though more marked 
than that seen with LC-MS/MS, indicates removal of more than 99% of lipoprotein. The mass 
spectrometry data showed a much cleaner preparation with marked reduction in all lipoproteins 
apart from ApoA1 for the UC DG SEC exosomes as compared to SEC exosomes.  Though ApoA1 
was present as determined by LC-MS/MS, western blot showed that after the density gradient, 
SEC successfully removed the vast majority of the HDL from the serum exosomes. This method 
described here possibly delivered better results than previous studies that had more prominent 
traces of HDL in their exosome isolation after using a similar DG SEC purification method of 
plasma exosomes (Karimi et al., 2018). Exosomal markers were increased substantially in the 
UC DG SEC exosomes. Particularly, exosome marker flotillin was detected in the UC DG SEC 
exosomes and not SEC exosomes. Furthermore, several novel proteins were identified as 
exosome components, most particularly platelet factor 4 variant and properdin. Additionally, a 
strong immune component was identified which is in agreement with findings of others (Radons 
and Multhoff, 2005, Wei et al., 2016a, Buzás et al., 2018, Huang et al., 2018). A limitation of the 
present study is the pilot nature of the proteomic study and this must be followed up with an 
analysis with biological repeats. Also though there is a significant reduction in lipoprotein content, 
the proteomic analysis indicates that they are still present. However, it should be noted that it is 
difficult to tell whether those remaining may in part be derived from exosomes (Liang et al., 2013, 
Van Niel et al., 2015, Welton et al., 2016, Andreu et al., 2017). 
As the recent methods investigating the removal of contaminating lipoproteins from exosomes 
have not as yet tested the functionality of the purified exosomes, cellular and in vivo responses 




CHAPTER 5: FUNCTIONAL ANALYSIS OF SERUM 




As discussed in the literature review (Section 1.7.4), there are numerous studies on the function 
of plasma/serum exosomes. Blood-derived exosomes have the regenerative capability to treat 
various ailments e.g. myocardial injury, hindlimb ischemia, dysferlinopathy, hepatic fibrosis, skin 
wounds and allergies; summarised in Table 2.1. The exosome isolation methods employed for 
these in vivo functional studies included UC, ExoQuick precipitation and density gradients or a 
step method using UC combined with a sucrose cushion, density gradient or ultrafiltration 
(Vicencio et al., 2015, Bei et al., 2017, Guo et al., 2017, Hu et al., 2018, Li et al., 2018b). The 
majority of the functional in vivo studies used UC which as discussed previously (Section 1.3.1) 
has significant potential issues, predominantly protein contamination especially when using 
blood-derived sources. SEC seemed to be a promising EV isolation method particularly with the 
minimal protein contamination (Böing et al., 2014) and our serum SEC exosomes were shown to 
have bioactivity increasing fibroblast proliferation and enhancing spheroid sprout numbers in vitro 
(Section 2.2.4); consistent with another study showing that plasma-derived EVs isolated using 
SEC are bioactive as shown by increased migration of HUVECs (Takov et al., 2019). However, 
as discussed in detail in Chapter 3, plasma/serum lipoproteins co-isolate with exosomes using 
various isolation methods including UC, PEG precipitation, density gradient, and SEC (Deregibus 
et al., 2016, Sódar et al., 2016, Grigor’eva et al., 2017, Foers et al., 2018, Karimi et al., 2018, 
Takov et al., 2019). These contaminating lipoproteins may influence or obscure the biological 
function of the exosomes, resulting in incorrect conclusions. We and other researchers (Karimi et 
al., 2018, Onódi et al., 2018) have investigated combining a density gradient with SEC to separate 
lipoproteins from exosomes. This study showed that combining a density gradient separation and 
SEC allows for significant separation of isolation of human serum exosomes from lipoproteins. 
An unsolved question is whether these blood-derived exosomes remain functional after being 
purified from lipoproteins. The biological function of the 2-step purified exosomes was assessed 
in vitro. This analysis was then followed by an in vivo subcutaneous implant study to assess the 
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influence of the SEC and purified UC DG SEC-derived exosomes on macrophage response and 






















5.2 Results and discussion 
5.2.1 In vitro functional analysis of serum exosomes purified by UC DG SEC 
The proliferation and spheroid assays (Section 2.2.4.2 and 2.2.4.3) were utilised to determine 
whether the purified human serum UC DG SEC exosomes retained the regenerative functions 
observed for the SEC purified exosomes (Figure 5.1).  
Human serum UC DG SEC exosomes (30% (v/v)) were incubated with HUVEC spheroids 
embedded in a fibrin hydrogel (3.25 mg/ml) for 48 hours. Phase contrast images of the spheroids 
revealed no difference in sprout activity when treated with UC DG SEC exosomes relative to the 
control (Figure 5.1A). The serum UC DG SEC exosomes had the same HUVEC sprout number 
(12 ±2.4) relative to the PBS control (12 ±1.3) (Figure 5.1B). To assess the effect of human serum 
UC DG SEC exosomes on HdFb proliferation, in an initial study fibroblasts were incubated in 
serum-free media containing 10% UC DG SEC exosomes or 10% PBS for 72 hours. Treatment 
with 10% UC DG SEC-derived exosomes caused a significant increase in cell proliferation 
compared to fibroblasts treated with 10% PBS (p < 0.05) (Figure 5.1C).  
In a follow up study, the effect of human serum SEC exosomes to UC DG SEC exosomes on 
HdFb proliferation was directly compared, fibroblasts were incubated with SEC and UC DG SEC 
isolated exosomes for 72 hours. Treatment with 10% SEC-derived exosomes and 10% UC DG 
SEC-derived exosomes both caused a significant increase in cell proliferation compared to 
fibroblasts treated with 10% PBS (p < 0.05) (Figure 5.1E). The SEC exosomes elicited a greater 
increase (22% relative to control) in cell proliferation than UC DG SEC exosomes (10% relative 
to control) though the increase between these two groups was not significant. When the protein 
concentration of the SEC exosomes was diluted (2.3% SEC exosomes) to the same concentration 
as UC DG SEC exosomes (according to absorbance at 280 nm), there was no increase in cell 
proliferation relative to control. This would still correspond to roughly 25 times as many particles 
(measured by NTA) within the SEC isolate. This is suggestive that the proliferative response is 
mainly due to exosomes. It could also reflect dilution of another stimulatory component within the 
SEC isolate such as the presence of lipoproteins.  Recently SEC-derived plasma EVs were found 
to promote migration of endothelial cells (Takov et al., 2019). However, as the migratory response 
was not proportional to increases in the level of exosome marker CD81, it was suggested that 
other blood components such as lipoproteins may have played a role.  
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The purified UC DG SEC exosomes retained their cell proliferative capabilities. Though the 
stimulatory effect was relatively low (10-17%), it was reproducibly significant across several 
studies. However, the more purified exosomes were unable to initiate spheroid sprouting which 
SEC exosomes were previously shown to do. It was observed that the two isolates had differing 
patterns of the exosome markers CD9 and TSG101 (Figure 5.1D). It is possible this reflects 
isolation of different subsets of exosomes with differing proliferative potential or another 
component in the SEC isolate may have played a role in stimulating sprouting. UC DG SEC 
exosomes were enriched for the 22 kDa form of CD9, whereas the SEC exosomes had increased 
concentration of the 25 kDa form of CD9. After quantifying the 22 kDa and 25 kDa bands, there 
was 3X more CD9 present in the UC DG SEC exosome relative to SEC exosomes. SEC 
exosomes contained 2X more TSG101 compared to UC DG SEC exosomes. It has been shown 
that different EV types (according to size) are enriched in exclusive proteins or different protein 
concentrations (Kowal et al., 2016). The EVs were isolated from dendritic cells using UC and an 
iodixanol gradient. The large EVs (medium >200 nm) were enriched in alpha-actinin-4 (ACTN4), 
mitochondrial inner membrane mitofilin (IMMT), HSP90B1 and major vault protein (MVP). 
Whereas, small EVs (<100 nm) were enriched in TSG101, syntenin-1 (SDCBP), a disintegrin and 
metalloproteinase domain-containing protein 10 (ADAM10) and CD81. Further observations of 
heterogenous exosomes, Bobrie et al. speculated that breast cancer cell-derived exosomes 
enriched in tetraspanins were found in high-density fractions (1.26 and 1.29 g/ml) compared to 
exosomes carrying milk fat globule EGF factor 8 (Mfge8) which were enriched in the low-density 











Figure 5.1: Investigating the functional activity of human serum exosomes isolated using UC DG SEC. (A) 
Sprouting of HUVEC spheroids in fibrin hydrogels. Each fibrin hydrogel (3.25 mg/ml) contained 8-12 spheroids 
consisting of 750 cells each. Fibrin hydrogels were treated with either 30% PBS or 30% serum UC DG SEC-derived 
exosomes in 2% FBS MCDB media. Micrographs taken at 24 and 48 hours. Scale bar = 20 µm; (B) Analysis of sprout 
number (30% PBS and 30% serum UC DG SEC-derived exosomes) after 48 hours. Combination of three independent 
experiments with four technical repeats; (C) In vitro effects of human serum UC DG SEC-derived exosomes on HdFb 
cell proliferation. Human fibroblasts were grown in MCDB media for 72 hours with various treatments shown. 
Proliferation was detected with the XTT assay. Combination of four independent experiments with four technical 
repeats. * p < 0.05 compared to PBS control; (D) Western blot to compare exosomal markers (CD9 and TSG101) in 
the SEC and UC DG SEC fraction 9 (6 μl loaded of isolates with 0.8 and 0.2 A280 absorbance units/ml respectively); 
(E) In vitro effects of human serum UC DG SEC and SEC-derived exosomes on HdFb cell proliferation over 72 hours. 
Proliferation was detected with the XTT assay. For the proliferation assays in (C) and (E), 10% UC DG SEC, 10% SEC 
and 2.3% SEC isolates represent a final A280 of 0.02, 0.08 and 0.02 respectively. Combination of four independent 
experiments with four technical repeats. * p < 0.05 compared to PBS control.  
 
It was thus decided to analyse the influence of ApoB containing lipoproteins on HdFb proliferation 
whereby the fraction 1 from the top of the step density gradient for the DG SEC isolation was 
used as the source (Figure 5.2). The isolate from the density gradient from the DG SEC procedure 
was considered more appropriate as a representation of the lipoproteins in the SEC exosome 
isolate as none were lost during an UC step. Additionally, as the lipoproteins in fraction 1 were 
likely to contain the main contaminants identified in the SEC fraction (VLDL and IDL, section 
3.2.1.2). 
The same concentration of ApoB present in SEC exosome fraction 9 (15 µg/ml) was tested for 
possible contribution to cell proliferation (Figure 5.2). Density gradient fraction 1 contained 596 
µg/ml of ApoB, and was diluted accordingly to 15 µg/ml. For determining potential influence of 
ApoB lipoproteins on HdFb proliferation, HdFb were incubated with serum-free media containing 
1.5 µg ApoB/ml (to mimic the use of 10% (v/v) SEC fraction 9) for 72 hours. Treatment with fraction 
1 of the density gradient had no effect on cell proliferation relative to HdFb treated with no serum. 
This is strongly suggestive that the presence of ApoB lipoproteins in SEC fraction 9 did not 















Figure 5.2: Determining the functional activity of ApoB lipoproteins at the same concentration of ApoB present 
in SEC exosomes. In vitro effects of human serum ApoB lipoproteins diluted to the same ApoB concentration (1.5 
µg/ml) as serum SEC exosomes on HdFb cell proliferation. 72 Hour reading using the XTT assay. Combination of four 
independent experiments with four technical repeats.   
 
No studies have investigated the regenerative capabilities of human serum exosomes purified to 
remove or substantially reduce the lipoprotein content. The human serum UC DG SEC-derived 
exosomes increased HdFb cell proliferation significantly and that an equal concentration of SEC 
exosomes did not influence cell proliferation; supporting the theory that the exosomes contributed 
to HdFb proliferation and not the lipoproteins. However, the UC DG SEC exosomes lost the ability 
to increase HUVEC spheroid sprout number which human serum SEC-derived exosomes had 
that capability (Figure 2.9). A possible cause could be a subpopulation of exosomes was lost 
using the multiple purification method. Interestingly the human serum UC DG SEC-derived 
exosomes were enriched for the 25 kDa CD9 exosome marker, whereas SEC-derived exosomes 
were enriched for TSG101. Thus, certain exosome types were enriched using the different 
purification methods. Another possible reason are the impurities in the SEC-derived exosomes 
caused the HUVEC sprouts, whereas UC DG SEC-derived exosomes are free from impurities. 
Thus, losing that function. There is no current literature to compare these functional studies of 
lipoprotein free purified human serum exosomes to. We then went on to further identify the 
regenerative capabilities of the purified exosomes and perform a subcutaneous implant in rats to 
test for an in vivo angiogenesis response.  
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5.2.2 In vivo functional analysis of serum exosomes purified by UC DG SEC 
As SEC and UC DG SEC exosomes showed functionality in vitro (Section 5.2.1), the immune and 
angiogenic potential of the exosomes were assayed in vivo in a rat subcutaneous model. This 
subcutaneous in vivo model is desirable ethically as it is relatively minimally invasive and a 
number of treatments can be tested simultaneously in one animal. 
In the rat subcutaneous model (described in section 7.15), 10 mg/ml fibrin hydrogels (with or 
without SEC or UC DG SEC exosomes at 72.7% (v/v)) were polymerised within porous 
polyurethane (PU) discs. These highly porous PU discs have been used many times by our group 
for angiogenesis studies as they allow for precise delineation of tissue response and vessel 
ingrowth into the hydrogel polymerised within their pores (Davies et al., 2008, Schmidt et al., 
2009, Bezuidenhout et al., 2010, Davies et al., 2011, Goetsch et al., 2015, van Rensburg et al., 
2017, Chokoza et al., 2019). The rats were killed after 7 days and the discs explanted. 
5.2.2.1 Tissue invasion 
Almost full ingrowth of tissue into the porous space was seen for all groups with occasional small 
patch of undegraded fibrin present in all groups (Figure 5.3). The latter observation indicates that 
carrier hydrogel was present throughout the implant period and based on the results derived from 
the release study for 3 mg/ml fibrin gels (see section 2.2.6), it might be expected that there was 


























Figure 5.3: Tissue ingrowth into subcutaneous implants. Representative micrographs of haematoxylin and eosin 
stained cross-sectional areas of explants. Treatments: (A) Fibrin alone; (B) SEC exosomes or (C) UC DG SEC 
exosomes. Arrowhead indicates pink/purple-stained fibrin hydrogel remnants, and arrows show ingrown tissue with 
nuclei stained dark purple. Asterisks denote polyurethane struts of the porous disks. The bar represents 100 μm (inset 
bar 20 µm). n=6 per group. 
 
5.2.2.2 Inflammatory response ED1 
As a strong immune component was determined for both isolates in the LC-MS/MS analysis, the 
influence of the isolates on the inflammatory response to the implants was analysed for CD68 
content, a pan-marker for macrophages (Holness and Simmons, 1993). A moderate inflammatory 
response can be seen in all explants (Figure 5.4A) as is expected for an implant after 7 days. The 
macrophage response was segmented automatically using the Visiopharm image analysing 
software. There was no difference between the experimental groups and the fibrin control (p > 
0.8) (fibrin alone: 3.3% ±2; SEC exosome: 4.9% ±2.6; UC DG SEC exosome: 4.3% ±2.5) (Figure 
5.4B). Thus, the presence of complement components and IgG contained in or on exosomes did 





Figure 5.4: Macrophage response. (A) Stitched microscopic images of ED1 (CD68) stained fibrin hydrogel discs. 
Treatments (from left): Fibrin alone, SEC exosomes or UC DG SEC exosomes. Nuclei (blue), CD68 (red). Scale bar = 
100 µm; (B) Area of macrophages relative to total area. n=6 per group. 
 
5.2.2.3 Vessel area 
The angiogenic response to the implants was assessed by staining for the mural cell marker 
smooth muscle actin (SMA) (Figure 5.5A). After automatic segmentation, the cross-sections were 
further examined by a blinded observer to remove any signal detection that did not correlate with 
vessels that had a clear vascular morphology and the vessel area as a percentage of total area 
calculated. Image analysis revealed a 21% increase in vessels for SEC isolates relative to fibrin 
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control (p=0.75) and a 60% increase for those containing UC DG SEC exosomes (p=0.07) (Figure 
5.5B). Thus, there is a suggestion of an increased angiogenic response for the highly purified UC 
DG SEC exosome isolate. Studies have shown an angiogenic potential of exosomes (Section 
1.7.4), such as myocardial ischemia patient coronary serum-derived exosomes increased blood 
flow recovery and neovascularisation in a hindlimb model after 21 days more than healthy serum-
derived exosomes (Li et al., 2018b). Human umbilical cord blood plasma-derived exosomes 
increased angiogenesis and re-epithelisation in mouse skin wounds compared to PBS control (Hu 
et al., 2018). Our result is somewhat in line with others; however, the regenerative potential was 
only observed for the more purified exosomes. 
The absence of an in vitro angiogenic response as determined in the spheroid model is in 
contradiction with the finding in vivo and this difference may reflect the complexity of the in vivo 
environment. It would be important to follow up these in vivo experiments with further 
investigations utilising more functionally orientated animal models such as the ischemic hindlimb 
model  (Anitua et al., 2015, Cavallari et al., 2017, Zhang et al., 2018) or a MI model (Khan et al., 
2015, Wang et al., 2018d) to determine whether the UC DG SEC exosome isolates can elicit a 
therapeutic response. Potentially the exosome isolates could be concentrated to achieve a more 
pronounced effect; however, at present most concentrating methods are deficient. With 
centrifugal filters such as Amicon Ultra-2 10k, Amicon Ultra-2 100k, Vivaspin 2 PES 10k, Vivaspin 
2 CTA 10k and Vivaspin 2 Hydrosart 10k having a considerable loss of 80% compared to a 10 





Figure 5.5: Capsule vessel density quantified in fibrin hydrogels mixed with SEC or UC DG SEC exosomes. (A) 
Stitched microscopic images smooth muscle cell actin stained fibrin hydrogel discs. Treatments (from left): Fibrin alone, 
SEC exosomes or UC DG SEC exosomes. Nuclei (blue), smooth muscle cells (red). Scale bar = 100 µm; (B) Area of 









5.3 Summary  
The purified UC DG SEC exosomes retained an ability to stimulate fibroblast proliferation; 
however, their enhancement of HUVEC spheroid sprout formation as observed for SEC isolates 
was not seen with the more purified exosomes. This indicated a possible loss of an exosome 
population or that another factor present in the less purified exosome preparation contributed to 
the regeneration. A low-density fraction of ApoB containing lipoproteins from the density gradient 
did not influence fibroblast proliferation suggesting that if it was a component in the SEC isolate 
responsible for sprout formation, it was not the lipoproteins. There was also an indication of pro-
angiogenic potential for the UC DG SEC isolates in the rat subcutaneous assay. This is the first 
time functionality has been tested for highly purified serum exosomes isolated using a combined 
density gradient and SEC approach.   
Strict EV isolation methods should be emphasised in order to standardise exosome research, 
particularly to avoid or substantially reduce confounding effects derived from non-exosome 
related particles. These results further the knowledge for serum exosome isolation methods and 
supports the suggested combined use of density gradient and SEC to isolate pure exosomes 
(Simonsen, 2017). The regenerative aspect seen by the SEC and purified UC DG SEC exosomes 
is relatively small but is reproducible and thus the findings above do to an extent support those of 
other researchers who have identified regenerative potential for blood-derived exosomes.  
Based on these findings here, it seems unlikely that there is a potent regenerative capacity being 
transported in the blood within or on exosomes but perhaps more likely indicates gentle capacity 
for repairing minor injuries/damage. The UC DG SEC method is time consuming and requires a 
relatively large quantity of starting material to isolate a workable amount. A clear limitation in the 
above studies is that increased dosages of exosomes were not assessed. Such an approach 
would possibly allow for a more definitive understanding of their regenerative potential to emerge. 
This type of undertaking is still a significant challenge in this field. Others who have scaled up the 
amount of serum processed have found minimal improvement in yield (Karimi et al., 2018, Onódi 







CHAPTER 6: CONCLUSION 
 
 
6.1 Main conclusions 
A range of in vivo studies have indicated the presence of regenerative elements in blood (Villeda 
et al., 2014, Wyss-Coray, 2016, Sun et al., 2019). This is appealing for regenerative medicine 
approaches as blood is easier to obtain and process than culturing cells and allowing the blood 
to clot activates the platelets which release a additional pool of proteins, growth factors, cytokines 
and exosomes (Anitua et al., 2015). Recently, a number of investigators have found that 
exosomes isolated from blood (plasma or serum) to have regenerative properties in myocardial 
injuries (Liu et al., 2015, Vicencio et al., 2015), hindlimb ischemia (Cavallari et al., 2017, Li et al., 
2018b), dysferlinopathy (Dong et al., 2018), hepatic fibrosis (Chen et al., 2018b) and wound 
healing (Nakamura et al., 2016).  
A potential concern related to the above and other similar studies was that UC was used almost 
exclusively to purify the exosomes. UC has been shown to co-isolate quite high levels of 
contaminating proteins (Baranyai et al., 2015) which we also found to be the case. It has been 
proposed that SEC is a more optimal isolation method to isolate exosomes from human serum 
(Böing et al., 2014, Baranyai et al., 2015). SEC here was found to isolate a protein poor fraction 
containing vesicles (30-100 nm detected by TEM) from human serum that was positive for the 
exosomal markers CD9, CD81 and TSG101. It should be noted that CD9 appeared to be a more 
precise marker for exosomes than TSG101. 
The serum SEC-derived fraction containing exosomes was shown to cause uptake into HT1080 
cells of 3 fluorescent dyes that label membrane, RNA and exosome proteins (BODIPY TR 
Ceramide, SYTO RNASelect and ExoGlow respectively). Importantly the fraction significantly 
increased both the proliferation of HdFb and promoted a significant increase in sprout number in 
HUVEC spheroids embedded in a fibrin hydrogel. It must be emphasised that these biological 
effects were obtained with an isolate that contained at least 400 times less protein than the starting 
serum. There are presently limited studies that have investigated the biological activity of SEC 
isolated exosomes. Indeed to our knowledge only one study has done so, showing that plasma 
EVs isolated using SEC promote migration of endothelial cells (Takov et al., 2019). 
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The stability of the SEC-derived exosomes stored at 37°C for 3 weeks was then determined. They 
retained their morphology and ability to enter cells and increase cell proliferation of HdFb. Though 
this was the most extended period assessed and the only to assess cell proliferation, other studies 
have seen morphological stability such as  storing urine for 24 hours at 37°C does not affect 
exosome size (Lv et al., 2013). Another study spiked 1 ml plasma with 35 µg of LIM 1863 
exosomes -20°C for 30 days and the exosomes still entered LIM 1215 colorectal cancer cells 
revealing functionality (Kalra et al., 2013).  
It must be considered likely that exosomes as a therapeutic will benefit from a controlled and 
localised delivery. Recently sustained delivery of exosomes from hydrogels have been 
investigated for therapeutic purposes in wound healing (Tao et al., 2017c), MI (Chen et al., 
2018a), hindlimb ischemia (Zhang et al., 2018) and enzyme prodrug therapy (Fuhrmann et al., 
2018). A fibrin hydrogel which is created naturally when blood clots and is FDA approved has not 
been previously considered for this purpose. The particles from the SEC exosome containing 
fraction were well distributed within the fibrin hydrogel and found to be released over 96 hours 
from a 3 mg/ml fibrin hydrogel. A novel transwell experiment was developed in which HT1080 
cells invaded a 3 or 10 mg/ml fibrin hydrogel and engulfed fluorescently labelled vesicles 
embedded within the hydrogel. This uptake still occurred when the transwell with the 10 mg/ml 
fibrin hydrogel containing the SEC exosomes were stored for 7 days in an excess volume of 20% 
FBS MCDB media, again indicating stability and the potential for sustained release.  
The field of exosomal research is a rapidly changing one due in part to its relevant novelty and 
the difficulties associated with working with particles in the nanometer range. It became apparent 
during these investigations that there was substantial lipoprotein contamination of isolated 
exosomes from blood in particular (Sódar et al., 2016, Takov et al., 2019). We also found that the 
SEC-derived exosomes contained 15 µg/ml ApoB lipoproteins. We also directly showed for the 
first time that these lipoproteins were primarily VLDL and IDL. The canonical ApoB lipoprotein 
LDL was shown to be able to transfer BODIPY TR Ceramide, SYTO RNASelect and ExoGlow 
into HT1080 cells. It is to our knowledge the first time that it has been shown for the latter two 
dyes that lipoproteins can interfere with exosomal uptake studies. Thus, it was important to 
develop an isolation method that removed lipoproteins as simply as possible, prior to re-evaluating 
their regenerative potential. The approach taken here was to utilise a density gradient that 
exploited the density differences between the ApoB containing lipoproteins and the exosomes 
followed by SEC to remove remaining LDL and HDL. It was found to be optimal for yield to 
concentrate exosomes from serum by UC prior to density gradient and SEC rather than after 
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density gradient and before SEC. The UC DG SEC isolates were found to more closely resemble 
the expected exosome shape with TEM and to contain non-detectable levels of ApoB as 
determined by a sandwich ELISA. NTA determined that there were 100 times lower number of 
particles in UC DG SEC isolates relative to SEC. This highlights the potential of lipoproteins to 
interfere with exosomal studies. Proteomic analysis with LC-MS/MS found a pronounced 
reduction of all lipoproteins (apart from ApoA1, a marker for HDL) in UC DG SEC relative to SEC 
and an increase in proteins identified from 135 in the SEC exosomes to 224 with a pronounced 
increase in exosomal proteins. We identified several novel exosomal proteins and saw a 
significant association with immune function for the isolates as determined by FunRich. 
We assessed these highly purified exosomes for functionality. They still elicited a significant 
increase in HdFb proliferation but did not encourage sprout formation from HUVEC spheroids 
embedded in fibrin. This latter difference from SEC isolated exosomes could be explained by the 
detection of enriched CD9 in the UC DG SEC-derived exosomes compared to the enrichment of 
TSG101 in SEC-derived exosomes suggestive of different exosome populations. The proliferative 
effects seen for both isolates could not be seen with lipoproteins purified away from exosomes 
suggestive that they are not involved in this function.  An in vivo subcutaneous analysis showed 
that even though there was a strong immune component in both exosome isolates, this did not 
influence the macrophage component of the inflammatory response. There was an indication of 
a stimulation of neovascularisation for the UC DG SEC exosomes.  
Though we are to our knowledge the first to investigate the function of exosomes isolated in this 
multi-step manner, others have also recently shown a DG SEC approach to effectively remove 
lipoproteins (Karimi et al., 2018, Onódi et al., 2018). Our density gradient was technically simpler 
and relied on flotation to remove lipoproteins to remove lipoproteins rather than sedimentation. 
We also used Sepharose CL-4B which has been shown to be superior to Sepharose CL-2B for 
exosome purification. The one study that also carried out a proteomic analysis (Karimi et al., 2018) 
showed a reasonable correlation with our data set with approximately 50% of our proteins 
identified being the same. 
Limitations of our study that we have mentioned above include the lack of a dosage study. This 
would help clarify the above but significant concentration of exosomes is a challenge. The 
subcutaneous angiogenesis model does not convey any information on functionality of the vessel 
bed generated and an ischemic hind limb or MI model should be investigated to reveal the true 
regenerative potential of these highly purified serum exosomes. The proteomic analysis of the 
exosomes needs to be replicated with a study that includes biological repeats and the potential 
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involvement of different exosome populations in the different spheroid outcomes needs to be 
further explored. 
 
6.2 Overall conclusion 
The protein poor serum SEC-derived exosomes co-isolated with ApoB lipoproteins; however, this 
fraction caused HdFb proliferation and increased sprout number in HUVEC spheroids. By 
purifying serum exosomes without significant lipoproteins using a novel and simple UC DG SEC 
method, the exosomes were shown to be bioactive causing HdFb proliferation and potentially 






















CHAPTER 7: MATERIALS AND METHODS 
 
 
7.1 Exosome isolation from human serum 
Two units of ± 250 ml of human serum (AB blood group) were obtained from Western Province 
Blood Transfusion Service (WPBTS). Serum was prepared by WPBTS in the following manner. 
The blood was collected and allowed to clot overnight at 4°C. The following morning the blood 
was centrifuged at 4000 rpm for 12 minutes at 4°C. A manual plasma extractor separated the 
serum. Both serum units were combined, aliquoted and stored at -80°C. Exosome isolations using 
SEC, DG SEC or UC DG SEC were performed on three batches of pooled human sera. 
To obtain fresh fasted serum, peripheral blood was collected from healthy donors (30 and 52 
years old, no chronic medications) after overnight-fasting. The blood (50 ml) was collected into 
falcon tubes and allowed to clot for 30 minutes at RT. Serum was isolated by centrifugation at 
2500 g for 10 minutes at RT. The supernatant was carefully removed avoiding disruption of the 
pelleted blood cells.  
7.1.1 Ultracentrifugation 
Isolation of exosomes by UC was performed as described previously (Eitan et al., 2015) with 
minor modifications.  
Human serum was thawed at RT in the hood. Human serum (6.5 ml) was diluted with 0.2 µm 
filtered sterile PBS (NaCl [137 mM], KCl [2.7 mM], KH2PO4 [1.4 mM], Na2HPO4.12H2O [8 mM], 
pH 7.4 (19.5 ml)) and centrifuged at 2000 g for 10 minutes, 4°C. The supernatant was transferred 
to Beckman UC tubes and centrifuged at 10 000 g for 40 minutes, 4°C (SW 60 Ti Rotor). The 
resulting supernatant was transferred to a new Beckman UC tube (6 x 3.6 ml) and centrifuged at 
120 000 g (34 000 rpm) for 2 hours. Each pellet in the UC tube was resuspended in 250 µl sterile 
filtered PBS. The resuspended pellets were pooled together, aliquoted into 50 µl and stored at     
-80°C. 
7.1.2 ExoQuick-TC 
ExoQuick-TCTM was used to isolate the exosomes from human serum. ExoQuick-TC precipitation 
was performed according to the manufacturer’s instructions. Human serum was centrifuged at 
171 
 
3000 g for 15 minutes, thereafter 500 µl human pooled serum was mixed with 120 µl ExoQuick-
TC and incubated for 30 minutes at 4°C. The exosomes were precipitated by centrifuging the 
sample at 1500 g for 30 minutes, supernatant aspirated followed by a further 5 minutes at 1500 
g. The pellet was resuspended in 200 µl PBS. 
7.1.3 Size exclusion chromatography 
SEC was used to isolate exosomes from human serum. Sepharose CL-4B (10 ml bed volume, 
12.7 cm bed volume height and 1 cm column width) was washed with PBS (pH 7.4, 0.22 µm 
filtered) and the solution was settled for about 30 minutes. The column was washed with 3 column 
volumes of PBS (10 ml).  
Serum was thawed and centrifuged at 6000 g for 10 mins to remove cellular debris and 
chylomicrons. A yellow and blue tip were used to carefully remove the top layer of chylomicrons, 
after which the serum was collected from below the top layer of serum. Human serum (1 ml) was 
loaded on the column, followed by elution with PBS under gravity with maximally a 5 cm head (pH 
7.4, 0.22 µm filtered). Fresh fasted serum was also tested. The eluate was collected in 26 
sequential fractions of 0.5 ml. For each fraction, A280 was read using a NanoDrop microvolume 
spectrophotometer (protein concentration further determined using the Bradford assay in some 
instances). The fraction with the maximum A280 in the first eluted peak was aliquoted (50 µl) and 
stored at -80°C for subsequent studies.  
The SEC column was washed with PBS until A280 ~ 0 and subsequently washed and stored with 
0.02% sodium azide at 4°C. When required the Sepharose was cleaned and stripped with 2 
column volumes of 0.5 N NaCl in 0.1 N NaOH and washed with 5 column volumes of PBS. 
7.1.4 ExoQuick-TC followed by size exclusion chromatography 
ExoQuick-TC was used to isolate the exosomes from human serum. ExoQuick-TC precipitation 
was performed according to the manufacturer’s instructions. Human serum was centrifuged at 
3000 g for 15 minutes, thereafter 500 µl human pooled serum was mixed with 120 µl ExoQuick-
TC and incubated for 30 minutes at 4°C. The exosomes were precipitated by centrifuging the 
sample twice at 1500 g for 30 minutes and 5 minutes. The pellet was resuspended in 500 µl PBS. 
The resuspended exosome pellet was loaded on the size exclusion column and the protocol was 




7.2 Protein concentration 
The Bradford assay can detect 0.1-1.4 mg/ml of BSA on a linear scale. A standard curve using 
the Bradford protein assay kit is shown in Figure 7.1. Briefly, 5 µl of sample was added to 95 µl 
PBS. Bradford reagent (900 µl) was mixed with the sample and incubated for 5 minutes before 
reading absorbance at 595 nm. 
 
 
Figure 7.1: Standard curve for the Bradford assay. Bovine serum albumin standards ranging from 0.05 to 0.3 µg/µl 
were added to the Bradford dye and the resulting absorbance values measured at 595 nm after incubation at RT for 5 
min. The equation of the trendline is given by y = 2.5009x with a correlation coefficient of 0.9932. n=4 (technical 
repeats). 
 
7.3 Gel electrophoresis and western blot analysis 
Samples were lysed with 3X reducing sample buffer (62.5 mM Tris-HCl, pH 6.8, 4% SDS, 10% 
Glycerol, 0.03% Bromophenol Blue and 5% β-mercaptoethanol) and boiled for 5 minutes at 95°C. 
Equal volumes or concentration of proteins from samples were loaded and resolved by 12% 
FastCast SDS-PAGE or 4-15% gradient gel. Gels were stained with 1% Coomassie Brilliant Blue 
R-250 Dye (1 g of dye dissolved in 100 ml dH2O and stirred for 1 hour at RT and subsequently 
filtered through Whatman No.1 filter paper) to visualise the proteins.  
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Western blot analysis of the samples were carried out as described previously (Towbin et al., 
1979) with modifications. Exosome samples were approximately 5X concentrated using Amicon 
ultra 0.5 ml 100 kDa centrifugal filters. A Hela cell lysate control was always used to demonstrate 
that the western blot was working (data not shown). Samples were lysed with 3X reducing sample 
buffer (62.5 mM Tris-HCl, pH 6.8, 4% SDS, 10% Glycerol, 0.03% Bromophenol Blue and 5% β-
mercaptoethanol) and boiled for 5 minutes at 95°C. The proteins were resolved by 12% FastCast 
SDS-PAGE and transferred over 45 minutes using a Trans-Blot® SD Semi-Dry Transfer Cell at 
10 V onto a nitrocellulose sheet. 
The transfers were blocked for 1 hour at RT with 5% (w/v) fat free milk powder in tris buffered 
saline-tween (TBS-T: 20 mM Tris, 200 mM NaCl, pH 7.4, 0.05% Tween-20). The nitrocellulose 
membrane was incubated with primary antibody diluted in TBS-T overnight at 4°C. Blot was 
washed with TBS-T (5 x 8 minutes), followed by incubation with secondary horseradish 
peroxidase (HRP) conjugated antibody (1 hour, shaking, RT) and washed again with TBS-T (5 x 
8 minutes). Protein bands were detected using WesternBright ECL HRP substrate. The following 
antibody dilutions were used: 1:1000 rabbit anti-human TSG101, 1:500 rabbit anti-human CD9, 
1:1000 rabbit anti-human TAPA1 (CD81), 1:20 000 rabbit anti-human ApoA1 and 1:10 000 goat 
anti-rabbit HRP.  
 
7.4 Transmission electron microscopy 
Briefly, 200 mesh carbon coated copper TEM grids were glow discharged and placed on 15 µl 
droplets of sample and incubated for 10 minutes or 3 µl of sample was directly applied to the grid. 
Distilled water was used to rinse the grids which were then carefully dabbed on Whatman paper. 
The grids were incubated on uranyl acetate (2%) to stain the sample. Grids were viewed using a 
Tecnai G2 TEM. Size analysis of the particles were calculated using ImageJ (1.46r, Wayne 
Rasband, National Institutes of Health, USA). The number of vesicles counted for size analysis 
across five TEM grids for the various methods were as follows: SEC fraction 8 (n=399), SEC 
fraction 9 (n=442), SEC fraction 10 (n=396), SEC exosome 37°C (n=314), SEC exosome -80°C 
(n=300), LDL (n=92), DG SEC fraction 9 (n=12, sample required 5X dilution) and UC DG SEC 




7.5 Cell culture conditions 
The cells used for in vitro experiments were HUVECs, isolated from waste tissue after obstetric 
procedures and were cultured up to passage 5. HdFbs and fibrosarcoma cell line HT1080 cells 
were obtained from laboratory stocks. All cell culturing was performed under sterile conditions 
with the laminar flow hood sterilised by use of UV light exposure for 15 minutes and 70% ethanol. 
All other items used were sterilised with 70% ethanol. Cells cultured in a humidified incubator at 
37°C with 5% CO2. 
Endothelial culture media consisted of MCDB-131, 1.18 g/L NaHCO3, 2 mM L-Glutamine, 1 µg/ml 
Hydrocortisone, 10 ng/ml EGF and 5 ng/ml bFGF. HT1080 and HdFb culture media consisted of 
MCDB-131 and 1.18 g/L NaHCO3. Both culture media contained 1% penicillin/streptomycin and 
10% FBS.  
7.5.1 HUVEC isolation 
Ethical approval was attained from the University of Cape Town (Cape Town, South Africa) 
Human Ethics Committee, in accordance with the Declaration of Helsinki (HREC REF: 407/2017). 
The isolation protocol was adapted from (Baudin et al., 2007). Briefly, umbilical cords were 
collected in Medium 199 (M199) containing 0.2% gentamicin. The umbilical vein was cannulated 
and the cannula was secured with a suture. The vein was rinsed with a solution of M199 
containing 0.2% heparin and 1% gentamicin. The cord was clamped and distended with a solution 
of M199 containing 0.07% collagenase. The cord was placed in sterile PBS at 37°C and 
maintained at 37°C for 12 minutes in the incubator. The vein was rinsed with the stop solution 
(M199 with 20% FBS) into a sterile 50 ml centrifuge tube. The tube was centrifuged (244 g, 5 
minutes), supernatant removed, and the cell pellet was resuspended in enriched culture medium 
and plated into collagen-coated wells. After 24 hours in the incubator at 37°C with 5% CO2, the 
cells were rinsed with PBS to remove debris and fresh HUVEC growth medium added. Anti-CD31 
flow cytometry confirmed the cells as endothelial cells (Figure A7, Appendix 7).  
7.5.2 Fibroblast isolation 
HdFbs were isolated by explant culture release. The isolation protocols have been described in 
depth (Takashima, 1998). Briefly, 3 mm skin biopsies were cultured in a minimal amount of 10% 
FBS MCDB media until a considerable number of fibroblasts had migrated out of the biopsy. A 
swirling growth pattern was used to identity the fibroblasts.  
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7.5.3 Cell passaging 
Once cells were about 70-90% confluent they were passaged. The flasks were washed 2X with 
PBS: 2.5 ml for a 25 cm2 (T25) flask or 5 ml for a 75 cm2 (T75) flask. Followed by the addition of 
0.25% trypsin-EDTA (volumes as above) for roughly 2-3 minutes in the 37°C, 5% CO2 incubator. 
Once the cells had detached, the trypsin was inactivated with an equal volume of 20% FBS MCDB 
media. The entire solution was pipetted into a 50 ml tube and centrifuged at 400 g for 5 minutes 
(HUVEC) or 1500 rpm for 3 minutes (HT1080 or HdFb). The cell pellet was resuspended into the 
required growth medium.  
The cells were counted using a haemocytometer. In brief, 20 µl of the cell suspension was mixed 
with 20 µl of Trypan Blue (0.4% (m/v)). The haemocytometer grid and coverslip were cleaned with 
70% ethanol prior to adding 10 µl of the cell suspension under the coverslip. The four corners of 
the grids were counted, averaged and the number of cells/ml was determined using the following 
equation: 
Average number of cells counted x 2 x 10 000 = Number of cells per milliliter 
The number of cells required for a particular experiment were then seeded. The remainder of the 
cell suspension was either divided into a new flask with fresh media or frozen as described below. 
7.5.4 Thawing of cells 
Cells were removed from the liquid nitrogen tank and thawed in a 37°C water bath. The contents 
were added to a T25 or T75 flask containing 5 ml or 10 ml 20% FBS media respectively. The flask 
was placed inside the incubator and after 24 hours to media was changed to 10% media. 
7.5.5 Freezing of cells 
Stocks of HT1080, HdFbs and HUVECs were cryopreserved. Cells were counted and frozen with 
roughly 500 000 cells per 600 µl in a 1.5 ml or 2.0 ml cryovial. The cells were diluted with an equal 
volume of 15% DMSO, to give a final concentration of 7.5% DMSO. Cells were frozen overnight 
in a polystyrene rack at -65°C and transferred to liquid nitrogen for long term storage. As 
endothelial cells are sensitive, they were frozen overnight in a Mr. Frosty cell freezing container, 
which was filled with isopropyl alcohol at RT before being transferred to the -65°C freezer.  
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7.5.6 Proliferation assay 
Cell proliferation was assessed with the XTT cell viability kit according to the manufacturer’s 
protocol. Briefly, 100 µl HdFb cell suspension (passage 4-11) were seeded into 96-well plates at 
5000 cells/well. After 12 hours the HdFbs were treated with SEC exosomes (10% (v/v) or 2.3% 
(v/v)), UC DG SEC exosomes (10% (v/v)), UC exosomes (3.33% (v/v)), ApoB lipoproteins (1.5 
ApoB µg/ml (determined by ELISA see section 7.11)), human serum (5% (v/v)) and PBS (10% 
(v/v)). After 72 hours the media was removed, each well was washed twice with 100 µl MCDB or 
DMEM media. 100 µl of media was added to each well and 4 wells as background control. After 
2 hour incubation with XTT the absorbance was measured at 450 nm, with background correction 
at 570 nm, using iMark microplate reader. Experiment was independently repeated 4 times and 
each treatment was carried out with 4 technical repeats. 
7.5.7 Uptake of human serum-derived exosomes 
Human serum-derived exosomes were fluorescently labelled with either SYTO™ RNASelect™ 
for RNA staining or BODIPY™ TR Ceramide for membrane staining. One µl of the dye stock 
solution (1 mM) was mixed with 100 µl exosome sample or 100 µl PBS (control) and incubated at 
37°C for 20 minutes in the dark. The excess unincorporated dye from the labelled exosomes were 
removed using exosome spin columns (MW 3000) according to the manufacturer’s protocol.  
Human serum SEC-derived exosomes were also labelled with ExoGlow™-protein label. Ten µl of 
the dye stock solution (10X) was mixed with 100 µl exosome sample or 100 µl PBS (control) and 
incubated at 37°C for 10 minutes in the dark. ExoQuick-TC (20 µl) was used to stop the reaction 
at 4°C for 30 minutes. Sample was centrifuged for 3 minutes at 14 000 rpm to pellet the labelled 
exosomes and resuspended in 100 µl PBS. 
A dosage study was performed where cells were treated with 6.25%, 12.5% or 25% (v/v) of SEC-
derived exosomes. The stability of exosomes was tested with SEC exosomes stored at -80°C, 
SEC exosomes stored at 37°C for 3 weeks with gentle agitation (50 rpm), UC exosomes stored 
at -80°C or UC exosomes stored at 37°C for 3 weeks with gentle agitation. Other samples tested 
for uptake included LDL (see section 7.7). 
CultureWell 16 chambered cover glasses were used for uptake studies. The cover glass was 
coated with collagen solution from bovine skin (100 µg/ml) diluted in PBS for 2 hours at 37°C. The 
cover glass was seeded with 15 000 HT1080 cells/well and left overnight. The following morning 
the labelled exosomes or LDL (12.5% (v/v)) were incubated with the cells for 3 hours at 37°C. 
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After incubation, the cells were washed with PBS and fixed with 10% formalin for 20 minutes at 
RT. The cells were washed with PBS (3 x 5 minutes) and permeabilised with 0.1% Triton-X 100 
in PBS for 3 minutes. Samples were washed with PBS (2 x 5 minutes) and the cytoskeleton was 
stained with either Alexa Fluor® 594 Phalloidin stain (1:10 000), ActinRed™ ReadyProbes® 
Reagent (1 drop per 5 ml PBS which was subsequently diluted 100X) or Alexa Fluor® 488 
Phalloidin stain (1:750). Chambered wells were mounted using fluoroshield with DAPI. Cellular 
uptake was analysed under the fluorescent microscope (Nikon Eclipse 90i DS-Ri1). 
7.5.8 Generation of endothelial cell spheroids 
HUVEC spheroids were generated as described previously (Korff and Augustin, 1998). In brief, 
750 HUVECs (P2-P5) in 150 µl 20% methylcellulose culture media were seeded in non-tissue 
cultured treated, round bottom 96-well plates. After 24 hours the suspended cells formed a single 
spheroid in each well.  
7.5.8.1 Siliconising 24-well plates 
The 24-well plates were siliconised using Sigmacote® to allow the hydrogels to form droplets for 
use in the spheroid assay. Briefly, Sigmacote® was added to cover each well and left for 30 
seconds before being removed and allowed to dry overnight in the laminar flow hood. The wells 
were rinsed 2X with sterile Nanopure water and allowed to dry. The plates were then sterilised 
using ethylene oxide. 
7.5.8.2 Methylcellulose preparation 
For preparation of methylcellulose stock solution, 3.6 g methyl cellulose was autoclaved in a 500 
ml Schott bottle with a clean magnetic stirrer bar. The autoclaved methylcellulose was dissolved 
and mixed on a stirrer for 20 minutes with preheated (60°C) culture medium (150 ml) at RT. 
Further 150 ml culture medium (RT) was added and mixed on a stirrer overnight at 4°C. The 
methylcellulose solution was aliquoted and centrifuged at 5000 g for 2 hours at RT and at 3500 g 
for 40 mins at RT. The cleared supernatant was collected and used for spheroids.   
7.5.8.3 Spheroid assay 
Roughly 3-6 HUVEC spheroids were embedded into each fibrin hydrogel. The fibrin hydrogels 
consisted of human fibrinogen (3.25 mg/ml), aprotinin (100 µg/ml) and thrombin (0.625 u/ml). The 
spheroids, fibrinogen and aprotinin were pipetted into a 48-well Sigmacote treated plate (20 µl 
containing 3-6 spheroids each). Sigmacote treatment (Section 7.5.8.1) through increasing 
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hydrophobicity caused the fibrin hydrogel to bead resulting in greater depth within the droplet. 
Thereafter 20 µl thrombin working solution was added to the spheroid fibrinogen mix. The gels 
were polymerised at 37°C for 30 minutes. The culture media (150 µl 2% FBS MCDB media) 
containing either PBS or treatment was pipetted on top of each gel. The gels were incubated in a 
humidified incubator at 37°C with 5% CO2. Spheroids were imaged at 24 and 48 hours (X10 
objective) with a Nikon Light microscope (Nikon Eclipse Ti-S). Sprout number was assessed with 
ImageJ 1.46r and 8-12 spheroids per treatment group were analysed. Briefly, a straight line was 
used to measure all individual sprouts. After all the spheroids’ sprouts per treatment were 
measured, the average sprout number was calculated. Spheroids that were in proximity, touching 
or near the side of the hydrogel were excluded. Experiment was independently repeated 3 times. 
 
7.6 Exosomes in a fibrin hydrogel 
SEC-derived exosomes labelled with BODIPY TR Ceramide (Section 7.5.7) (13.5 µl) were 
entrapped within a fibrin hydrogel (3 mg/ml), 45 µl gel crosslinked with thrombin (Section 
2.2.6.1.1). The distribution of the exosomes was visualised using a confocal microscope (ZEISS 
LSM510). 
7.6.1 Cumulative release of exosomes from a fibrin hydrogel 
A dilution curve was obtained for BODIPY TR Ceramide labelled SEC exosomes (Section 
2.2.6.1.2). Exosomes (from the same batch as those entrapped in fibrin) were labelled with 
BODIPY TR Ceramide (Section 7.5.7). The exosomes were serially diluted to prepare dilutions of 
1:5, 1:25, 1:50, 1:125 in a final volume of 100 µl. The dilutions were stored in a white plate for 24 
hours at 37°C and subsequently the fluorometer signal of the dilutions were read using a 
Fluorescent spectrophotometer (excitation 594 nm and emission 617 nm). They were stored in a 
white plate for 24 hours at 37°C as the fluorometer signal was found to increase over the 24 hours 
prior to stabilising (Figure A3, Appendix 3). Four technical repeats.  
To obtain a cumulative exosome release curve 63.6% BODIPY TR Ceramide labelled exosomes 
were entrapped in a 50 µl 3 mg/ml fibrin hydrogel and incubated with 100 µl of PBS at 37°C with 
gentle shaking (50 rpm). After 24 hours PBS was removed and stored in a white plate for 24 hours 
at 37°C and subsequently the fluorometer signal was read. A baseline fluorometer signal was 
accounted for by collecting supernatant from a fibrin hydrogel with no exosomes. Supernatant 
was replaced with PBS every 24 hours over 96 hours. Four technical repeats were performed.  
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7.6.2 Transwell experiment: Cellular uptake of exosomes embedded in a fibrin 
hydrogel 
63.6% of SYTO RNASelect labelled SEC exosomes in a 50 µl 3 mg/ml fibrin hydrogel were gelled 
inside the 8 µm pore upper inserts of a 6.5 mm transwell insert for 30 minutes at 37°C followed 
by the seeding of 20 000 HT1080 cells in 100 µl (resuspended in serum-free media) on top of the 
fibrin hydrogel. The inserts were placed inside 24-well plates containing 600 µl MCDB media (10% 
FBS, 2% penicillin/streptomycin, 10 ng/ml bFGF) to promote migration of cells through the 
hydrogel to the bottom of the transwell insert. After 5.5 or 24 hours, the transwells were processed 
for fluorescent imaging. The inserts were washed with PBS and fixed with 10% formalin for 20 
minutes at RT. Cells that remained on the top surface and the fibrin hydrogel inside the insert 
were removed with cotton swabs. The insert was washed with PBS (3 x 5 minutes) and 
permeabilised with 0.1% Triton-X 100 in PBS for 3 minutes. They were then washed with PBS (2 
x 5 minutes) and the cytoskeleton of the cells were stained with ActinRed™ ReadyProbes® 
Reagent (1 drop per 5 ml PBS which was subsequently diluted 100X) for 20 minutes at RT and 
washed with PBS (2 x 5 minutes). The transwell inserts were cut out with a fine scalpel and 
mounted on a glass slide using fluoroshield with DAPI. Fluorescent micrographs were captured. 
Three independent experiments with two technical repeats.  
To assay the biostability of the exosomes in the fibrin hydrogel, 63.6% (v/v) of SYTO RNASelect 
labelled exosomes in a 50 µl 3 mg/ml fibrin hydrogel were incubated for 1, 3 or 7 days in 20% 
FBS MCDB media and a 10 mg/ml fibrin hydrogel containing SEC exosomes were incubated for 
7 days in 20% FBS MCDB media. Followed by the seeding of 20 000 HT1080 cells (resuspended 
in 100 µl serum-free media) on top of the fibrin hydrogel, they were processed as described 
directly above. Two technical repeats.  
7.6.3 Controls to ensure the transwell experiment was not an artefact of released 
fluorescent dye 
SYTO RNASelect labelled SEC-derived exosomes (80 µl) in MCDB media (560 µl) (12.5% 
exosomes (v/v)) were sonicated (Virsonic 100 probe) with six cycles of 25 Hz at 25 second 
intervals on ice.  
After sonication of the SEC-derived exosomes they were visualised by TEM (Section 7.4) to 
determine extent of disruption. The uptake of sonicated exosomes was then assayed as 
described in section 7.5.7. 
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7.6.4 Physical properties of exosomes embedded in a fibrin hydrogel 
SEC exosomes (31.8 µl) were entrapped within a 50 µl fibrin hydrogel (10 mg/ml). The hydrogel 
was digested with 100 µl proteinase K (500 µg/ml) for 90 minutes at 37°C and overnight at 4°C. 
Proteinase K was added to exosomes not entrapped in a hydrogel to test if the enzyme had an 
adverse effect on the exosomes. Fibrin hydrogel without exosomes was also digested to visualise 
the background of digested hydrogel. Fibrin gel (10 mg/ml) containing SEC exosomes incubated 
for 1 day at 37°C prior to being digested with proteinase K were also examined. After the digestion 
of the fibrin hydrogel, the morphology of the exosomes was visualised on a TEM.  
 
7.7 LDL 
LDL were supplied by Dr Dee Blackhurst from the Division of Chemical Pathology, University of 
Cape Town. In brief, the LDL from human plasma were isolated by KBr gradient (0.5 g/ml) 
centrifuged at 100 000 g for 17 hours, after which the LDL was removed and dialysed to remove 
the KBr. TEM was used to visualise the structure LDL stored at 4°C. TEM protocol described in 
section 7.4. The LDL 12.5% (v/v) were tested for uptake into HT1080 cells using the fluorescent 
dyes (SYTO RNASelect, BODIPY TR Ceramide and ExoGlow-protein label) used for exosome 
uptake studies. LDL (2.61 µg/µl) were diluted to the same protein concentration as the SEC 
exosomes (0.24 µg/µl). Uptake protocol described in section 7.5.7. 
 
7.8 Platelet exosome isolation 
7.8.1 Platelet exosome isolation with calcium activation 
Method modified from (Goetzl et al., 2016, Tan et al., 2016). Blood (25 ml) was collected from 
fasted healthy donors into a 2 x 50 ml falcon tubes containing 5 mL acid citrate dextrose each. 
The first 3 ml was discarded. Aliquots of blood (10 ml) were made in 15 ml falcon tubes and 
centrifuged at 200 g at RT for 12 minutes without brake. PRP was carefully removed with a plastic 
Pasteur pipette and centrifuged at 900 g at RT for 12 minutes without brake. The platelet pellet 
was carefully resuspended in 2-4 ml of Tyrode’s buffer (137 mM NaCl, 0.3 mM NaH2PO4, 3.5 mM 
Hepes, pH 7.35) and adjusted to 250×106 platelets/ml. Platelets were then activated with CaCl2 
(1 mM), 30 minutes at 37°C. Platelets and cell debris were removed by centrifugation 4000 g at 
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RT for 10 minutes. The supernatant was mixed with ExoQuick-TC solution according to their 
protocol. The exosomes were precipitated at 4°C overnight and centrifuged at 1500 g for 30 
minutes at 4°C. The pellet was resuspended in 250 µl PBS. 
7.8.2 Scanning electron microscopy of platelets 
A sample of platelets (100 µl) were fixed in 2% glutaraldehyde for 30 minutes, and subsequently 
centrifuged at 300 g (RT, 20 minutes). The platelet pellet was washed in distilled water and 
centrifuged at 200 g (RT, 10 minutes). Platelet suspension (100 µl) was added on top of a 3-
aminopropyltriethoxysilane (APES) coated cover slip and stored at 4°C. The platelets were 
dehydrated in an ethanol series for 5 minutes each (dH2O, PBS, 25%, 50%, 60%, 70%, 90%, 
100%) and dried by the critical point method (CO2). The platelet coverslips were mounted on 
copper stubs and coated with 20 nm gold in a sputter coater. SEM micrographs were taken with 
a Nova NanoSEM 230. 
 
7.9 Separating lipoproteins from exosomes 
7.9.1 Determining the best density gradient conditions to separate lipoproteins 
from exosomes 
Human serum was centrifuged at 13 000 g for 10 minutes to remove chylomicrons and 
microvesicles (Coumans et al., 2017) (Section 7.1.3). Human serum was then fractionated using 
an OptiPrepTM density gradient. Briefly, a discontinuous iodixanol gradient was prepared by 
diluting a stock solution of OptiPrep (60% (w/v)) with 0.25 M sucrose/10 mM Tris, pH 7.5 to 
generate 40% and 18% (w/v) iodixanol solutions and their densities were assessed. Density was 
determined by measuring the mass of 1 ml of each iodixanol solution. The 18% iodixanol solution 
was formed by dilution of stock solution with human serum. With care, the discontinuous iodixanol 
gradient was generated by underlayering in Beckman centrifuge tubes polyallomer tubes. A 5 ml 
syringe was used with a long bone marrow needle (bevel removed). The gradient tested consisted 
of 3 ml 18% iodixanol solution in serum and 0.5 ml 40% iodixanol solution. The gradient was 
centrifuged using a SW 60 Ti rotor for 3 hours at 200 000 gavg at 4°C. Fractions (7 x 0.5 ml) were 
collected from the top of the gradient. The density gradient fractions 1-6 were diluted with 3 ml 




Gradients as above were also formed with 2 ml 4% or 6% iodixanol solution, 1 ml 18% iodixanol 
solution in serum and 0.5 ml 40% iodixanol solution (See Figure 4.2). The gradient was 
centrifuged using a SW 60 Ti rotor for 20 hours at 265 000 gavg at 4°C with no brake. Fractions 
were collected from the top of the gradient (7 x 0.5 ml).   
7.9.2 Density gradient and size exclusion chromatography (DG SEC) 
In brief, 0.5 ml 60% and 6 ml 18% in serum were layered underneath 6.5 ml 6% iodixanol OptiPrep  
in UC tubes. The gradient was centrifuged using a SW 40 Ti rotor for 24 hours at 195 000 gavg at 
4°C. Seven fractions were collected from the top of the gradient (2 ml each, except fraction 6 was 
1 ml). Fraction 6-7 from 4 tubes were diluted in PBS and concentrated by centrifuging at 100 000 
gavg for 3 hours at 4°C with a Type 40 Ti rotor. The resulting pellets were resuspended in a final 
volume of 1 ml which was separated on the SEC column as described previously (Section 7.1.3). 
7.9.3 Ultracentrifugation, density gradient and size exclusion chromatography (UC 
DG SEC) 
UC was used to preconcentrate the exosomes before the density gradient step. Human serum 
(31 ml) diluted in PBS (31 ml) was centrifuged for 40 minutes at 10 000 gavg at 4°C and the 
resulting supernatant was centrifuged for 2 hours at 120 000 gavg at 4°C to pellet the exosomes. 
The resulting pellets were resuspended in final volume of 2 ml of 18% iodixanol which was further 
purified using an OptiPrep density gradient. In brief, 0.25 ml 60% and 1 ml 18% iodixanol UC 
pellet (from 15.5 ml serum) was layered underneath 2.6 ml 6% iodixanol OptiPrep in UC tubes. 
The gradient was centrifuged using a SW 60 Ti rotor for 24 hours at 195 000 gavg at 4°C. Four 
fractions were collected from the top of the gradient (fraction 1&2 (1 ml), fraction 3 (0.5 ml), fraction 
4 (1.1 ml)). Fraction 4 was separated on the SEC column as described previously (Section 7.1.3). 
 
7.10 Determining the functional activity of ApoB lipoproteins at the same 
concentration of ApoB present in SEC exosomes 
ApoB lipoproteins were obtained from density gradient fraction 1 described in section 7.9.2. The 
concentration of ApoB was determined using an ApoB ELISA (Section 7.11). The ApoB 
lipoproteins were diluted to 15 µg ApoB/ml, the same ApoB concentration as in SEC-derived 
exosome fraction 9. The effect of 10% (v/v) ApoB lipoproteins (1.5 µg/ml) on HdFb cell 
proliferation was assessed using the XTT assay described in section 7.5.6. 
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7.11 ApoB ELISA 
Samples were diluted as follows: DG Fr 1-7 (1:250), UC DG Fr 1 (1:50), UC DG Fr 2-4 (1:25), DG 
UC pellet (1:50), UC pellet (1:50), SEC Fr 7-10 (1:25), SEC Fr 11-14 (1:100), DG SEC Fr 7-14 
(none), UC DG SEC Fr 7-14 (none). Samples (50 µl) were added to a precoated 96-well ApoB 
immunoplate containing 200 µl assay diluent and incubated for 2 hours at RT on a horizontal 
orbital shaker. Thereafter the plate was washed three times with PBS and incubated with 200 µl 
conjugate for 2 hours at RT on a horizontal orbital shaker. The plate was washed three times with 
PBS and incubated with substrate solution according to the manufacture’s instructions and 
absorbance was measured at 450 nm, with background correction at 570 nm, using an iMark 
microplate reader. Human ApoB standard solutions were made (39.1-2500 ng/ml) to obtain a 4 
parameter logistic curve as the standard curve (Figure 7.2). The ApoB concentrations in SEC, 














Figure 7.2: Standard curve (4 parameter logistic curve) generated from serial dilution of ApoB (39.1-2500 ng/ml) 

















Human ApoB (ng/ml) 
R-squared = 0.999 
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7.12 Quantification of HDL and LDL subclass distribution 
The Lipoprint® System (Hoefner et al., 2001) was used from the Hatter Institute for 
Cardiovascular Research in Africa, University of Cape Town, to assess the HDL and LDL 
subclass distribution. Serum, SEC fraction 8 and 9 and platelet exosomes from calcium activation 
of the platelets (25 µl) were mixed with Lipoprint loading gel (300 μl). The Sudan black dye present 
attaches proportionally to any cholesterol in the sample. The mixed sample was applied to the 
top of a high resolution 3% polyacrylamide gel. Photopolymerisation of the gels was performed 
for 30 minutes at RT and electrophoresis for 50 minutes at 3 mA per gel tube. The gel tubes were 
scanned after 30 minutes and analysed using the Lipoware software. A Lipoprint® HDL and LDL 
System were performed. 
 
7.13 Nanoparticle tracking analysis 
The particle concentration in the SEC, DG SEC and UC DG SEC fractions were analysed with 
NTA, using the NanoSight LM10. Aliquots from the isolation fractions were diluted 10 to 50-fold 
in PBS to obtain a suitable particle number per frame. Particle concentration was determined by 
analysing three x 1-minute videos. All samples were measured using the same instrument 
settings, camera level was set to 16 and threshold set to 7. In between each reading the frame 
was completely flushed of the previous sample. 
 
7.14 Mass spectrometry 
7.14.1 Exosome lysis, buffer exchange and tryptic digestion 
Human serum exosome fraction 9 isolated using either SEC or UC DG SEC (500 µl) were lysed 
with 167 µl 3X RIPA buffer and vortexed for 1 minute. They were then processed using the filter-
aided sample preparation protocol (Wisniewski et al., 2009). The lysed exosome sample was 
incubated with 0.1 M dithiothreitol at 95°C for 3 minutes to reduce cysteine bonds. The reduced 
sample solution was transferred to a 30 kDa centrifugal filter unit and centrifuged for 10 minutes 
at 14 000 g two times to reduce the volume. The sample was denatured and washed with 200 µl 
8 M urea in 0.1 M Tris at 14 000 g for 15 minutes two times. The sample was incubated for 20 
minutes in the dark with 100 μl of 0.05 M iodoacetamide in urea buffer (for alkylation of cysteine 
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residues), followed by centrifugation at 14 000 g for 10 minutes. The samples were washed three 
times with 100 µl 8 M urea in 0.1 M Tris at 14 000 g for 15 minutes. To remove the urea buffer, 
the sample was washed with 100 µl of 0.05 M ammonium bicarbonate at 14 000 g for 10 minutes 
three times. The final retentate was ensured to be alkaline pH of roughly pH 9, using pH paper, 
for trypsin activity to occur. The samples were then digested overnight with 2 µg of Trypsin-ultra™ 
modified trypsin at 37°C overnight in a wet chamber. The tryptic peptides were eluted through the 
spin filter by centrifugation at 14 000 g for 10 minutes, in a total volume of 80 µl of 0.05 M 
ammonium bicarbonate. The samples were acidified with formic acid (0.1%) prior to desalting.  
7.14.2 Desalting of tryptic peptides 
The samples were desalted using a C18 resin embedded in an in-house produced stage tip. All 
C18 tips were activated, equilibrated, samples bound, washed and eluted by centrifugation at 
4000 rpm for 1 minute. The C18 resin was activated using 100 µl 80% acetonitrile and 0.1% formic 
acid (four times), followed by equilibration with 100 µl 2% acetonitrile and 0.1% formic acid (three 
times). Acidified tryptic peptides were bound to the stage tip by centrifugation at 4000 rpm until 
the entire volume of tryptic digest had passed through the filter. Contaminants were washed out 
using 100 µl 2% acetonitrile and 0.1% formic acid (four times). The tryptic peptides were eluted 
out into a glass insert using 50 µl 60% acetonitrile and 0.1% formic acid (four times) at 6000 rpm 
for 1 minute. The eluted samples were dried in a vacuum centrifuge, and resuspended in 2% 
acetonitrile and 0.1% formic acid prior to mass spectrometry analysis. The samples were both 
diluted 1:10 prior to mass spectrometry analysis. 
7.14.3 Liquid chromatography with tandem mass spectrometry analysis 
LC-MS/MS analysis was carried out in the Institute of Infectious Disease and Molecular Medicine, 
University of Cape Town core facility. Samples were separated by UHPLC inline on a Thermo 
Dionex Ultimate 3000 instrument prior to mass spectrometry analysis. The maximum injection 
volume, as determined by the sample loop (12 μl), of peptides from each sample were loaded 
onto an in-house packed 2 cm C18 trap (100 µm ID, packed with Phenomenex Luna 100 Å hollow 
core beads) and washed at a flow rate of 5 µl/min with 2% acetonitrile and 0.1% formic acid. The 
trap was switched in-line to an in-house packed 30 cm analytical column (75 µm ID, packed with 
Phenomenex Aeiris peptide C18 3.6 µm solid core beads) and the peptides were separated from 
6% solvent B (100% acetonitrile, 0.1% formic acid) in solvent A (100% water, 0.1% formic acid) 
to 30% solvent B over 30 minutes at a flow rate of 0.4 µl/min. Peptides eluted directly into a 
Thermo QExactive hybrid orbitrap mass spectrometer. 
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The QExactive acquired spectra in data-dependent (Top10) mode, with an MS1 resolution of 
70 000 and an MS2 resolution of 17 500. MS1 scans were acquired with an AGC target of 3e6 or 
an IT of 250 ms. MS2 scans were acquired with an AGC target of 1e6 or an IT of 80 ms. Dynamic 
exclusion was set to 30 seconds, roughly half the average chromatographic peak width.  
7.14.4 Data analysis 
Raw data were analysed using MaxQuant version 1.3.1.12 with default settings for the QExactive 
instrument. Match between runs was off and LFQ was used for protein-level label free quantitative 
comparison. The protein groups output file from MaxQuant was used for functional analysis of the 
exosomes in Funrich (Pathan et al., 2017).  
The quality control used weekly by the mass spectrometry department was running a complex 
reference sample (human neuroblastoma cell line) with the calibration of the mass spectrometer. 
This was used to benchmark their instrument.  
 
7.15 In vivo study: Subcutaneous implantation 
This animal study was approved by the Animal Research Ethics Committee, Faculty of Health 
Sciences, University of Cape Town (HSF AEC 014/016) and complied with the Principles of 
Laboratory Care as well as the guidelines within the National Research Council’s Guide for the 
Care and Use of Laboratory Animals (National Institutes of Health, publication no. 86-23). 
7.15.1 Preparation of porous polyurethane discs 
The various fibrin hydrogels were polymerised within highly porous PU discs. In preparation, 
porous PU discs were produced by the Polymer Laboratory as previously described by 
(Bezuidenhout et al., 2002) with a diameter of 5.4 mm, thickness of 2 mm, 82% porosity and 157 
µm diameter pores. These highly porous discs allow for a defined tissue ingrowth volume and 
accurate location of implants when explanted. Discs were sterilised by immersion in 70% ethanol 
and subsequently sonicated for 20 minutes. The discs were then air dried in the tissue culture 
laminar flow hood and placed into the wells of a sterile 96-well plate. The unpolymerised fibrin 
constituents (10 mg/ml fibrinogen, 55 µl total volume) were mixed and aspirated into the PU disc 
immediately by squeezing the disc at least 3 times with the plunger of a 1 ml syringe to remove 
all trapped air inside the disc and to efficiently load the hydrogel. For the treatment groups (SEC 
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exosomes and UC DG SEC exosomes), 40 µl of the exosome solutions were mixed with the fibrin 
gel components (maintaining 10 mg/ml fibrin) prior to uptake and polymerisation within PU discs 
(55 µl total).  
7.15.2 Subcutaneous implantation 
Implants were carried out in male Wistar rats (n=6) as previously described by (Goetsch et al., 
2015). Aseptic techniques were used for the surgical procedures. Animals were anaesthetised 
using isoflourane, shaven and the dorsal skin was disinfected with povidine iodine. Up to six 1.0 
cm longitudinal incisions were made subcutaneously on the dorsal midline and a pocket for each 
disc was secured by gentle blunt dissection (Figure 7.3). The discs were implanted into the 
pockets, with each rat receiving only one disc of each group (n=6). The incisions were closed with 
single 4-0 prolene sutures. The study was amalgamated with another study carried out in the 
laboratory that was examining differently pegylated versions of fibrin. As the control group in this 
other study consisted of fibrin alone and there were 3 experimental groups, this left 2 free implant 
positions free per rat. Thus, no extra rats were required to carry out the study described here. The 
surgeon was blinded to the treatment groups and the implantation was randomised for each 
animal.  
After 7 days of implantation, the animals were euthanised by inhalation of halothane. Discs were 
explanted with their surrounding capsules, halved into equal semi-cylindrical sections, and fixed 





Figure 7.3: Illustration of the subcutaneous implant model in rats. (A) Incision of subcutaneous pockets, disc 
implantation and sutured closed; (B) Discs placed along the dorsal midline, with 6 randomised discs per rat. Surgical 
images modified from (Palhares et al., 2009). 
 
7.15.3 Histology 
7.15.3.1 Wax processing and embedding 
The discs were taken out of the ethanol, inserted into histology cassettes and placed into wire 
mesh baskets. The samples were immersed in graded alcohol (70% to 90%), for 60 minutes in 
each. Followed by immersion in 100% alcohol three times for 60 minutes each. The samples then 
had three changes of iso-octane, three changes of paraffin wax for 60 minutes each at 60°C, with 
the final change being 120 minutes. The cassettes were opened, and the samples were 
embedded in paraffin wax using embedding molds. The samples were sectioned from the mid-
region of the explanted discs using a microtome.  
7.15.3.2 Staining 
The cross-sections were mounted on microscope slides and were stained with H&E in order to 
quantify cellular tissue invasion. The sections were dewaxed using trimethylpentane for 10 
minutes, repeated twice. The sections were placed in 100% alcohol three times, then in 96% 
alcohol two times and in 70% alcohol two times. The slides were then placed in distilled water. 
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The sections were incubated in haematoxylin and then under running tap water, both for 5 
minutes. The slides were then placed in eosin for 30 seconds, dipped in distilled water and 
dehydrated through the alcohols as mentioned above. The slides were mounted with Canada 
Balsam and allowed to dry.  
The cross-sections were mounted on microscope slides and were stained with ED1 (rat CD68) in 
order to quantify inflammation. The sections were dewaxed using trimethylpentane for 10 minutes, 
repeated twice. Cross-sections underwent Proteinase K digestion (diluted to manufacturer’s 
specifications) for 10 minutes at 37°C. Incubated with mouse anti-rat ED1 1:100 dilution in TBS 
overnight at 4°C. Secondary biotinylated anti-mouse 1:250 dilution for 1 hour at RT. Followed by 
CY3 labelled streptavidin 1:500 dilution for 1 hour at RT. The slides were mounted in Fluoroshield 
DAPI.  
In order to visualise vascularisation data, sections were incubated in 0.5% triton-100 in TBS for 
10 minutes at RT. Then primary mouse anti-human monoclonal SMA diluted (1:100) in TBS 
overnight at 4°C. Further stained as described above. 
7.15.3.3 Microscopic analysis 
Samples were viewed and micrographs of entire cross-sections across the mid-region of the 
explanted disc were captured on a Nikon Eclipse 90i microscope with the stitching algorithm of 
the Nikon Eclipse software. Micrographs covering the entire disc cross-section were stitched 
together per explant by a blinded observer using Visiopharm Integrated Systems (VIS) analysis 
software. For analysis of macrophage content and vascular area, the VIS software was trained to 
automatically detect CD68 and SMA staining using the decision forest classifier. After 
segmentation vascularisation analysis cross-sections were then examined by a blinded observer 
to remove any signal detection that did not correlate with vessels that had a clear vascular 
morphology. It is to be noted the researcher was blinded to the treatment groups in all analyses.  
 
7.16 Statistical analysis 
One-way ANOVA with a block design with Dunnett’s post-hoc testing for significance was 
performed for proliferation assays. This approach was specifically used as it is the most 
appropriate methodology for repeated cell culture studies (Lew, 2007). 
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Animal studies were randomised and blinded. One-way ANOVA with Tukey post-hoc testing for 
significance where appropriate was performed on inflammatory and vascularisation data.  
Analyses of all other data were conducted using Student’s T-tests (two-sample equal variance 
(homoscedastic)) in Excel (Microsoft Office). Results are expressed as the mean and error bars 
are standard error of the mean unless otherwise stated. 
 
7.17 Reagents, equipment and general consumables 
 
Table 7.1: Reagents 
Product Producer/Supplier Product No. 
2-Mercaptoethanol Sigma-Aldrich, St Louis, MO, USA M6250 
3-Triethoxysilylpropylamine Sigma-Aldrich, St Louis, MO, USA A3648 
Acid citrate dextrose  Sigma-Aldrich, St Louis, MO, USA C3821 
ActinRed™ ReadyProbes® Reagent Life Technologies, Carlsbad, CA, 
USA 
R37112 
Alexa Fluor™ 488 Phalloidin Life Technologies (Molecular 
probes), USA 
A12379 
Alexa Fluor™ 594 Phalloidin Life Technologies (Molecular 
probes), USA 
A12381 
Aprotinin Roche, Basel, Switzerland 70257723 
BODIPY™ TR Ceramide (red-fluorescent 
dye) 
Thermo Fisher Scientific, Waltham, 
MA, USA 
D7540 
Bradford reagent Sigma-Aldrich, St Louis, MO, USA B6916 
Bromophenol Blue Sigma-Aldrich, St Louis, MO, USA B0126 
C18 resin  Sigma-Aldrich, St Louis, MO, USA 66883-U 
Calcium chloride (CaCl2) Sigma-Aldrich, St Louis, MO, USA C4901 
Collagen type I (bovine skin) Sigma-Aldrich, St Louis, MO, USA C4243 
Collagenase type II (HUVEC isolation) Worthington Biochemical 
Corporation, Lakewood, NJ, USA 
LS004174 
Coomassie Brilliant Blue R-250 Sigma-Aldrich, St Louis, MO, USA B0149 
Cy3 conjugated strepavidin Jackson Immuno Research Lab, 
West Grove, PA, USA 
016-160-084 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, St Louis, MO, USA D2650 
DMEM media Sigma-Aldrich, St Louis, MO, USA D5648 
Donkey anti-mouse biotin conjugated IgG Rockland, Limerick, PA, USA 610-706-124 
ELISA: Quantikine® ELISA human 
apolipoprotein B/ApoB immunoassay 
R&D Systems, Minneapolis, MN, 
USA 
DAPB00 
Ethanol Servochem (PTY) LTD, Montague 
Gardens, Cape Town, South Africa 
– 
ExoGlow™ (protein EV labelling kit, 
green) 
System Biosciences, Palo Alto, CA, 
USA 
EXOG200A-1 





FastCast SDS-PAGE (12%) Bio-Rad, Hercules, CA, USA 1610175 
Fat free milk powder  LabScientific, Highlands, NJ, USA M-0841 
Fluoroshield with DAPI  Sigma-Aldrich, St Louis, MO, USA F6057 
Foetal bovine serum (FBS) (gamma 
irradiated) 
Gibco® by Life Technologies™, 
Paisley, UK 
10499-044 
Gentamicin solution Sigma-Aldrich, St Louis, MO, USA G1272 
Glycerol Sigma-Aldrich, St Louis, MO, USA G5516 
Goat anti-rabbit horseradish peroxidase 
(HRP) conjugated antibody  
Abcam, Cambridge, MA, USA ab97051 
Heparin NaCl Sigma-Aldrich, St Louis, MO, USA H3393-50KU 
Hepes Sigma-Aldrich, St Louis, MO, USA H3375 
Human epidermal growth factor (EGF) Peprotech, Rocky Hill, NJ, USA AF-100-15  
Human fibrinogen  Sigma-Aldrich, St Louis, MO, USA F3879 
Human fibroblast growth factor-basic 
(bFGF) 
Peprotech, Rocky Hill, NJ, USA 100-18B 
Human serum (Blood group AB) Western Province Blood Transfusion 
Service, Cape Town, South Africa 
- 
Hydrocortisone Sigma-Aldrich, St Louis, MO, USA H0396 
L-Glutamine Sigma-Aldrich, St Louis, MO, USA G-8540 
MCDB-131 media Sigma-Aldrich, St Louis, MO, USA M8537 
Medium 199 growth medium  Sigma-Aldrich, St Louis, MO, USA M4530 
Methyl cellulose: 4000 centipoises Sigma-Aldrich, St Louis, MO, USA M0512 
Mini-PROTEAN® TGX™ precast protein 
gels (4-15%) 
Bio-Rad, Hercules, CA, USA 4561083 
Mouse anti-human monoclonal SMA Agilent Technologies, Santa Clara, 
CA, USA 
M0851 
Mouse anti-rat monoclonal ED1  Bio-Rad, Hercules, CA, USA MCA341R 
OptiPrep™ density gradient medium  Sigma-Aldrich, St Louis, MO, USA D1556 
Penicillin streptomycin (10 000 U penicillin 
and 10 mg streptomycin/ml) 
Sigma-Aldrich, St Louis, MO, USA P0781 
Potassium chloride (KCl) Sigma-Aldrich, St Louis, MO, USA P9541 
Potassium phosphate monobasic 
(KH2PO4) 
Sigma-Aldrich, St Louis, MO, USA P5655 
Prostaglandin E1 (PGE1) Sigma-Aldrich, St Louis, MO, USA P5515 
Protein G-Agarose  Sigma-Aldrich, St Louis, MO, USA P7700 
Proteinase K Dako, Glostrup, Denmark S3020 
Proteinase K Sigma-Aldrich, St Louis, MO, USA P2308 
Rabbit anti-human ApoA1 Abcam, Cambridge, MA, USA ab52945 
Rabbit anti-human CD9  Abcam, Cambridge, MA, USA ab92726 
Rabbit anti-human TAPA1  Abcam, Cambridge, MA, USA ab109201 
Rabbit anti-human TSG101  Abcam, Cambridge, MA, USA ab30871 
RIPA buffer Sigma-Aldrich, St Louis, MO, USA R0278 
Sepharose CL-4B  GE Healthcare, Chicago, IL, USA 17-0150-01 
Sigmacote® Sigma-Aldrich, St Louis, MO, USA SL2 
Sodium azide  Sigma-Aldrich, St Louis, MO, USA S2002 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich, St Louis, MO, USA S5761 
Sodium chloride (NaCl) Sigma-Aldrich, St Louis, MO, USA S7653 
Sodium dihydrogen phosphate (NaH2PO4) Sigma-Aldrich, St Louis, MO, USA S3139 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, St Louis, MO, USA L3771 
Sodium hydroxide (NaOH) Sigma-Aldrich, St Louis, MO, USA S-5881 
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Sodium phosphate dibasic dodecahydrate 
(Na2HPO4.12H2O) 
Sigma-Aldrich, St Louis, MO, USA 71649 
SYTO™ RNASelect™ (green fluorescent 
cell stain) 
Thermo Fisher Scientific, Hillsboro, 
OR, USA 
S32703 
Thrombin from bovine plasma Sigma-Aldrich, St Louis, MO, USA T4648 
Triton-X 100  Sigma-Aldrich, St Louis, MO, USA T8532 
Trizma® hydrochloride (Tris-HCl) Sigma-Aldrich, St Louis, MO, USA T3253 
Trypan Blue Sigma-Aldrich, St Louis, MO, USA T8154 
Trypsin-EDTA (10X) Sigma-Aldrich, St Louis, MO, USA 59427C 
Trypsin-ultra™ mass spectrometry grade 
modified trypsin 
New England BioLabs, Ipswich, MA, 
USA 
P8101S 
Tween® 20 Sigma-Aldrich, St Louis, MO, USA P1379 
WesternBright ECL HRP substrate  Advansta, Menlo Park, CA, USA K-12045-D50 





















Table 7.2: Equipment 
Product Producer/Supplier 
-65 °C freezer Snijders Scientific, Tilburg, Netherlands 
Centrifuge: 5415R (for microcentrifuge tubes) Eppendorf, Hamburg, Germany 
Centrifuge: 5810R Eppendorf, Hamburg, Germany 
Centrifuge: J2-21 with a JA20 rotor (for 
centrifuging methylcellulose) 
Beckman Coulter Life Sciences, Indianapolis, IN, 
USA 
Centrifuge: Megafuge 1.0R Heraeus, Hanau, Germany 
Dionex Ultimate 3000 instrument  Thermo Fisher Scientific, Waltham, MA, USA 
Fluorescent spectrophotometer: Cary Eclipse 
serial no. e101124662  
Agilent Technologies, Santa Clara, CA, USA 
Haemocytometer Improved Neubauer, Baxter Scientific, Deerfield, 
IL, USA 
HERA cell incubator (for all 37 °C cell culture) Heraeus, Hanau, Germany 
iMark plate reader Bio-Rad, Hercules, CA, USA 
Lipoprint® System  Quantimetrix, Redondo Beach, CA, USA 
Liquid chromatography columns: C4169 Sigma-Aldrich, St Louis, MO, USA 
Mass spectrometer: QExactive hybrid orbitrap Thermo Fisher Scientific, Waltham, MA, USA 
Microscope: Nikon fluorescent microscope (Nikon 
Eclipse 90i DS-Ri1) 
Nikon, Tokyo, Japan 
Microscope: Nikon light microscope (Nikon 
Eclipse Ti-S) 
Nikon, Tokyo, Japan 
Microscope: ZEISS LSM510 Confocal microscope 
with MaiTai two photon laser 
Carl Zeiss Microscopy GmbH, Göttingen, 
Germany 
NanoDrop: NanoDrop 2000 Thermo Fisher Scientific, Waltham, MA, USA 
NTA: NanoSight LM10  Malvern Instruments, Malvern, UK 
pH meter: Jenway 3510 Bibby Scientific, Staffordshire, UK 
Pipettes Gilson Inc., Middleton, WI 
Rotor: SW 40 Ti Rotor, swinging bucket, titanium, 
6 x 14 ml 
Beckman Coulter Life Sciences, Indianapolis, IN, 
USA 
Rotor: SW 60 Ti Rotor, swinging bucket, titanium, 
6 x 4 ml 
Beckman Coulter Life Sciences, Indianapolis, IN, 
USA 
SEM microscope: Nova NanoSEM 230  FEI, Hillsboro, OR, USA 
Shaking incubator: IncoShake Labotech, Cape Town, South Africa 
Sonicator: Virsonic 100 probe Virtis, Gardiner, NY, USA 
SpeedVac™ concentrator: Savant™ SPD131DDA Thermo Fisher Scientific, Waltham, MA, USA 
Sputter coater: Polaron Emitech SC7640  Quorum Technologies, Lewes, UK 
TEM microscope: Tecnai G2 Thermo Fisher Scientific, Waltham, MA, USA 
Trans-Blot® SD Semi-Dry Transfer Cell  Bio-Rad, Hercules, CA, USA 
Ultracentrifuge: Beckman L-80  Beckman Coulter Life Sciences, Indianapolis, IN, 
USA 
Ultracentrifuge: Beckman L8-55M  Beckman Coulter Life Sciences, Indianapolis, IN, 
USA 







Table 7.3: General consumables 
Product Producer/Supplier Product No. 
24-well cell culture plate Costar® by Corning 
Incorporated, NY, USA 
3524 
96-well cell culture plate Costar® by Corning 
Incorporated, NY, USA 
3595 
96-well clear, round bottomed, sterile plate, 





96-well opaque, flat bottomed, non-sterile Nunc® MicroWell, Roskilde, 
Denmark 
Z688665 
Agar TEM grids 200 mesh copper Agar Scientific, Essex, UK 04G2220C 
Amicon ultra 0.5 ml 100 kDa centrifugal 
filters 
Millipore, Burlington, MA, 
USA 
UFC510096 
Amicon ultra 0.5 ml 30 kDa centrifugal 
filters 
Millipore, Burlington, MA, 
USA 
UFC503096 
Centrifuge tube (15 ml) Falcon by BD Biosciences, 
San Jose, CA, USA 
352096 
Centrifuge tube (50 ml) Falcon by BD Biosciences, 
San Jose, CA, USA 
352070 
CultureWell 16 chambered cover glasses  Life Technologies, 
Carlsbad, CA, USA 
C-37000 
Exosome spin columns (MW 3000)  Invitrogen™, Thermo Fisher 
Scientific, OR, USA 
4484449 
Filter, syringe filter unit (0.2 μm) Abluo™, GVS Lifesciences, 
Sanford, ME, USA 
FJ25ASCCA002DL01 
Micro centrifuge tube, flat cap (0.6 ml) Thermo Scientific QSP, San 
Diego, CA, USA 
502-GRD-Q 
Micro centrifuge tube, flat cap (1.5 ml) Thermo Scientific QSP, San 
Diego, CA, USA 
509-GRD-Q 
Micro centrifuge tube, flat locking cap (2.0 
ml) 
Thermo Scientific QSP, San 
Diego, CA, USA 
L-508GRD-Q 
Mr Frosty freezing container Nalgene, Sigma-Aldrich®, 
St Louis, MO, USA 
C1562 
Nitrocellulose membrane Hybond ECL  Amersham Biosciences, 
Sigma-Aldrich, St Louis, 
MO, USA 
GE10600002 
Transwell insert, 6.5 mm with 0.8 µm pore 
polycarbonate membrane 
Corning, NY, USA 3422 
Ultracentrifuge tubes for SW 40 Ti, 14 ml, 
14 x 95 mm 
Beckman Coulter Life 
Sciences, Indianapolis, IN, 
USA 
331374 
Ultracentrifuge tubes for SW 60 Ti, 4 ml, 11 
x 60 mm 
Beckman Coulter Life 
Sciences, Indianapolis, IN, 
USA 
328874 
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Figure A2: Exosomes purified from pooled human serum using ExoQuick-TC followed by SEC.  (A) Absorbance 
profile of ExoQuick isolated exosomes from 500 µl human serum and the resuspended exosome pellet was loaded 
onto the SEC column; (B) TEM micrograph of exosomes purified from pooled human serum using ExoQuick-TC 


























Figure A3: Standardising the standard curve generated from dilutions of BODIPY TR Ceramide labelled SEC-














Appendix 4: TEM analysis of LDL 
 
























 Average vesicle size (nm) Min vesicle size (nm) Max vesicle size (nm) 
LDL 21.7 ±2.5 13.9 27.8 
236 
 



















Figure A5: Representative graph of particles/ml vs particle diameter (nm) from a nanoparticle tracking analysis 























Appendix 6: Mass spectrometry data 
 
Appendix 6: Mass spectrometry data of Funrich analysis (SEC and UC DG SEC), SEC and UC 


























































Figure A7: Flow cytometric analysis of isolated HUVECs. Histograms showing secondary (2°) antibody control (2° 
antibody alone, purple peak) and the primary anti-CD31 antibodies (1°) and 2° antibody sample (1° and 2°, turquoise 
peak).  
 
